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ABSTRACT 
Computational Analysis of the Colonic Transciptome & In Vitro Biomarker 
Analysis Using a Novel Microfluidic Quantum Dot Linked Immunoassay 
 Peter M. Clark  
Aydin Tozeren, Ph.D. & Elisabeth Papazoglou, Ph.D. 
 
DNA microarray technology facilitates the high throughput analysis of 
transcriptional disease regulation by measuring the relative expression levels of 
transcripts present within a tissue.  While such computational approaches have 
been used to study the genetic regulation of a variety of illnesses, such studies 
often suffer from inadequate patient sample sizes and statistical power resulting 
in conflicting results and lab-specific bias.  In order to overcome these limitations 
and fully utilize the wealth of publicly available genomic data, an integrated 
microarray analysis method was used to analyze and interpret microarray data 
in the context of colonic diseases including colorectal carcinoma (CRC) and 
inflammatory bowel disease (IBD). 
The results of this work indicate widespread genetic perturbations related 
to IBD in which a variety of cell types are implicated including resident host 
enterocytes, innate and adaptive immune cells as well as native luminal 
microflora.  Our work has identified subtle genetic differences between IBD 
phenotypes for the realization of disease specific therapeutic treatments as well 
as novel diagnostic biomarkers.  Furthermore, our analysis has revealed 
significant overlap in the genetic regulation and predisposition to IBD, lupus, 
type 1 diabetes, graves disease and rheumatoid arthritis, providing the first 
genetic link between the enteropathic disease symptoms associated with IBD.  
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Druggable pathways involved in these diseases as well as known therapeutic 
drug targets were also analyzed for the potential repositioning of existing 
therapeutics for the treatment of IBD. 
IBD patients are known to be at an elevated risk for developing colorectal 
carcinoma, with risk increasing with the duration of the disease.  In order to 
better understand the phenotype shift from IBD to cancerous phenotypes, 
integrated microarray analysis was used to identify gene signatures, implicated 
pathways and novel discriminatory biomarkers for differentiating between IBD 
and CRC phenotypes.  Our diagnostic panels were shown to accurately 
differentiate between phenotypes using an independent dataset for validation.   
In order to transition the identified biomarkers to the clinic for diagnostic 
use, a novel microfluidic quantum dot linked immunosorbent assay platform 
was developed with enhanced surface chemistry and reaction kinetics.  The 
developed prototype has the capability of multiplexed biomarker detection 
within clinically relevant samples for the stratification of disease phenotypes.  In 
order to validate our design, human samples spiked with the fecal IBD 
biomarker lactoferrin were analyzed.  Results indicate increased sensitivity and 
signal to noise ratios over our predicate device, with a reduction of the limit of 
detection.  This proof of concept device shows great promise as a portable 
bedside diagnostic device for multiplexed biomarker analysis within a clinical 
setting. 
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CHAPTER 1 
BACKGOUND & SIGNIFICANCE 
 
1.1 THESIS ORGANIZATION 
 The organization of this thesis is article based in which this 
introductory chapter is succeeded by three freestanding manuscripts.  The 
introductory chapter serves to both frame the thesis and provide the 
reader with relevant background information related to the topics covered 
herein.  The introduction is followed by a computational, systems biology 
manuscript entitled, “Bioinformatics analysis reveals transcriptome and 
microRNA signatures, and drug repositioning targets for IBD and other 
autoimmune diseases.”  The manuscript identifies differentially expressed 
genes and pathways involved in the pathogenesis of IBD as well as 
therapeutic targets and genes related to the transcriptional regulation of 
other autoimmune diseases for therapeutic repositioning of existing 
drugs.  The third chapter is a manuscript entitled, “Meta-Analysis of IBD 
and Colorectal Carcinoma Microarray Data Reveals Transcriptional 
Regulation, Disease Biomarkers and Regulatory Pathway Associations 
Between Disease Phenotypes,” which identifies unique genes and 
pathways involved in the transition from IBD to colorectal carcinoma 
(CRC) as well as unique gene signature biomarker candidates for 
distinguishing between IBD phenotypes and the four stages of CRC.  A 
biomarker identified within our analysis, was then assessed within spiked 
human samples using a novel high throughput microfluidic quantum dot 
linked immunoassay (QLISA) platform (chapter 4).  This chapter describes 
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the design, fabrication and characterization of a second-generation 
microfluidic QLISA platform with improved surface functionalization to 
enhance immunoassay kinetics and biosensor performance.  This work 
was presented as a conference paper presented at Micro-Total-Analytical-
Systems (uTAS) 2011, one of the foremost international conferences on 
micro-scale devices.  An IBD fecal biomarker, lactoferrin, was then 
detected within spiked human stool samples in order to characterize 
biosensor performance in the detection of IBD biomarkers.  The 
concluding chapter summarizes my contributions to the field and 
addresses future research directions and concerns.   
  
 3 
1.2 MOTIVATION & APPROACH 
 Inflammatory bowel disease is known to affect over 1.5 million 
people within the United States, although international incidence of the 
disease are on the rise [1, 2].  Current diagnosis of IBD requires a 
colonoscopy in combination with endoscopic, radiologic and histological 
tests.  In order to circumvent such invasive procedures, both serological 
and fecal biomarker assays have been developed for the diagnosis of IBD 
but require analysis by lab technicians often at a centralized lab facility 
and often suffer from high false positive rates since many of the markers 
are inflammatory related proteins that may be elevated due to the 
presence of other systemic inflammatory conditions [3].  Furthermore, 
there is currently no biomarker that can accurately distinguish between 
the two phenotypes of IBD; ulcerative colitis (UC) and crohn’s disease 
(CD).   
 In order to identify potential IBD biomarkers and better understand 
the transcriptional regulation of IBD as well as susceptibility genes 
leading to the progression from IBD to CRC, computational approaches 
were developed to integrate and analyze large sets of microarray data in a 
functional context.  Biomarkers identified using this approach may then 
be used to develop clinical biomarker panels for the non-invasive 
stratification of colonic diseases including differentiating between IBD 
phenotypes and the stages of CRC.   
 Lastly, our patented QLISA system was enhanced using novel 
surface chemistry and translated onto a microfluidic platform to facilitate 
increased sample thoughput and multiplexed biomarker analysis and 
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integration with electrothermal flow components to enhance 
immunoassay kinetics for the realization of a rapid point of care 
immunosensor platform for the detection of IBD biomarkers. 
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CHAPTER 2: 
Bioinformatics Analysis Reveals Transcriptome And MicroRNA 
Signatures, and Drug Repositioning Targets for IBD and other 
Autoimmune Diseases 
 
2.1 ABSTRACT 
 Inflammatory bowel disease (IBD) is a complex disorder involving 
pathogen infection, host immune response, and altered enterocyte 
physiology. Incidences of IBD are increasing at an alarming rate in 
developed countries, warranting a detailed molecular portrait of IBD. 
 We used large-scale data, bioinformatics tools, and high throughput 
computations to obtain gene and microRNA signatures for Crohn's 
Disease (CD) and Ulcerative Colitis (UC). These signatures were then 
integrated with systemic literature review to draw a comprehensive 
portrait of IBD in relation to autoimmune diseases. 
 The top upregulated genes in IBD are associated with diabetogenesis 
(REG1A, REG1B), bacterial signals (TLRs, NLRs), innate immunity 
(DEFA6, IDO1, EXOSC1), inflammation (CXCLs), and matrix degradation 
(MMPs). The downregulated genes coded tight junction proteins 
(CLDN8), solute transporters (SLCs), and adhesion proteins. Genes highly 
expressed in UC compared to CD included anti-inflammatory ANXA1, 
transporter ABCA12, T cell activator HSH2D, and immunoglobulin 
IGHV4-34. Compromised metabolisms for processing of drugs, nitrogen, 
androgen and estrogen, and lipids in IBD correlated with increase in 
specific microRNA. Highly expressed IBD genes constituted targets of 
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drugs used in gastrointestinal cancers, viral infections, and autoimmunity 
disorders such as rheumatoid arthritis, and asthma.  
 This study presents a clinically relevant gene-level portrayal of IBD 
phenotypes and genetic co-regualtion of genes involved in other 
autoimmune diseases. This Study identifies potential therapeutic 
candidates for the repositioning of existing drugs to manage IBD. 
Integration of mice and human data point to altered B cell response as a 
cause for upregulation of genes in IBD involved in other aspects of 
immune defense such as interferon-inducible responses. 
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2.2 INTRODUCTION 
Inflammatory bowel disease (IBD) is a debilitating illness 
associated with the altered regulation of the gastrointestinal mucosal 
immune system leading to intestinal inflammation in the presence of 
native luminal flora.  Nearly 1.5 million people within the United States 
are affected by IBD, and incidence and prevalence of the disease continue 
to increase internationally [1, 2].  IBD is comprised of two distinct 
phenotypes; ulcerative colitis (UC) and Crohn’s disease (CD), each of 
which have unique clinical manifestations despite sharing many genetic 
and consequently mechanistic features [4-6].  Although, the exact 
pathophysiology of IBD is not yet fully understood, the etiology of this 
disease is known to be multifactorial, driven by a number of genetic and 
environmental factors including loss of regulation of the host's innate 
immune response, and defects in mucosal barrier function [7].   
 There appears to be a correlation between IBD and autoimmune 
disorders. Over a quarter of IBD patients have been known to experience 
musculoskeletal complications resulting from various subtypes of arthritis 
[8, 9]. Moreover, microRNA (miRNA) expression changes have high 
similarity in autoimmune disorders including IBD [10].  The complex 
host-pathogen interactions within the colon are also known to play a vital 
role in the pathogenesis of IBD and drive differential gene expression.  
Recent studies of the intestinal microbiome have shown a shift in the 
composition of bacterial populations in patients with UC and CD and the 
involvement of bacterial-host interactions in the pathogenesis of IBD [11-
18].  However, it still remains unclear how resident bacteria interact with 
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the host to activate and sustain chronic activation of the intestinal immune 
system through genetic regulation.   
A system approach has already emerged in the literature for 
studying IBD within the context of autoimmune disorders. A 
comprehensive first draft of the human disease network (HDN) was 
constructed recently using the disease gene information in the literature 
[19]. This and other system models [20-25] identified disease-disease 
associations not readily observed in disease-phenotype based Medical 
Subject Headings (MeSH) disease classification tree. Some of these models 
utilized text search based data whereas others based the draft network on 
gene lists identified via literature and genome wide association studies 
[26, 27]. A number of other disease network drafts utilized protein-protein 
interaction networks in addition to gene lists to identify gene-disease 
modules [28, 29]. In all cases, however, the starting point is a set of gene 
lists specific for each disease.  Hu and Agarwal [30] obtained such lists 
utilizing high throughput microarray analysis of thousands of genomic 
expression profiles existent in the literature. Their draft of the human 
disease-drug network brought out new possibilities for further 
investigation such as the use of malaria drugs in treating Crohn’s disease 
and also showed the potential of known fold changes in transcript copy 
numbers in guiding the type of drugs (agonists, antagonists) to be 
targeting druggable proteins and pathways. 
The present study benefits from the previous work on the human 
disease network and studies of global gene and miRNA expression 
profiling of IBD. It presents gene signature analysis of IBD subtypes UC 
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and CD in terms of altered pathways, biological processes, disease 
correlations, transcripts, and possible drug targets, all determined via 
bioinformatics analysis of integrated microarray and miRNA datasets 
with open-access datasets. Gene lists derived from microarray data have 
the advantage of having features such as statistical significance and fold 
changes to be used for additional annotation. However, previous disease 
and drug network modeling studies suggest potentially high levels of 
noise in predictions, extent of which depending on the accuracy of gene 
lists used to represent the specific diseases [30]. In that regard, our 
previous meta- and large-scale microarray analyses of cancer tissue 
datasets from hundreds of different laboratories point to accurate 
replication of non-microarray literature with microarray data [31]. Our 
gene lists derived from integrated datasets intersected with the shorter 
gene lists produced by Noble et al. [32, 33] with highly significant p values 
in hypergeometric test. Moreover, cellular pathways statistically enriched 
by Noble et al. gene lists turned out to be a subset of our predicted 
pathways. Our predictions of IBD associated genes captured non-
microarray IBD research literature with significant p values.  Taken 
together, these results illustrate the predictive potential of microarray 
datasets in identifying genes associated with CD and UC subtypes of IBD. 
The resulting gene lists come with statistical significance, rank, and fold 
changes; parameters, which are invaluable in biomarker discovery and 
drug repositioning and have been included in supplemental files. 
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2.3 METHODS 
Microarray Datasets, Normalization & Probe To Gene Mapping 
The microarray datasets used in this study were all in public 
domain and were generated from RNA isolated from the inflamed colonic 
mucosa of UC and CD patients and hybridized onto the Affymetrix 
Human Genome U133 Plus 2.0 GeneChip® Array platform for analysis.  A 
total of 176 colonic mucosal microarray dataset samples were obtained 
from the NCBI Gene Expression Omnibus (GEO) [34, 35] in raw CEL 
format.  Following the removal of duplicate samples, sample outliers were 
removed using principal component analysis (PCA) [36]. Two of the 
principal components accounted for 91% of the variance within the data 
set. There were a total of 15 outliers detected and removed from further 
analysis.  The final sample population is comprised of 29 healthy control 
(HC) samples, 48 UC samples and 41 CD samples from six independent 
studies (GSE9452 [37], GSE9686 [38], GSE10191 [39], GSE10616 [40], 
GSE13367 [41], and GSE16879 [42]).  Gene expression datasets were 
normalized using robust multi-array averaging (RMA) background 
adjustment, quantile normalization with median polishing and log2 
transformed summarization procedures within MATLAB [43-45] and 
were mapped to Entrez gene IDs using a custom CDF file during the 
normalization process [46, 47].  Following pre-processing, batch effect 
removal was performed using the COMBAT source code in R [48].  
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Significant Genes 
Two distinct microarray data analysis methods – Significance 
Analysis of Microarrays (SAM) [49] and the rank product (RP) method 
[50, 51] representing meta analysis – were performed in MATLAB and R 
(2.10.0), respectively, in order to identify statistically significant 
upregulated and downregulated genes in UC/HC and CD/HC 
comparisons. In SAM, statistically significant genes were determined 
using a fold change (FC) and p-value cutoff of 1.5 and 0.001 respectively 
over 1000 permutations [48].  For the RP method, only those genes with an 
enrichment p-value less than 10-6 were identified as significant.    
 
Comparison With Gene Lists Obtained Using Other Microarray Platforms 
The significant gene lists determined in this study were compared 
with corresponding lists obtained by Noble et al. comparing UC and CD 
biopsies to controls on the Agilent platform.  In addition to the Agilent 
annotation file, NCBI, DAVID [52, 53], Clone/Gene ID Converter [54] and 
Source [55] databases were used to map the Agilent probe IDs to their 
corresponding Entrez gene IDs.  The Agilent platform mapped to 18,989 
genes, of which 17,211 were also present on the Affymetrix array.  The CD 
and UC gene lists identified from our analysis were then compared to the 
two gene lists obtained from Noble et al.  A hypergeometric test was used 
to determine the significance of the intersections in terms of p-value. 
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Literature Citation Algorithm 
 Differentially expressed gene lists were used in an automated 
PubMed text search algorithm [56].  Briefly, a query of the gene symbol 
and the applicable search term was conducted in PubMed abstracts for all 
genes available on the Affymetrix HG-U133 Plus 2.0 platform, limiting 
results to non-microarray literature. The six gene lists were then annotated 
with these results, identifying those genes that were cited in relation to the 
particular search terms. Random gene lists from the same platform of 
equal size to the lists under consideration were obtained and used as a 
control. The number of related genes in each of the random iterations was 
determined, and the mean and standard deviation were calculated from 
these values to obtain the parameters of a normal distribution. The 
expected value and the standard deviation were then used to compute the 
p-values for the significant association of each of our cancer gene lists with 
the known non-microarray literature. 
 
Functional Enrichment 
The physiological pathways and biological processes implicated in 
IBD were determined through the functional enrichment of significant 
gene lists using DAVID [52, 53].  KEGG and BioCarta pathway enrichment 
of the differentially expressed gene lists as well as for gene lists identified 
by Noble et al. were determined using a p-value cutoff of 0.01.  KEGG 
color was used to generate enriched pathway images for a few selected 
enriched pathways [57].  Gene ontology (GO) biological process 
enrichment was performed using GO level 3 and a p-value cutoff of 5*10-5.  
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Identification Of Known Drug Targets 
 In order to identify significant genes that encode for known 
therapeutic targets, differentially expressed genes for both UC and CD 
(Union, table 2) were first converted to UNIPROT accession numbers 
using DAVID [52, 53] and then queried against a CHEMBL database [58].  
A histogram of the targeted differentially expressed genes is presented in 
Figure 5 along with their respective fold change in UC and CD and the 
number of therapeutics targeting each significant gene product. 
 
Gene-miRNA Interactome 
 Previous research has identified significant differentially expressed 
colonic miRNAs for both active Crohn’s Colitis and active Ulcerative 
Colitis relative to healthy controls [59-63].  Overall, there were found to be 
26 and 33 differentially expressed miRNA extracted from relevant 
literature for UC and CD respectively.  The corresponding validated 
miRNA targets were found using miRWalk [64].  Targeted mRNAs were 
then intersected with our list of differentially expressed genes for IBD to 
find interactions in which miRNAs were upregulated and targeted 
mRNAs were downregulated and vice versa.   
 
Disease Network Related To IBD 
 Statistically significant genes identified within this study were 
queried against the Genetic Association Database (GAD) to find 
associations of identified genes with other MeSH disease terms as 
annotated within published, peer reviewed genetic association studies 
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such as genome wide association studies (GWAS) [27].  The disease list 
was then further limited to include only those MeSH disease terms with 
the parent term “Autoimmune Diseases” in order to see linkages between 
differentially expressed genes within IBD and autoimmune disorders.  
The node size shown in the resulting network diagram is proportional to 
the degree of edges associated with each node.   
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2.4 RESULTS 
In this study we integrated microarray data obtained from multiple 
laboratories (Table 1a) along with other publicly available data and 
various knowledge bases to better define the transcriptional regulation of 
UC and CD and discover genetic commonalities with other diseases. Each 
unique patient sample was hybridized onto the Affymetrix Human 
Genome U133 Plus 2.0 GeneChip® Array platform, which contains 54,675 
oligonucleotide probes, covering over 47,000 human transcripts mapped 
onto 17,778 NCBI Entrez gene IDs [46]. These samples were merged into 
one dataset and normalized together prior to subsequent analysis to 
reduce laboratory specific noise and increase statistical power. Figure 1 
shows the sample clustering based upon the principal components, which 
account for 82% of the variance within the dataset.  Significant genes were 
identified using both SAM and RP (Table 1b) methods.  PCA plots were 
generated using the Matlab code presented in Appendix A.  The 
significant gene lists were then intersected, resulting in 1229 upregulated 
and 828 downregulated UC/HC genes, 1050 upregulated and 539 
downregulated CD/HC genes (Table 1b).  From these four lists, 
significant genes common to both UC and CD (common genes) and 
exclusive to either UC or CD (exclusive genes) were identified for each 
phenotype by finding the intersection and unique elements of each list.  
The resulting six gene lists were then used for subsequent analysis.  The 
top 200 up- and down-regulated gene lists for UC/HC and CD/HC 
comparisons are provided as appendices E-D. Table 2 shows the top 40 
genes present within each of the six comparisons, as ranked by fold 
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change. Since mucosal tissue is a composite, multiple cell types 
(enterocytes and inflammatory cells) contribute to the altered regulation of 
genes in these lists and provide a system level perspective of 
transcriptional regulation.   
 
 
Figure 1.  Principal component scatter plot of IBD phenotypes.  The ellipse 
was constructed around the centroid of each data cluster with the 
semimajor and semiminor axis are equal to two standard deviations of the 
data in x and y respectively 
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1a) 
GEO Accession # PMID HC UC CD 
 
Total 
GSE9452 19177426 5 8 0 
 
13 
GSE9686 18069684 8 5 11 
 
24 
GSE10191 18981162 11 8 0 
 
19 
GSE10616 18758464 11 10 32 
 
53 
GSE13367 19834973 10 8 0 
 
18 
GSE16879 19956723 6 24 19 
 
49 
Subtotal 
 
51 63 62 
 
176 
Duplicates 
 
19 13 11 
 
43 
Outliers 
 
3 2 10 
 
15 
Total 
 
29 48 41 
 
118 
       1b) 
Microarray Data Analysis 
  UC/HC CD/HC 
SAM Upregulated 1262 1063 
SAM Downregulated 828 539 
   RP Upregulated 1315 1237 
RP Downregulated 1044 867 
   SAM ∩ RP Upregulated 1229 1050 
SAM ∩ RP Downregulated 828 539 
   Exclusive Up 264 85 
Exclusive Down 349 60 
   Common Up 965 
Common Down 479 
   Union 2202 
 
Table 1.  An Overview of the microarray datasets used in the study. Table 
1a presents for each dataset the corresponding NCBI GEO accession 
number and the PubMed citation ID (PMID) as well as the numbers of 
HC, UC, and CD samples in each dataset. Table 1b is summary of results 
of the microarray data analysis. 
Significant genes in UC and CD 
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 The Table 2A shows nearly 40 fold upregulation of pancreatic 
cancer associated [65] regenerating islet-derived growth factor genes 
REG1A and REG1B as the most highly upregulated genes in both 
phenotypes of IBD.  REG1A is a biomarker for celiac disease [66] and was 
also linked to beta cell generation and damage in type I diabetes [67]. 
Moreover, REG1A and REG1B are known to induce CXCL6 expression in 
cancer [68]. Consistent with this observation, CXCL6 is also highly 
upregulated in our list.  Approximately 20 percent of the top 40 commonly 
upregulated genes in IBD with highest fold rank are CXC chemokines 
involved in inflammation, including CXCL13, IL8, CXCL6, CXCL11, 
CXCL9, and CXCL5. The top chemokine in this list, CXCL13 promotes the 
migration of B lymphocytes to the tissue and is associated in the literature 
with systemic lupus [69], prostate cancer [70], and rheumatoid arthritis 
[71]. The second most highly expressed chemokine in IBD is IL8 (CXCL8), 
one of the major mediators of the inflammatory response. IL8 functions as 
a chemoattractant, and is also a potent angiogenic factor. The third most 
highly upregulated gene in our list, S100A8, codes a soluble IBD 
biomarker protein calprotectin [72-75]. Altered expression of this protein 
is also linked to cystic fibrosis. [76]. Other genes involved in inflammatory 
processes such as CHI3L1, ANXA1, TNIP3, BCL2A are also highly 
upregulated in both phenotypes of IBD. The matrix metalloproteinase 
(MMP) family proteins are abundant among the top forty most highly 
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2a) 
Significant Genes Common to UC and CD 
Upregulated 
 
Downregulated 
Gene UC pval CD pval UC FC CD FC 
 
Gene UC pval CD pval UC FC CD FC 
REG1A 2.2E-04 3.5E-04 50.7 46.3 
 
CLDN8 4.0E-04 8.0E-07 -22.5 -9.0 
REG1B 1.5E-05 9.9E-05 26.6 40.3 
 
OSTALPHA 1.5E-05 4.2E-08 -9.6 -7.5 
S100A8 3.1E-04 2.5E-04 35.2 26.5 
 
GUCA2B 7.9E-04 3.3E-04 -7.9 -5.3 
MMP3 3.0E-04 2.3E-04 22.6 19.1 
 
SLC16A9 5.0E-04 9.7E-04 -6.5 -6.0 
CHI3L1 4.5E-04 6.1E-04 19.1 15.7 
 
MT1M 4.7E-05 7.6E-08 -7.5 -4.9 
MMP1 5.7E-05 2.9E-05 17.8 16.6 
 
CA1 2.9E-04 4.7E-05 -8.3 -2.5 
IDO1 4.0E-04 3.9E-04 12.1 12.4 
 
GHR 3.2E-04 3.8E-06 -6.6 -3.9 
MMP12 3.9E-04 1.5E-04 13.1 10.1 
 
SLC30A10 4.9E-04 2.2E-04 -5.9 -4.5 
CXCL13 1.0E-05 1.6E-06 11.4 10.8 
 
ADH1C 5.0E-04 1.3E-07 -6.8 -2.8 
FCGR3B 3.2E-04 2.1E-04 11.1 10.2 
 
VLDLR 9.1E-04 9.7E-04 -4.8 -4.5 
IL8 1.2E-04 3.4E-05 11.1 9.1 
 
ANPEP 7.6E-06 4.4E-08 -5.1 -4.1 
CXCL6 1.0E-04 3.7E-05 9.3 8.5 
 
MEP1B 6.2E-07 2.1E-06 -5.0 -3.8 
PI3 5.1E-04 2.8E-05 11.5 5.9 
 
SLC3A1 8.4E-05 1.5E-05 -4.9 -3.8 
ANXA1 6.8E-04 3.5E-05 11.2 5.3 
 
HSD17B2 5.6E-04 9.0E-04 -4.2 -4.2 
MMP10 6.0E-04 3.6E-04 9.6 6.3 
 
CNTN3 5.9E-04 2.1E-06 -5.6 -2.5 
TNIP3 5.0E-04 1.7E-04 10.3 5.7 
 
BEST4 1.6E-04 1.3E-07 -5.1 -2.8 
REG4 8.6E-04 4.7E-05 9.9 5.9 
 
PRAP1 5.2E-05 8.2E-05 -4.0 -3.9 
DEFA6 2.0E-05 3.3E-04 5.8 9.8 
 
SLC16A1 4.6E-04 3.7E-04 -4.2 -3.7 
IGHV1-69 6.1E-04 2.4E-05 9.6 4.4 
 
PNLIPRP2 9.1E-08 7.0E-05 -4.9 -3.0 
IGKV4-1 1.5E-04 2.6E-05 8.3 5.7 
 
GBA3 1.7E-04 9.2E-05 -5.4 -2.3 
MMP7 9.3E-04 5.6E-05 8.7 4.6 
 
NPY1R 7.5E-05 2.8E-06 -4.8 -2.8 
BCL2A1 3.7E-05 3.7E-05 6.2 7.1 
 
UGT1A7 1.2E-04 9.5E-08 -4.6 -3.0 
LOC651536 5.3E-05 1.3E-05 6.8 6.2 
 
PTPRR 2.9E-05 6.8E-05 -3.5 -3.8 
SERPINB5 2.5E-04 3.9E-08 8.6 4.3 
 
MS4A12 3.7E-06 1.3E-07 -3.9 -3.3 
CXCL11 1.3E-05 3.2E-07 6.4 6.3 
 
CD177 7.6E-05 4.2E-08 -4.0 -3.1 
IL1B 5.1E-04 5.3E-04 6.1 6.5 
 
MT1G 9.3E-05 7.1E-08 -4.1 -2.9 
C4ORF7 1.1E-07 2.7E-07 6.8 5.7 
 
CWH43 3.4E-04 7.5E-06 -4.8 -2.2 
SPINK4 4.2E-04 9.7E-05 6.9 5.2 
 
OSTBETA 3.7E-04 1.0E-05 -3.9 -2.9 
DMBT1 6.4E-05 1.2E-05 6.4 5.7 
 
PITX2 9.4E-06 1.1E-05 -3.3 -3.4 
IGHV3-11 1.1E-05 1.1E-04 5.0 6.6 
 
MT1X 5.2E-05 3.2E-05 -3.4 -3.3 
CTHRC1 9.7E-05 1.5E-05 6.1 5.4 
 
TRHDE 1.0E-04 3.0E-07 -4.0 -2.6 
LY96 3.1E-04 1.6E-04 6.1 5.3 
 
SLC17A4 3.2E-04 4.5E-05 -3.8 -2.8 
MNDA 5.5E-05 5.0E-06 5.8 5.6 
 
PKIB 6.8E-04 6.1E-09 -4.0 -2.5 
CXCL9 1.1E-06 3.5E-07 4.7 6.5 
 
C10ORF116 5.3E-04 1.6E-04 -3.7 -2.8 
C2CD4A 2.3E-04 1.6E-04 6.3 4.8 
 
CA7 2.4E-04 7.7E-06 -3.7 -2.7 
IGLV3-1 1.4E-04 9.2E-07 7.6 3.4 
 
MT1F 1.3E-04 1.2E-06 -3.5 -2.8 
SELL 1.9E-05 2.6E-06 5.6 5.2 
 
FLJ32063 8.2E-04 4.1E-08 -4.0 -2.3 
TNC 1.5E-04 4.8E-06 6.4 4.4 
 
CDKN2B 7.8E-04 7.6E-04 -3.4 -2.8 
CXCL5 2.2E-06 1.0E-06 5.4 5.3 
 
EXPH5 5.9E-04 6.2E-08 -4.0 -2.3 
HLA-DQB1 7.2E-04 3.4E-04 5.5 5.2 
 
MEP1A 6.8E-04 1.2E-04 -3.4 -2.8 
 
Table 2: Microarray gene signatures obtained from microarray analysis of 
IBD patients. Table 2a shows the top 40 significantly genes common in 
UC/HC and CD/HC  comparisons ranked by average fold change (FC) 
and Table 2b presents the top 40 genes uniquely expressed in either UC or 
CD. 
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2b) 
Ulcerative Colitis 
 
Crohn's Disease 
Exclusive Upregulated 
 
Exclusive Downregulated 
 
Exclusive Upregulated 
 
Exclusive Downregulated 
Gene Pval FC 
 
Gene Pval FC 
 
Gene Pval FC 
 
Gene P-Value FC 
DEFA5 2.2E-04 20.8 
 
NR1H4 1.0E-06 -3.2 
 
DUOX2 2.9E-04 12.1 
 
AQP8 7.9E-04 -12.0 
LCN2 9.1E-04 15.5 
 
RETSAT 9.2E-04 -2.4 
 
DUOXA2 8.0E-04 6.2 
 
PCK1 1.1E-04 -6.9 
UBD 8.1E-04 9.1 
 
ACVR1C 5.6E-05 -2.4 
 
TIMP1 1.0E-03 5.5 
 
UGT2A3 1.4E-05 -5.8 
SERPINB7 5.7E-07 4.7 
 
EYA2 5.7E-08 -2.3 
 
CD55 8.7E-04 4.2 
 
LOC10050678
2 
4.4E-04 -5.2 
CD74 5.5E-04 4.1 
 
PTPRO 4.9E-07 -2.3 
 
TCN1 6.7E-05 4.1 
 
GUCA2A 5.3E-05 -4.8 
ASRGL1 7.8E-04 3.1 
 
HOXA5 1.1E-05 -2.2 
 
VNN1 5.5E-08 3.5 
 
LAMA1 3.8E-04 -3.9 
TFF1 1.3E-05 2.5 
 
SGK223 4.5E-04 -2.1 
 
FKBP11 9.9E-04 3.3 
 
SLC26A2 2.3E-08 -3.7 
DSG3 6.5E-08 2.5 
 
MST1P9 1.5E-04 -2.1 
 
PDZK1IP1 2.2E-05 3.1 
 
CHP2 3.3E-05 -3.5 
SLC6A20 3.1E-05 2.4 
 
ZG16 1.9E-07 -2.1 
 
DUSP4 3.2E-08 2.1 
 
APOBEC3B 5.0E-04 -3.4 
PIM3 8.3E-04 2.3 
 
LOC283070 3.8E-05 -2.1 
 
ARNTL2 1.6E-04 2.1 
 
TUBAL3 2.9E-04 -3.2 
SERPINB3 1.8E-05 2.3 
 
HRCT1 7.8E-07 -2.0 
 
ABI3BP 6.5E-06 2.0 
 
PHLPP2 8.1E-04 -3.0 
POSTN 1.1E-05 2.2 
 
LOC100128822 5.7E-05 -2.0 
 
FPR2 3.1E-07 2.0 
 
RUNDC3B 6.9E-04 -3.0 
KLK10 1.1E-05 2.2 
 
LGALS2 3.3E-06 -2.0 
 
IFNG 1.8E-05 1.9 
 
DHRS11 3.4E-05 -2.7 
SLCO1B3 1.3E-08 2.2 
 
ZBTB10 2.0E-07 -2.0 
 
P2RY14 4.9E-04 1.8 
 
LRRC19 2.2E-05 -2.3 
CTSE 1.3E-07 2.1 
 
CHPT1 9.4E-04 -2.0 
 
GOLGA8B 6.9E-04 1.7 
 
CHRNA1 4.0E-04 -2.1 
IGHV3-11 1.3E-05 2.1 
 
MS4A8B 3.5E-07 -1.9 
 
RGL1 1.1E-07 1.7 
 
LOC10028809
2 
3.2E-06 -2.1 
IGLV4-60 9.9E-08 2.1 
 
FLJ32810 1.4E-05 -1.9 
 
CLEC4E 6.3E-07 1.7 
 
HIGD1D 4.0E-04 -2.1 
SERPINB4 1.3E-04 2.1 
 
NDRG2 2.5E-04 -1.9 
 
PTPN13 1.3E-04 1.7 
 
SEMA5A 2.5E-04 -2.1 
TESC 1.0E-04 2.1 
 
NEDD4L 1.1E-05 -1.9 
 
FYB 3.4E-07 1.7 
 
WSCD1 5.4E-04 -2.1 
VIP 1.6E-04 2.1 
 
TCEA3 2.9E-05 -1.9 
 
HCP5 3.3E-06 1.7 
 
SNX30 1.9E-04 -2.0 
CCL21 2.7E-05 2.0 
 
PRR5L 7.6E-05 -1.9 
 
CYP27B1 1.2E-06 1.7 
 
SLC39A5 2.8E-04 -2.0 
HBEGF 2.0E-06 2.0 
 
IL1R2 1.3E-06 -1.9 
 
GSDMB 3.1E-06 1.7 
 
PXMP2 5.4E-04 -2.0 
PMEPA1 2.5E-05 2.0 
 
SPHAR 1.2E-04 -1.9 
 
NLRC3 3.2E-04 1.6 
 
SH3BGRL2 1.6E-04 -1.9 
SPRR1B 4.9E-05 2.0 
 
RNF125 7.5E-06 -1.9 
 
TFEC 6.9E-07 1.6 
 
CNNM2 1.3E-04 -1.9 
ADAM9 2.1E-05 2.0 
 
FMO4 1.6E-04 -1.9 
 
ENTPD3 1.9E-06 1.6 
 
PRDX6 4.6E-04 -1.8 
SAA4 5.9E-05 1.9 
 
TP53TG1 4.8E-05 -1.9 
 
SLFN12 1.0E-07 1.6 
 
CIDEC 9.3E-06 -1.8 
ANXA3 8.5E-08 1.9 
 
PSD3 6.2E-05 -1.8 
 
DOCK10 6.3E-05 1.6 
 
TNFRSF21 3.2E-06 -1.8 
OSMR 4.3E-06 1.9 
 
AMT 2.3E-04 -1.8 
 
MAGEH1 8.5E-06 1.6 
 
NUAK2 2.4E-04 -1.8 
NMU 3.4E-07 1.9 
 
KLHL34 2.6E-05 -1.8 
 
IL7 2.1E-04 1.6 
 
USP30 4.4E-04 -1.8 
KRT7 5.6E-06 1.9 
 
CFTR 1.1E-05 -1.8 
 
MRPS21 2.4E-04 1.6 
 
CDHR2 2.8E-07 -1.8 
TM4SF1 2.3E-04 1.9 
 
CYP2J2 7.0E-06 -1.8 
 
LPAR6 8.8E-08 1.6 
 
HAS3 3.7E-06 -1.7 
XDH 2.1E-06 1.9 
 
NRARP 1.1E-05 -1.8 
 
TNF 2.9E-07 1.6 
 
PPP2R3A 6.4E-05 -1.7 
RND1 1.3E-07 1.9 
 
RPS6KA6 1.9E-04 -1.8 
 
LOC73142
4 
3.1E-05 1.6 
 
NT5E 1.5E-06 -1.7 
SLC40A1 6.4E-06 1.8 
 
FAM162A 6.8E-04 -1.8 
 
IL18RAP 9.5E-05 1.6 
 
PRSS23 1.7E-05 -1.6 
PTP4A3 1.4E-05 1.8 
 
METTL7A 1.2E-05 -1.8 
 
BEX5 9.4E-04 1.6 
 
C17ORF97 4.5E-06 -1.6 
SLPI 5.0E-06 1.8 
 
TLE2 6.0E-07 -1.8 
 
IL2RA 6.6E-08 1.6 
 
SDCBP2 3.1E-07 -1.6 
MIF 3.5E-05 1.8 
 
CFDP1 1.9E-04 -1.8 
 
PVRIG 1.8E-05 1.6 
 
POF1B 3.4E-05 -1.6 
GJB3 1.1E-07 1.8 
 
NIPSNAP3A 1.1E-04 -1.8 
 
SLC16A6 4.5E-05 1.6 
 
C20ORF54 9.6E-05 -1.6 
ALDH1A2 4.4E-06 1.8 
 
OTC 3.2E-07 -1.8 
 
PGCP 3.7E-08 1.6 
 
PRSS3 4.9E-07 -1.6 
LRP8 3.7E-05 1.8 
 
TSHZ1 1.5E-05 -1.8 
 
SPG20 5.9E-08 1.6 
 
MIER1 1.0E-04 -1.6 
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upregulated genes in IBD. MMP proteins partake in the breakdown of 
extracellular matrix in biological processes and in disease events, such as 
arthritis and metastasis [75, 77, 78]. Genes involved in the host defense, 
antimicrobial enzyme IDO1, exosome component PI3, and defensin 
DEFA6, were found to be highly expressed in both IBD phenotypes. Thus, 
top upregulated genes in IBD relate to processes such as diabetogenesis, 
innate immunity, chemokine-induced inflammation and adapted 
immunity, and breaking down of the extracellular matrix.  
 The gene in IBD with the most diminished expression is CLDN8, 
encoding a claudin tight junction protein. Its expression is downregulated 
in colorectal and renal carcinoma [79]. Diminished expression of CLDN8 
in IBD suggests a breakdown in the physical barrier preventing solutes 
and water from passing freely between epithelial cell sheets. Several other 
downregulated genes in the list are also associated with the control of 
water and ion flux in intestinal epithelia: the solute transporter genes 
SLC16A9, SLC16A1, SLC30A10 and SLC3A1; and the organic solute 
transporter OSTα. These genes are all markers of enterocyte differentiation 
and indicate that IBD is associated with alterations in differentiated cell 
function.  
 Differentially expressed genes unique to each phenotype were also 
identified for both UC and CD (Table 2b). The most upregulated gene 
exclusive to UC codes for the antimicrobial defensin protein DEFA5. 
Defensins are abundant in the epithelia of mucosal surfaces of the 
intestine, respiratory tract, urinary tract, and vagina [80].  Other genes, 
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which are highly expressed in UC but not in CD include protease and 
protease inhibitors (SERPINB3, SERPINB4, SERPINB7, ASRGL1, KLK10, 
CTSE, and ADAM9), transporter genes (SLC6A2, SLCO1B3, ABCA12); 
anti-inflammatory ANXA1; and the zinc binding glycoprotein AZGP1P1.  
Several immunoglobulin heavy and light chain variable region encoding 
genes such as IGHV1-46, IGHV1-69, IGHV2-5, IGLV3-25, IGHV3-73 and 
IGHV4-34 are also highly expressed in UC but not in CD. Genes with high 
expression in CD but not in UC include oxireductase DUOX2 and 
DUOXA2, the protease TIMP1, and the abundant neutrophil granulocyte 
protein TCN1. Whether such genes can be used as biomarkers 
differentiating UC from CD will require further investigation using 
standard assays in stool samples and rectal swaps.  
 The genes with diminished expression in CD but with typical 
expression in UC include the water channel protein AQP8, also in the bile 
secretion pathway.  This protein facilitates the diffusion of GPX2, a radical 
scavenger. The downregulation of Aqp8 in IBD mouse models was related 
to defending against severe oxidative stress [81]. Other genes 
downregulated expclusively in UC code for the cytosolic enzyme PCK1 
involved in the regulation of gluconeogenesis; the basement membrane 
protein LAMA1; and the two solute transporters SLC26A2 and SLC39A5.  
Although downregulated genes are not optimal as biomarkers, 
nevertheless, when statistically enriched on signaling pathways, these 
genes can point to the molecular mechanisms of deregulation in IBD.  The 
gene NR1H4 (FXR) is diminished in expression in UC (but not in CD). 
This gene codes a bile-dependent transcription factor in the bile secretion 
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pathway. Its downregulation may be responsible for the presence of 
excessive lipids in the stools of individuals with UC. Other genes poorly 
expressed in UC include those coding TGFB receptor ACVR1C; tyrosine 
phosphatase PTPRO, a tumor suppressor; and IL1R2, a cytokine receptor 
that belongs to the interleukin 1 receptor family. 
 
Validation Of Microarray Predictions Using Independent Data 
 We have evaluated the statistical significance of our gene lists in 
comparison to other published gene lists derived from microarray studies 
not used in our analysis since these datasets were generated on a different 
platform: Agilent-012391 Whole Human Genome Oligo Microarray 
G4112A.  Comparison of our gene lists to previously published significant 
gene lists provided by Noble et al. [32, 33] showed a high degree of 
overlap with significant p-values for each comparison based upon a 
hypergeometric test (Table 3a). The results shown in Table 3a point to a 
high degree of match between upregulated gene lists obtained using 
different platforms. The intersection for downregulated genes is smaller 
although still statistically significant.  
We have also determined the enrichment of our top 200 
significantly altered gene lists for both phenotypes (Appendices E-D) 
within relevant non-microarray literature.  Table 3b shows that our 
predicted genes are highly statistically enriched within cancer literature, 
establishing a possible link between IBD and colorectal cancer.  The match 
between our IBD upregulated gene list and non-microarray IBD literature 
is also good, with significant p values. The match between IBD research 
 24 
literature and our downregulated gene lists lead to higher but still 
significant p values; a trend also observed when directly comparing our 
significant gene lists with those obtained by Noble et al 
3a) 
Cutoffs HC/UC UP HC/UC DOWN HC/CD 
UP 
HC/CD 
DOWN top 50 1.30E-11 3.00E-03 6.95E-14 1.89E-04 
top 100 < E-50 8.32E-03 < E-50 9.80E-04 
top 200 4.44E-16 1.74E-02 < E-50 3.00E-03 
top 500 2.00E-14 3.70E-04 < E-50 3.00E-02 
All 3.50E-14 1.00E-04 < E-50 3.00E-02 
 
3b) 
Search Terms List Name P-value List Articles Search 
Articles 
Article 
Overlap cancer NOT microarray UC_DOWN 2.62E-03 19392 946 78 
cancer NOT microarray UC_UP 2.62E-09 68801 946 279 
cancer NOT microarray CD_UP 2.61E-10 65790 946 298 
cancer NOT microarray CD_DOWN 3.11E-04 15443 946 69 
crohn's disease NOT microarray UC_UP 2.62E-09 68801 946 279 
crohn's disease NOT microarray CD_UP 2.61E-10 65790 946 298 
crohn's disease NOT microarray UC_DOWN 2.62E-03 19392 946 78 
crohn's disease NOT microarray CD_DOWN 3.11E-04 15443 946 69 
ulcerative colitis NOT microarray CD_UP 2.61E-10 65790 946 298 
ulcerative colitis NOT microarray UC_DOWN 2.62E-03 19392 946 78 
ulcerative colitis NOT microarray UC_UP 2.62E-09 68801 946 279 
ulcerative colitis NOT microarray CD_DOWN 3.11E-04 15443 946 69 
 
Table 3: Comparison of significant UC and CD transcriptional enrichment 
signatures to independent data. a) Statistics for the intersection of the 
results from our study with Noble et al. [32, 33].  b) Literature enrichment 
using the top 200 genes from each of the six significant gene lists (up UC, 
down UC, up CD, down CD, common up, and common down).  
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Activated Pathways And Processes In IBD 
 Commonly upregulated pathways involved in the pathogenesis of 
IBD (CD and UC) include cytokine-cytokine interaction, chemokine 
signaling, intestinal immune network for IgA production, adhesion and 
diabedesis of lymphocytes and granulocytes, cell adhesion molecules, 
complement and coagulation cascades (Table 4). Other upregulated 
pathways included the NOD-like receptor signaling pathway and the 
Toll-like Receptor pathway. NOD-like receptor pathway shown in Figure 
2a relates bacterial effects on the cell surface (bacterial peptidglycans, pore 
forming toxins, and other bacterial secretion systems) to expression 
changes of chemokines and cytokines, which subsequently activate innate 
and adapted immunity. The nodes upregulated in both UC and CD were 
shown in yellow, those upregulated in CD, and UC, only shown in red, 
and brown, respectively. The Toll-like pathway shown in Figure 2b relates 
the recognition of conserved microbial components by Toll-like receptors 
to subsequent cellular events, which ultimately lead to inflammation and 
activation of sentinel immune cells. The genes CASP1, CASP5 and CARD6 
are highly upregulated in both UC and CD along the NOD receptor 
signaling.  The genes TLR1 and TLR2 are highly expressed in 
lipopolysaccharide (LPS) interactions in both phenotypes in the Toll-like 
pathway.  The biological processes associated with these pathways are 
also significantly enriched within GO biological processes including 
immune defense response, cellular response to wounding, leukocyte 
activation, cell proliferation, and response to molecules of bacterial origin 
amongst others (Figure 3).  
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4a) 
Pathway UC UP CD UP Noble UC UP Noble CD UP 
Natural killer cell mediated cytotoxicity 
 
9.0E-03 
 
3.5E-03 
Lck and Fyn tyrosine kinases in TCR Activation 8.2E-03 
   The Co-Stimulatory T-cell Activation 6.9E-03 
   Prion diseases 4.5E-03 8.4E-03 
  Antigen Processing and Presentation 2.1E-03 6.1E-03 
 
1.8E-08 
Antigen processing and presentation 2.1E-03 6.1E-03 
 
1.8E-08 
NOD-like receptor signaling pathway 4.7E-03 6.0E-04 
  IL-10 Anti-inflammatory Signaling Pathway 
 
1.8E-03 
  Toll-like receptor signaling pathway 1.7E-03 4.9E-04 
  T Cytotoxic Cell Surface Molecules 2.4E-04 1.3E-03 
  T Helper Cell Surface Molecules 2.4E-04 1.3E-03 
  Autoimmune thyroid disease 5.1E-04 8.2E-04 
 
6.6E-08 
Focal adhesion 6.4E-04 
   B cell receptor signaling pathway 2.1E-04 6.2E-04 
  Asthma 5.5E-04 4.0E-05 5.5E-04 2.7E-04 
Primary immunodeficiency 5.3E-05 1.1E-04 
  Systemic lupus erythematosus 1.5E-04 2.5E-06 
 
4.8E-03 
Viral myocarditis 1.2E-04 8.3E-06 7.3E-03 6.3E-08 
Type I diabetes mellitus 2.7E-05 1.4E-06 1.6E-03 4.9E-10 
Allograft rejection 2.6E-05 1.3E-06 1.0E-03 1.1E-10 
local acute inflammatory response 2.1E-05 7.3E-07 
  ECM-receptor interaction 3.3E-07 1.4E-05 
  B Lymphocyte Cell Surface Molecules 7.8E-06 3.9E-06 
  Chemokine signaling pathway 1.8E-06 8.7E-06 3.7E-03 2.0E-04 
Adhesion Molecules on Lymphocyte 3.9E-06 2.1E-06 
  Neutrophil and Its Surface Molecules 3.9E-06 2.1E-06 
  Adhesion and Diapedesis of Granulocytes 4.1E-06 6.2E-09 3.1E-03 8.4E-04 
Hematopoietic cell lineage 3.3E-06 2.7E-08 
  Leukocyte transendothelial migration 4.3E-07 2.3E-06 
  Graft-versus-host disease 9.4E-07 3.2E-08 1.3E-03 2.4E-10 
Complement and coagulation cascades 1.8E-07 5.0E-09 
  Intestinal immune network for IgA production 1.1E-07 2.3E-08 
  Monocyte and its Surface Molecules 7.4E-08 3.3E-08 
  Adhesion and Diapedesis of Lymphocytes 7.8E-09 8.7E-08 
  Cytokine-cytokine receptor interaction 6.2E-10 1.1E-10 5.2E-04 5.6E-04 
Cell adhesion molecules (CAMs) 6.5E-12 3.0E-11 
 
1.5E-06 
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4b) 
Pathway UC DOWN CD DOWN 
Arginine and proline metabolism 7.0E-03 
 Tryptophan metabolism 5.4E-03 
 Nuclear Receptors in Lipid Metabolism and Toxicity 5.1E-03 
 Drug metabolism 7.0E-03 8.2E-04 
Mitochondrial Carnitine Palmitoyltransferase (CPT) System 3.7E-04 6.0E-03 
Starch and sucrose metabolism 
 
2.2E-03 
Selenoamino acid metabolism 1.7E-03 
 Metabolism of xenobiotics by cytochrome P450 
 
6.6E-04 
Valine, leucine and isoleucine degradation 3.3E-07 4.8E-04 
Nitrogen metabolism 1.9E-04 7.0E-05 
PPAR signaling pathway 4.9E-05 1.1E-05 
Propanoate metabolism 4.1E-06 
 Butanoate metabolism 4.1E-06 
 Fatty acid metabolism 4.3E-09 3.8E-07 
 
Table 4. KEGG and BioCarta cellular pathways statistically enriched by 
differentially expressed genes in UC/CD and CD/HC comparisons. 
Pathways enriched by upregulated and downregulated genes are shown 
in a) and b), respectively, along with associated p-values.  Bolded 
pathways are involved in the pathogenesis of other diseases. 
 
 Drug metabolism pathway is downregulated in both UC and CD 
(Table 4).  Drug metabolism genes ADH1C, ADH6, CYP2B6, FMO5, 
GSTA1, GSTM4, MAOA, UGT1A7, UGT2A3 are all downregulated in IBD 
compared to healthy controls.  A highly related pathway, the metabolism 
of xenebiotics by cytochrome p450 is downregulated in CD. The detox 
enzymes with diminished expression in this pathway include the drug 
metabolism genes ADH1C, ADH6, UGT1A7, UGT2A3 as well as genes 
CYP2B6 and CYP2S1 that code enzymes to metabolize anti-cancer drugs, 
gene EPHX1 for epoxide enzyme, and genes GSTA1 and GSTM4 coding 
enzymes involved in the detoxification of electrophilic compounds, 
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including carcinogens, therapeutic drugs, environmental toxins and 
products of oxidative stress. 
 Table 4 shows that PPAR signaling as well as nitrogen metabolism 
are diminished in IBD. Genes downregulated in the nitrogen metabilism 
pathway consist of zinc metalloenzymes that catalyze the reversible 
hydration of carbon dioxide (CA1, CA2, CA4, CA7), cytoplasmic enzyme 
CTH, and the K-type mitochondrial glutaminase GLS.  The PPAR 
signaling pathway clearly demonstrates the downregulation of the 
transcription factor PPARG within adipocytes leading to the 
downregulation of lipid metabolism through a variety of interactions 
(Figure 2c).  The attenuated metabolism of lipids is also represented 
within the enriched GO biological processes (Figure 3).  
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2a) 
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2b) 
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2c) 
 Figure 2.  Examples of cellular pathways statistically enriched with significantly upregulated genes in IBD. Figure 2a 
shows Nod-like receptor signaling pathway, 2b Toll-like receptor signaling pathway, and 2c the PPAR signaling pathway. 
The nodes shown in brown, red, and yellow indicate significantly upregulated genes in UC/HC, CD/HC and (UC U 
CD)/HC comparisons, respectively. 
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Figure 3.   Gene Ontology biological processes (level 3) statistically enriched by 
significantly upregulated and downregulated genes for UC and CD. 
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Autoimmune Diseases Related To IBD 
A number of KEGG pathways related to other autoimmune 
diseases are identified in Table 4 as being statistically enriched with IBD 
genes including type 1 diabetes mellitus, systemic lupus erythematosus, 
autoimmune thyroid disease, and primary immunodeficiency. For this 
reason, we investigated the involvement of identified significant genes 
related to IBD and other autoimmune diseases using GAD. We found 280 
differentially expressed genes in IBD in our gene list known to be 
associated with 35 different autoimmune and IBD related MeSH disease 
terms through 918 unique associations in (Figure 4). The three largest 
disease nodes in Figure 4 (nodes with the highest connectivity to IBD 
genes) are type 1 diabetes mellitus, rheumatoid arthritis, and systemic 
lupus erythematosus.  The Matlab code used for GAD enrichment is 
presented in Appendix B.   
IBD genes found to be associated with autoimmune diseases 
include the upregulated leukocyte antigen genes HLA-DMB, HLA-DOB, 
HLA-DPB1, HLA-DQB1, HLA-DRB4, and HLA-F. In addition to the 
aforementioned genes common with IBD, lupus and IBD share central 
pattern recognition proteins such as C1QA, C1C1QB, C1QC, C1R, and 
C1S. Recent research implicated hereditary C1Q deficiency as associated 
with systemic lupus erythematosus and increased susceptibility to 
bacterial infections [82]. Other genes common to lupus include the ADA 
gene coding an enzyme deficiency of which causes immunodeficiency 
disease, and the genes FCGR2B, FCGR3B code for proteins regulating the 
antibody production by B cells 
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Figure 4.  Interactome map of autoimmune diseases. The map was obtained by 
projecting IBD significant gene list onto gene lists of autoimmune diseases 
(obtained from the Genetic Association Database).  Diseases are colored in green 
and genes are colored in pink.  The size of each node corresponds to the number 
of interactions with other nodes, with larger nodes having more interactions. 
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Identification Of Known Drug Targets With Altered Gene Expression In IBD 
 The significant gene lists were projected onto genes with UNIPROT 
accessions in ChEMBL, the database for bioactive drug-like small 
molecules [58]. Those genes with a minimum fold change of 2.0 are 
presented in Figure 5.  The top 200 significantly upregulated and 
downregualted genes for both UC and CD are presented in appendices E-
D.  The figure shows gene targets along with their respective fold change 
in UC and CD relative to HC. The majority of the small-molecule targeted 
genes encode cell surface receptors, oxidoreductase, G-protein coupled 
receptors, and kinases.  Among the drug targets with the largest fold 
change expression are MMP3, MMP1, IL-8, PLAU, PTGS2, and CXCR4. 
Drugs targeting MMP3 include nonspecific MMP inhibitor with poor 
performance in clinical trials [83]. Doxycycline, a tetracyclin antibiotic, is 
known to inhibit MMP activity, and is used clinically for the treatment of 
periodontal disease.  IL-8 is an antibody therapeutic target in 
inflammatory diseases [84] but with mixed results stemming from side 
effects. The small molecule drugs with activity on IL-8 include Diclofenac, 
Ibuprofen, Indomethacin, and Tolmetin. The drug target PTGS2 is known 
to play a role in promoting colon cancer [85].  Nonsteroidal anti-
inflammatory drugs targeting PTGS2 appear to inhibit the proliferation of 
cultured hepatocellular cancer cells [86]. CXCR4 is a receptor playing a 
role in immune system signaling between cells and is involved in the 
growth of tumors. It is a drug target in metastatic lung cancer [87]. These 
observations indicate the challenges of repositioning existing drugs 
targeting IBD genes with highly elevated expression. 
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Figure 5. IBD genes targeted by bioactive small molecules. The number of 
therapeutics targeting each gene is presented in parentheses next to the 
gene symbol on the y-axis. The fold change of each differentially 
expressed gene is also shown for both UC and CD. 
 
Drugs with activity on CXCR proteins include Ibuprofen, 
Naproxen, Indoprofen, and Ketoprofen.  Drug targets with negative fold 
changes include carbonic anhydrases CA1 and CA2, and PPARγ. Existing 
drugs such as Acetazolamide (Diamox), Methazolamide (Neptazane) lead 
to the inhibition of carbonic anhydrase and as such appear unsuitable for 
the treatment of IBD. PPARγ is another drug target with lower expression 
in IBD. This gene encodes a member of the peroxisome proliferator-
activated receptor subfamily of nuclear receptors regulating transcription 
of genes implicated in the pathology of numerous diseases including 
obesity, diabetes, atherosclerosis and cancer. Small drugs with activity 
against PPARγ including Fenofibrate, Pioglitazone, and others have found 
use in treating Type II diabetes.  Drug targeted genes VCAM1, ICAM1, 
ITGAL, TNF, and IL8 map into the acute inflammatory pathway whereas 
the leukocyte migration pathway contains drug targets VCAM1, ICAM1, 
ITK, ITGAL, CXCR4, MMP9, and MMP2. Combination therapies designed 
for IBD with existing drugs will be limited by the poor drug metabolism 
associated with this disease.   
 
 
 38 
Mirna - Gene Interactome 
 A total of 26 and 33 miRNA are known to be differentially 
expressed within active UC and CD respectively as compared to healthy 
controls [59-63].  Of these miRNA, 20 were shown to interact with 90 
significant genes for UC (Figure 6a) and 19 miRNA were shown to interact 
with 44 significant genes for CD (Figure 6b).  Gene interactions with 
miRNA in which both were either upregulated or downregulated were 
not considered for our analysis since these interactions defy the 
understood paradigm of miRNA-mRNA interactions [88].  We identified 9 
miRNA that are coexpressed within UC and CD including miR-126, miR-
126*, miR-127-3p, miR-155, miR-21, miR-29b, miR-31, miR-324-3p and 
miR-375.  Each miRNA is upregulated in both phenotypes except miR-375, 
which is reported to be downregulated in UC [60] and upregulated in CD 
[62].  There were found to be 17 and 8 genes within the network that are 
targets for bioactive small molecules for UC and CD respectively.  The 
figure indicates a widespread downregulation of significant genes due to 
the upregulation of several miRNA.   
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6a) 
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6b) 
 
Figure 6.  Micro-RNA – Transcript Interactome Map. The figure illustrates the possible regulation 
patterns of a subset of IBD significant genes by miRNA, significantly increased or decreased in UC 
(7a) and CD (7b).  The colors pink and blue indicate upregulated and downregulated nodes, 
respectively. The links shown in the figure indicates gene/miRNA pairings reported in the literature 
(not necessarily for IBD). The miRNA shown in the figure correspond to those significantly 
upregulated or downregulated in IBD.   
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2.5 DISCUSSION 
 Inflammatory bowel disease is a complex disorder involving 
commensal bacteria, multiple human cell types and a variety of cellular 
networks including those related to adaptive and innate immunity. Our 
integrated microarray analysis of inflamed human colonic mucosa 
captures the widespread genetic perturbations of IBD phenotypes as 
associated with a variety of cell types, pathways and biological processes; 
a system level perspective of transcriptional regulation attributable to the 
heterogeneous nature of colonic biopsy samples.  By combining raw 
microarray data from six independent studies, we were able to increase 
the statistical power of our analysis while minimizing lab specific bias and 
experimental noise.  A total of 118 unique patient samples were used 
including 48 UC, 41 CD and 29 healthy controls.  Differentially expressed 
miRNA obtained through literature curation were also incorporated into 
our analysis in order to investigate possible mechanisms of post 
transcriptional regulation through validated interactions with 
differentially expressed genes related to IBD [64].  Bioactive therapeutic 
small molecules targeting differentially expressed genes as well as gene 
involvement in other autoimmune diseases were also investigated to 
facilitate the identification of druggable pathways and therapeutic targets 
that may be candidates for a wide variety of related illnesses or existing 
therapeutics that may be repositioned for the treatment of IBD. 
Our analysis of microarray data showed as much as forty-fold 
increase in transcript number for some of the genes in IBD relative to 
healthy controls. The most upregulated gene in IBD is REG1A, coding a 
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protein typically secreted by the exocrine pancreas and associated with 
islet cell regeneration. A survey of the literature shows upregulated 
REG1A as associated with pancreatic cancer, celiac disease, and type I 
diabetes [65-67]. The top upregulated genes for IBD in our list were 
abundant with CXC chemokines involved in inflammation, and were 
previously linked to such diseases as lupus, prostate cancer, and 
rheumatoid arthritis [69-71]. The matrix metalloproteinase (MMP) family 
proteins are also abundant among the top forty most highly upregulated 
genes in IBD. MMP proteins were previously shown to be involved in 
arthritis and metastasis [89]. The third most highly upregulated gene in 
our list, S100A8, codes a soluble IBD biomarker protein calprotectin [72-
75]. High levels of expression of this protein is also linked to cystic fibrosis 
[76]. Commonly upregulated pathways in IBD included the previously 
recognized Toll-like and NOD-like receptor signaling pathways, cytokine-
cytokine interaction, and chemokine signaling. Cellular processes 
activated by IBD include immune defense response, cellular response to 
wounding, leukocyte activation, and regulations of immune response and 
cell proliferation as well as response to molecules of bacterial origin. Some 
of the pathways activated in IBD appear to be druggable such as the 
calcium signaling pathway, endocytosis, cytokine-cytokine receptor 
interaction and leukocyte transendothelial migration pathways. In our 
gene signatures, the genes UGT1A, HSD11B2, HSD17B2, HSD3B2, LCMT1 
are all significantly downregulated and are known to play a role in 
androgen and estrogen metabolism. The specific role sex hormones play 
in the pathology of IBD is yet to be explored extensively in the literature 
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[90] [91]. All these pathways contain at least 8 drug targets each, which are 
also significant genes in our healthy control to IBD comparison. 
 KEGG disease pathways enriched by IBD significantly upregulated 
genes included those with an autoimmune component, namely 
autoimmune thyroid disease, asthma, primary immunodeficiency, 
systemic lupus, viral myocardidatis, type I diabetes mellitus, autograft 
rejection, and the graft-vs-host disease.  Patients with IBD were previously 
associated with a higher prevalence of rheumatoid arthritis, lupus and 
hypothyroidism, with increased prevalence of asthma, eczema, allergic 
rhinitis and diabetes [92]. Moreover, literature also contains links with 
already recognized IBD associated diseases (cancer and malaria) and the 
diseases statistically enriched by our IBD genes cited above. A 
polymorphism in FCGR2B, an IBD significant gene, is associated with 
protection against malaria but susceptibility to systemic lupus 
erythematosus [93]. Histone deacetylase inhibitors are currently being 
harnessed as a potential treatment for malaria, systemic lupus 
erythematosus and a wide range of neurodegenerative conditions, and 
asthma [94]. In addition, the beneficial effects of malaria drugs have been 
recognized in the management of systemic lupus erythematosus and 
rheumatoid arthritis [95].  Add to these other examples listed in the results 
section, it appears that many of the top upregulated genes in IBD are also 
upregulated in autoimmune disorders. For this reason, we investigated 
the upregulated genes shared by IBD and other autoimmune diseases as 
possible drug targets by intersecting our gene list with the genes 
associated with specific diseases in the Genetic Association Database [27]. 
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The genes known as drug targets and upregulated in multiple 
autoimmune diseases provide clues for the multidimensional nature of 
IBD. For example, the ATP binding transporter gene ABCC1 – 
significantly upregulated in a number of diseases including, IBD, and 
rheumatoid arthritis, and is known to bind to HIV Tat protein – is targeted 
by drugs/supplements such as Abacavir, Tenovir, Nevirapin, and 
Quercetin, all with antiviral effects, as well as by the anticancer 
supplement Apigenin and the transplant rejection medicine Cyclosporine. 
Other significantly upregulated genes shared by rheumatoid arthritis and 
IBD include TLR8 (a target of the immune response modifier 
Amiquimod); MMP3 (a target of failed drug Marimastat); ICAM-1 
(targeted indirectly by cholesterol lowing Lovastatin); IL8 (targeted by 
Tolmetin and Ibuprofen); and IL2RA (targeted by Ascomysin and 
Budesonide, used for treating Crohn’s disease and asthma). The 
supplemental file associated with the present study presents a collection 
of drug target – drug – disease relationships relevant to IBD and other 
autoimmune diseases.  The intersection of IBD significant genes with 
known drug targets provides valuable information for possible 
repositioning of existing drugs in the treatment and management of IBD. 
The data on significantly altered miRNA expression in IBD, when 
integrated with literature and our significant gene lists, indicate a strong 
role for miRNA in the down regulation of genes in IBD. Increased 
expression of miR-16 has been shown in the literature to downregulate 
genes CNTN3, C1QTNF3, ACVR2A, and CYCS, while Let-7f-1 has been 
shown to downregulate CNTN3, ANPEP, NAAA, PDCD, UGDH, HSDL2, 
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and ACVR2A. These two microRNAs are highly expressed in UC and the 
genes shown are highly downregulated. Similarly, increased expression of 
mir-23b is linked to downregulation of PRAP1 in both CD and UC and 
increased miR-21 is associated with downregulated CTN3, PDK4, and 
PDCD genes in CD. The aforementioned proteins play roles in a multitude 
of events ranging from mitochandrian electron transport (CYCS), anti-
auto immune processes (PDCD), regulation of glucose metabolism 
(PDK4), small intestinal microvillar events (ANPEP), neurite outgrowth-
promoting activity (CNTN3), signaling through serine kinases (ACVR2A), 
and induction of glycosylation (UGDH). It is shown in figure 6 that CEBP 
is the most connected gene node for both UC and CD miRNA innervation.  
This gene is shown to be downregulated in the presence of upregulated 
miRNA.  CEBP is known to be upregulated in the presence of platelet 
activation factors (PAF) and endotoxins such as bacterial 
lipopolysaccharides (LPS) leading to an inflammatory response though 
the transcriptional regulation of pro-inflammatory cytokines and proteins 
[96].  The downregulation of this protein in our analysis indicates  
These results suggest the restorative potential of a micro RNA 
based therapies on IBD specific diminished biological processes.The 
results of our study can be put in context with mouse studies, 
emphasizing the effect of B lymphocytes on immunity and metabolism in 
the gut. A recent study in mice [97] showed that the lack of B cell 
immunity was associated with upregulation of genes involved in other 
aspects of immune defense, inflammatory, and interferon-inducible 
responses. The gene list provided in Supplemental Table 1 of Shulzhenko 
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et al. [97] contains 14 significant genes from our CD/HC and UC/HC 
comparisons. Among these genes, DUOX2 and DUOXA2, involved in 
synthesis of hydrogen peroxide, are highly upregulated in CD. The genes 
significantly upregulated in both UC and CD with fold changes greater 
than 2.5 include CFI, which codes complement factor I. This protein 
proteins is involved in the destruction of foreign invaders (such as 
bacteria and viruses), trigger inflammation, and remove debris from cells 
and tissues.  Also upregulated in protein deficient mouse and human IBD 
are interferon-induced proteins IFIT3, which potentiates antiviral 
signaling, and IFITM1, with antiproliferative effects; and chemokine 
CXCL9, thought to be involved in T cell trafficking. The genes 
downregulated in B cell deficient mice and in CD and UC consist of 
CYP27A1 in the in synthesis of cholesterol, steroids, and other lipids. and 
EDN3, essential for generation of enteric neurons and was previously 
linked to Hirschsprung disease and Waardenberg syndrome. NR1H4 is a 
gene significantly downregulated both in B cell defficient mouse and in 
UC. It encodes a ligand-activated transcription factor, involved in bile acid 
synthesis and transport. These observations suggest the role of ineffective 
B-cell mediated immunity in IBD, possibly causing activation of innate 
immunity and a reduction in ability to process lipids.  
 In conclusion, this study presents a portrayal of the molecular 
rewiring of the human gut mucosa altered by IBD. Our statistical 
analysis reveals cellular processes altered in IBD, with focus on 
biomarker selection, and possible repositioning of currently available 
drugs for the treatment of IBD. Our results show gene signature 
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commonalities between IBD, and asthma, lupus, and rheumatoid 
arthritis, among others. Results raise the question of compromised B cell 
immunity in IBD patients along with over compensation of other 
components of the immune system, possibly facilitating research on 
new treatment protocols for this chronic disorder.   
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CHAPTER 3 
Meta-Analysis of IBD and Colorectal Carcinoma Microarray Data 
Reveals Transcriptional Regulation, Disease Biomarkers and 
Regulatory Pathway Associations Between Disease Phenotypes 
 
3.1 ABSTRACT 
 Patients with IBD are known to have an increased risk of 
developing colorectal carcinoma (CRC), with the likelihood increasing 
with the duration of IBD.  This phenotype shift is however poorly 
understood as are the genetic factors leading to the development of CRC.  
In order to better understand this transition, microarray meta-analysis 
was performed to characterize the gene expression profiles of IBD and 
CRC patients in a functional context.  Disease classifiers were also 
determined in order to accurately stratify colonic disease phenotypes as 
well as the various stages of CRC according to the Dukes staging system.  
Our analysis represents a comprehensive analysis of the colonic 
transcriptome under various disease conditions and provides for the 
interpretation of significant genes in the context of physiological pathways 
and discrete clinical biomarkers. 
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3.2 INTRODUCTION 
 Colorectal cancer (CRC) is estimated to affect over 1.2 million 
people worldwide with over 600,000 attributed deaths annually making it 
the third most commonly diagnosed cancer in men and the second in 
women, while being having the fourth and third highest contributor to 
cancer related mortality among men and women respectively [98].  There 
are known to be a number of risk factors associated with the onset of CRC 
including hereditary syndromes of familial adenomatous polyposis, 
hereditary nonpolyposis colorectal cancer and inflammatory bowel 
disease (IBD) [99].  The incidence of IBD related CRC varies widely within 
the literature, although a meta-analysis of 116 studies involving 55,000 UC 
patients revealed a relative risk of 2%, 8% and 18% in developing CRC 
after 10, 20 and 30 years respectively [100].  Similarly, a meta-analysis of 
over 60,000 CD patients revealed a relative risk of 2.9% for CRC and 33.2% 
for small bowel carcinoma [101].    
 Previous microarray analysis studies of colonic gene expression in 
colorectal cancer patients have led to many important findings.  Survival 
outcomes of CRC patients were predicted using a 34-gene classifier set 
and was found to significantly discriminate patients with recurrence of 
metastatic tumors from remissive patients [102].  Similarly, a 128 
matastasis–associated gene expression profile was shown to accurately 
predict patient outcomes and may be used to optimize adjuvant treatment 
strategies for subsets of CRC patients [103].  The response of CRC patients 
to COX2 inhibitors was also investigated using gene expression 
measurements and was found to be associated with a shift in gene 
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expression patterns between normal and ademona cell types, suggesting 
the efficacy in COX2 inhibitor treatment during early cancer stages [104].  
Research performed by the same group previously identified 
discriminative gene signatures for the differential diagnosis of colorectal 
disease types and their correlation with gene expression within peripheral 
blood samples [105].   
 Diagnosing IBD is also problematic and often requires a 
colonoscopy or histopathological examination to be performed by a 
gastroenterologist.  Although this practice may allow for a definitive 
diagnosis, such procedures are costly, time consuming, and invasive.  
Biomarkers have alternatively been studied as a means to diagnose IBD, 
monitor disease activity and responsiveness to various treatment 
modalities.  Such diagnostic procedures for IBD may be based on elevated 
intestinal inflammation, since IBD patients excrete an increased quantity 
of leukocytes within their stool.  The leukocytes in the gastrointestinal 
tract can be quantified via radioactive labeling in conjunction with an 
abdominal scintigraphy to identify which regions of the intestine are 
inflamed. This costly technique, however, requires specialized facilities, 
and subjects the patient to radiation exposure [106, 107]. An alternative to 
measuring leukocytes directly in vivo is to measure leukocyte derived 
proteins. This approach has shown promise in identifying indicators of 
IBD including fecal lactoferrin [108, 109], calprotectin, lysozyme, 
polymorphonuclear neutrophil elastase, lipocalin and myeloperoxidase 
[73, 74, 110].  Among the fecal biomarkers, lactoferrin and calprotectin 
have been shown to be the most sensitive and specific in discriminating 
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IBD patients from a population of healthy patients [111], while ASCA and 
pANCA have shown mixed results in discriminating UC patients from 
those with CD [112, 113].  Consequently, there is a clear need to identify a 
set of biomarkers to differentiate patients with IBD from healthy patients 
as well as identify drug targets for new treatment protocols for IBD.   
 While previous microarray studies have focused solely on CRC our 
integrated microarray analysis approach aims elucidate the genetic factors 
responsible for the transition from IBD to CRC including physiological 
pathways and unique disease biomarkers that may be used to clinically 
differentiate between disease phenotypes.    
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3.3 METHODS 
 The microarray datasets used in this study were all in public 
domain and were generated from mRNA isolated from the affected 
colonic mucosa of UC, CD and CRC patients.  Samples were all 
hybridized onto the Affymetrix Human Genome U133 Plus 2.0 GeneChip® 
Array platform for analysis.  A total of 698 colonic mucosal microarray 
dataset samples were obtained from the NCBI Gene Expression Omnibus 
(GEO) [34, 35] in raw CEL format.  Following the removal of duplicate 
samples, sample outliers were removed using principal component 
analysis (PCA) [36]. There were a total of 15 IBD and 41 CRC outliers 
detected and removed from further analysis.  The final sample population 
is comprised of 29 healthy control (HC) samples, 48 UC samples, 41 CD 
and 309 CRC samples from nine independent studies (GSE9452 [37], 
GSE9686 [38], GSE10191 [39], GSE10616 [40], GSE13367 [41], GSE16879 
[42], GSE17536 [102], GSE17537 [102] and GSE14333 [103]).  Gene 
expression datasets for IBD (UC & CD) as well as CRC were 
independently normalized using robust multi-array averaging (RMA) 
background adjustment, quantile normalization with median polishing 
and log2 transformed summarization procedures within MATLAB [43-45] 
and were mapped to Entrez gene IDs using a custom CDF file during the 
normalization process [46, 47].  Following pre-processing, batch effect 
removal was performed using the COMBAT source code in R [48].  
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Significant Genes 
Two distinct microarray data analysis methods – Significance 
Analysis of Microarrays (SAM) [49] and the rank product (RP) method 
[50, 51] representing meta analysis – were performed in MATLAB and R 
(2.10.0), respectively, in order to identify statistically significant 
upregulated and downregulated genes in UC/HC, CD/HC, Dukes 
A/HC, Dukes B/HC, Dukes C/HC, Dukes D/HC comparisons. For IBD 
comparisons, statistically significant genes were determined using a fold 
change (FC) and p-value cutoff of 1.5 and 0.001 respectively over 1000 
permutations [48], while a FC and pvalue cutoff of 2 and 0.001 were used 
to identify significant genes for CRC/HC comparisons.  For the RP 
method, only those genes with an enrichment p-value less than 10-6 were 
identified as significant in both cases. 
 
Functional Enrichment 
Significantly enriched KEGG [114] and BioCarta pathways were 
determined for UC, CD, Dukes A, Dukes B, Dukes C and Dukes D 
phenotypes using DAVID [52, 53].  A pvalue cutoff of 0.05 was used to 
identify significant pathways enriched by significant gene lists for each 
phenotype.  Genes implicated in pathways of interest were colored using 
KEGG color [57] and MATLAB.   
 
  
 54 
Disease Classifiers 
 Disease classifier sets were identified by first filtering the 
normalized data matrix to only contain upregulated genes common to 
both phenotypes under comparison since downregulated transcripts and 
related proteins may not exist in sufficient quantity for detection.  A 
second filter was used to identify only those proteins that are expressed 
within the extracellular region, extracellular space or plasma membrane 
according to GO cell compartment category.  This filter ensures that the 
identified biomarkers will be present within the stool for use as a fecal 
biomarker.  The data for each sample comparison is then randomly split 
evenly into training and test classes.  Classifiers were then identified on 
the training set using the ROC class separability metric within Matlab.  
The resulting classifier sets were used to classify the test samples using a 
logistic regression model and subsequently calculate the area under the 
ROC curve (AUC) [115, 116].  This process was performed over 1000 
iterations in order to identify the best ten classifiers for each comparison 
as weighted by their AUC for each comparison.  Each optimal classifier set 
was then used to classify the test samples independently to assess their 
performance as reported by their AUC.  
 
In Silico Disease Classifier Validation 
 Classifier performance was evaluated on an independent dataset 
obtained form GEO, which contained IBD, CRC and healthy control 
biopsies obtained from the colon of affected individuals [104].  RNA 
isolated from the samples were hybridized onto the Affymetrix HGU133 
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plus2 microarray platform for analysis.  The dataset did not differentiate 
between the various cancer stages or IBD phenotypes related to each 
patient, allowing for the evaluation of only HC/IBD, HC/CRC and 
IBD/CRC biomarker sets.  The dataset contains 8 HC samples, 15 CRC 
samples and 15 IBD samples. 
Data was first normalized using robust multi-array averaging 
(RMA) background adjustment, quantile normalization with median 
polishing and log2 transformed summarization procedures within 
MATLAB [43-45] and were mapped to Entrez gene IDs using a custom 
CDF file during the normalization process [46, 47].  The top 5 disease 
classifiers were then used to classify the samples using logistical 
regression.  ROC plots were generated and AUC was calculated to assess 
classifier performance.  The Matlab script used to classify the samples 
within the validation set using logistic regression and generate ROC 
curves is provided within appendix C. 
 
Disease-Gene Interactome 
 Genes with known associations to the disease terms “Colitis, 
Ulcerative”, “Crohn Disease”, “Colorectal Neoplasms” and “Colonic 
Neoplasms” were found using the Genomic Association Database (GAD) 
[27].  A Gene-disease interaction network map was generated using 
cytoscape [117]. The node size and node label font size in the resulting 
network diagram is proportional to the degree of edges associated with 
each node.  Significant genes for each phenotype identified within our 
study were colored according to phenotype.  
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Genetic Regulation by Transcription Factors and miRNA 
 Transcription factor (TF) regulation was inferred from the results of 
our integrated microarray analysis based upon well-characterized TF 
target genes using TFactS [118].  Significant TFs were identified using a p-
value cutoff of 0.01 for each respective phenotype.   
Significant differentially expressed miRNA were obtained from 
recent reviews of miRNA regulation in both CRC [119] and IBD [120].  
Only miRNA identified as being significantly altered in CRC by at least 
two studies were considered for subsequent analysis.  Gene targets of the 
identified miRNA were found using miRWalk [64].  Only those Gene-
miRNA interactions in which an upregulated miRNA interacts with a 
downregulated gene as identified by our analysis and vise versa were 
considered for subsequent analysis.  MiRNA-Gene-disease networks were 
then constructed in order to infer the involvement of miRNA and their 
target genes on regulation of IBD and CRC phenotypes.   
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3.4 RESULTS 
 In this study we integrated microarray data obtained from multiple 
laboratories (Table 5a) along with other publicly available data and 
various knowledge bases to better define the transcriptional regulation 
IBD related CRC and identify sets of discrete genetic classifeirs. Each 
unique patient sample was hybridized onto the Affymetrix Human 
Genome U133 Plus 2.0 GeneChip® Array platform, which contains 54,675 
oligonucleotide probes, covering over 47,000 human transcripts mapped 
onto 17,778 NCBI Entrez gene IDs [46]. Integrated microarray analysis was 
performed to reduce laboratory specific noise and increase statistical 
power. Figure 7 shows the sample clustering based upon the principal 
components, which account for 82% of the variance within the dataset.  
Significant gene lists were compared in order to identify commonly 
regulated genes for IBD (UC & CD) as well as CRC (Dukes A-D) (Table 
5b).  There were found to be 965 upregulated genes common to both UC 
and CD, while CRC phenotypes were found to have 315 upregulated 
genes common to each phenotype.  There were found to be 111 genes 
commonly upregulated within each phenotype (both IBD and CRC).  
Conversely, IBD phenotypes were found to share 479 downregualted 
genes, while CRC phenotypes were found to share 712 downregulated 
genes.  There were found to be a total of 227 downregulated genes shared 
by IBD and CRC phenotypes.  The top 200 up and downregulated genes 
identified within CRC cancer stages as ranked by average fold change 
across cancer stages is provided in Appendices F and G respectively. 
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Figure 7.  Principal component analysis scatter plot of CRC cancer stages 
and IBD phenotypes.  Colorectal cancer Dukes A (CaA), Dukes B (CaB), 
Dukes C (CaC), Dukes D (CaD), ulcerative colitis (UC_) , crohns disease 
(CD_) and healthy control (HC_) samples contained within the meta-
analysis are represented. 
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5a) 
GEO Accession # PMID HC UC CD Dukes A Dukes B Dukes C Dukes D   Total 
GSE17536 19914252 0 0 0 24 57 57 39 
 
177 
GSE17537 19914252 0 0 0 4 15 19 17 
 
55 
GSE14333 19996206 0 0 0 44 94 92 60 
 
290 
GSE9452 19177426 5 8 0 0 0 0 0 
 
13 
GSE9686 18069684 8 5 11 0 0 0 0 
 
24 
GSE10191 18981162 11 8 0 0 0 0 0 
 
19 
GSE10616 18758464 11 10 32 0 0 0 0 
 
53 
GSE13367 19834973 10 8 0 0 0 0 0 
 
18 
GSE16879 19956723 6 24 19 0 0 0 0   49 
Subtotal   51 63 62 72 166 168 116 
 
698 
Duplicates 
 
19 13 11 23 53 57 39 
 
215 
Outliers   3 2 10 3 14 10 14   56 
Total   29 48 41 46 99 101 63 
 
427 
 
5b) 
MICROARRAY DATA ANALYSIS 
  UC/HC CD/HC Dukes A Dukes B Dukes C Dukes D 
Upregulated Genes 1229 1050 424 465 495 486 
Downregulated Genes 828 539 917 892 946 957 
       Common Up 965 315 
 
111 
Common Down 479 712 
 
227 
Union (All Significant Genes) 2202 1715 
  801 
Table 5.  Overview of the samples used within the IBD-CRC meta-analysis (a).  Identified significant genes for each 
phenotype including gene list intersections for various sample comparisons (b).   
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Functional Enrichment 
 Functional enrichment of individual gene lists for each phenotype 
was performed in order to visualize significantly altered disease pathways 
common to both IBD and CRC.  Figure 8 demonstrates the widespread 
pathway alterations associated with IBD and CRC.  Figure 8b shows the 
upregulation of cytokine-cytokine interactions, complement and 
coagulation cascade and ECM receptor interactions in both IBD and CRC.  
IBD is shown to be associated with an upregulation in NOD and toll like 
receptor signaling, leukocyte transendothelial migration, chemokine 
signaling and numerous other pathways related to an immune response 
including those related to T and B cell mediated immunity.  Significantly 
upregulated pathways for CRC include the p53 signaling pathway, 
colorectal cancer, baldder cancer, wnt signaling, small cell lung cancer, cell 
cycle and pathways in cancer.   
 Downregulated pathways were found to drastically differ between 
IBD and CRC phenotypes (Figure 8b).  Commonly downregulated 
pathways include fatty acid metabolism, nitrogen metabolism, PPAR 
signaling pathway, nitrogen metabolism, valine, leucine and isoleucine 
degradation, drug metabolism, butanoate metabolism and mitochondrial 
carnitine palmitoyltransferase (CPT) system.  Downregulated pathways 
solely associated with CRC include pentose and glucuronate metabolism, 
retinol metabolism, steroid hormone synthesis, amino sugar and 
nucleotide sugar metabolism and ascorbate and aldarate metabolism.   
 61 
8a) 
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8b) 
 
Figure 8.  Functional enrichment of identified significant genes for IBD phenotypes and CRC 
Dukes A-D staging.  Statistically enriched upregulated (8a) and Downregulated (8b) KEGG 
and BioCarta pathways. 
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Disease Classifiers 
 Discrete transcriptional disease markers were identified between 
healthy controls and IBD phenotypes as well as various stages of CRC in 
order to identify unique classifier sets and assess their performance in 
differentiating patient populations.  The identified classifier lists are 
provided in Table 6 along with their performance in classifying samples 
within the test dataset (Figure 9).  Classifiers were found to adequately 
separate healthy controls from IBD and CRC samples regardless of 
staging, with AUC’s approaching unity.  There was however great 
difficulty in differentiating between cancer stages as with AUCs ranging 
between 0.65 and 0.85 indicating significant overlap in genetic regulation 
of the various stages of CRC.  
 
In Silico Disease Classifier Validation 
 Classifier performance was evaluated on an independent dataset 
obtained form GEO, which contained IBD, CRC and healthy control 
biopsies obtained from the colon of affected individuals [104].  However 
since the dataset was not annotated with cancer staging or IBD phenotype 
only the HC/IBD, HC/CRC and IBD/CRC biomarker sets were validated.  
It was found that using all 10 disease classifiers perfectly separated 
disease classes, with an AUC of 1.  Consequently, we investigated the 
minimum number of disease classifiers that could be used to accurately 
classify samples (AUC>0.9).  It was found that using the top five 
biomarkers for each comparison resulted in an acceptable AUC (Figure 
10).
 64 
 
Colorectal	  Cancer	  Comparisons	  
HC/A	   HC/B	   HC/C	   HC/D	   A/B	   A/C	   A/D	   B/C	   B/D	   C/D	  
WNT2	   TIMP1	   WNT2	   WNT2	   CCL20	   COL10A1	   SPP1	   DEFA6	   CXCL3	   CXCL3	  
CALU	   MMP14	   MMP14	   TIMP1	   TREM1	   SPP1	   GRP	   ESM1	   CXCL1	   CXCL1	  
COL1A1	   ADAMTS2	   THBS2	   TG	   SPP1	   AGT	   CXCL3	   CMTM7	   CXCL2	   CMTM7	  
TG	   TG	   COL12A1	   MMP14	   OLR1	   OLR1	   CXCL1	   C8ORF84	   CHI3L1	   MMP12	  
IL28A	   SFRP4	   MFAP2	   IL28A	   IGHV@	   TREM1	   CXCL2	   IGFBP3	   APOD	   AGT	  
ESM1	   ECM1	   CALU	   THBS2	   COL10A1	   TIMP1	   APOD	   SERPINA1	   CXCL9	   SERPINB5	  
PGLYRP4	   ESM1	   TIMP1	   LOXL2	   AGT	   ISLR	   LCN2	   CCL25	   SFTA2	   MMP1	  
TIMP1	   COL1A2	   SFRP4	   PGLYRP4	   TNC	   CCL20	   ASPN	   NMU	   IL8	   LPL	  
MFAP2	   LOXL2	   COL1A1	   TGFBI	   SERPINE1	   SERPINE1	   CFB	   STC1	   CCL18	   IL8	  
ADAMTS2	   SPON2	   IL28A	   MFAP2	   CFB	   FLNA	   CCL20	   TCN1	   MMP1	   FOLR1	  
	   	   	   	   	   	   	   	   	   	  IBD	  Comparisons	  
	   	  HC/UC	   HC/CD	   UC/CD	   UC/CRC	   CD/CRC	   HC/IBD	   IBD/CRC	   HC/CRC	  
	   	  CALU	   CHI3L1	   AZGP1P1	   COL11A1	   COL11A1	   CHI3L1	   COL11A1	   WNT2	  
	   	  REG4	   MMP3	   GALNT2	   IGFL2	   IGFL2	   TIMP1	   IGFL2	   MMP14	  
	   	  GALNT2	   TIMP1	   CKLF	   GKN2	   GRP	   MMP3	   GRP	   TIMP1	  
	   	  LCN2	   SPINK4	   LAMB2	   GRP	   PRB2	   SPINK4	   PRB2	   CALU	  
	   	  LTF	   PCSK1	   TCN1	   PRB2	   ESM1	   CALU	   PNOC	   MFAP2	  
	   	  CD44	   IGKV4-­‐1	   IGLV3-­‐25	   PNOC	   PNOC	   MMP12	   PGLYRP4	   IL28A	  
	   	  CRELD2	   MMP12	   MGC29506	   CFP	   SFRP4	   REG4	   CCL25	   COL1A1	  
	   	  TNFRSF6B	   LTF	   ST3GAL1	   PGLYRP4	   GKN2	   MMP10	   GKN2	   TG	  
	   	  SPINK4	   CALU	   IL23A	   NUCB2	   COL10A1	   APOL1	   SFRP4	   THBS2	  
	   	  SPON2	   LIPG	   IGHV3-­‐11	   CCL25	   CEL	   CRELD2	   ESM1	   PGLYRP4	  
	   	   
Table 6.  Classifier lists for phenotype comparisons identified by ROC analysis.  The classifiers used to classify the exernal 
validation set samples by logistic regression are highlighted.   
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Figure 9.  Classifier performance identified for each phenotype comparison on 
the internal test set.  The color bar represents the AUC of each comparison on the 
respective test dataset. 
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 Figure 10.  ROC for classification by logistic regression of HC/IBD (AUC = 0.98), HC/CRC (AUC = 0.98) and IBD/CRC 
(AUC = 0.94) comparisons. 
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Disease-Gene Interactome 
 According to GAD, there are 10 genes with known associations to both 
UC and CD, and 30 genes associated with both IBD and CRC phenotypes (Figure 
11).  Significant genes identified by our integrated microarray analysis for UC, 
CD and CRC are colored within Figure 11 in order to portray the overlap with 
our results and known gene-disease associations.  Only one gene, PPARG, is 
known to be associated with UC, CD and CRC and was also found to be 
significantly downregulated in HC/UC, HC/CD and HC/CRC comparisons.  
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Figure 11.  Disease-Gene interactome.  Genetic associations for MeSH disease 
terms related to CRC and IBD.  Significant genes identified by this meta-analysis 
are highlighted. 
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Genetic Regulation by Transcription Factors and miRNA 
 Transcription factor enrichment shows differential expression of 
transcription factors in both IBD and CRC phenotypes.  It is shown that CEBPE, 
CREM, NR2F1, ATF1, HIF1A, STAT3, SP3, COX2, TBP, TP53, RELB and EGR1 
are all significantly enriched for CRC, while NRC, REL and CEBPD are all 
significantly enriched in IBD phenotypes (Figure 12).   
 
Figure 12.  Significantly enriched transcription factors for IBD phenotypes and 
stages of CRC.   
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Upregulated miRNA were found to interact with downregulated genes 
identified within our analysis and overlap between UC, CD and CRC 
phenotypes.  Mir-155 and miR-29b were found to be upregulated in both UC and 
CD, while miR-21, miR-29a and miR-31 were found to be upregulated in UC, CD 
and CRC.  UC and CRC were found to both have upregulated miR-223, while CD 
and CRC were found to both have upregulated miR-107 and miR-200c (Figure 
13a).   
Downregulated miRNA were also found to overlap between UC and CRC 
phenotypes including miR-143, miR-145 and miR-192 (Figure 13b).  The 
interacting genes of these commonly regulated miRNA were then determined to 
see the influence of miRNA on the regulation of significant genes for each 
phenotype.  Upregualted miRNA-21 was shown to downregulate PDCD4, 
THRB, SMAD7, FGFR3, ENPP3 and CNTN3 within all phenotypes.  Upregulated 
miRNA-29a was shown to downregulate FZD5 across all phenotypes.  
Upregulated miR-31 was shown to downregulate the expression of SATB2, 
FGFR3, CDKN2B and TRIM36 amongst all phenotypes.  FGFR3 was the only 
gene commonly downregulated across every phenotype by more than one 
miRNA.  The upregulation of miR-223 was shown to downregulate KLF4 in UC 
and CRC phenotypes, while the upregualtion of miR-107 was associated with the 
downregulation of PDK4 in UC and CRC.  Interestingly, downregulated miRNA 
were only shown to overlap between UC and CRC phenotypes including miR-
143, miR-145 and miR-192.  Genes commonly upregulated by the attenuation of 
miR-192 inlcude COL1A1, COL1A2, COL4A1, CTGF and TGFB1.  Genes 
commonly downregulated by miR-143 include MMP3, TAGLN and VCAN.  The 
only gene commonly downregulated in both phenotypes by miR-145 is CDH11.  
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Interestingly, P53 and VEGFA were found to be upregulated in CRC by the 
attenuation of miR-143, miR-145 and miR192. 
 
 
 
Figure 13a.  Upregulated miRNA with validated interactions with significant 
downregulated genes identified by our integrated microarray analysis for UC, 
CD and CRC. 
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Figure 13b.  Downregulated miRNA with validated interactions with significant 
upregulated genes identified by our integrated microarray analysis for UC, CD 
and CRC. 
  
 73 
3.5 DISCUSSION 
 Our analysis of 427 unique patient samples obtained from 9 independent 
microarray studies revealed gene signatures, pathways, biomarkers, 
transcriptional factors and the role of miRNA regulation in IBD phenotypes and 
the stages of CRC.  Our results indicate transcriptional factors, miRNA and genes 
involved in the transition from IBD to CRC phenotypes as well as unique genetic 
regualtors involved in each phenotype respectively.  We have furthermore 
identified biomarker sets that may be used to diagnose and assess the prognosis 
of colorectal cancer patients. 
The identified biomarkers for HC and IBD patient classification that were 
used to classify the samples within the validation set include CHI3L1, TIMP1, 
MMP3, SPINK4 and CALU.  Chitinase 3-like 1 (CHI3L1) is a glycoprotein 
member of the glycosyl hydrolase 18 family, secreted by activated macrophages, 
chondrocytes, neutrophils and synovial fluid.  CHI3L1 was found to have a FC 
value of 19 and 16 for UC and CD respectively.  The shear abundance of this 
transcript make it an excellent biomarker candidate for active inflammation and 
interventional effectiveness.  The second marker, TIMP1 is a natural inhibitor of 
MMPs and is also known to promote cell proliferation and anti-apoptotic 
functions.  TIMP1 gene expression is known to be induced by various cytokines.  
Other markers in the list include matrix metallopeptidase 3 (MMP3), serine 
peptidase inhibitor, kazal type 4 and calumenin (CALU).   
 Biomarkers identified for the classification of HC and CRC patients 
include WNT2, MMP14, TIMP1, CALU and MFAP2.  TIMP1 and CALU were 
also found to be excellent classifiers for IBD and HC patients.  WNT2 is a 
member of the wingless-type MMTV integration site (WNT) gene family, which 
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consists of structurally related genes which encode signaling proteins implicated 
in oncogenesis.  Microfibrillar-associated protein 2 (MFAP2) is  major antigen of 
elastin associated microfibrils and is believed to play a role in the etiology of 
inherited connective tissue diseases.  Biomarkers found to differentiate between 
IBD and CRC phenotypes include COL1A1, IGFL2, GRP, PRB2 and PNOC.  
UC and CRC phenotypes are shown to both have downregulated miR-
143, miR-145 and miR-192.  The validated interacting mRNA transcripts that 
were found to be upregulated within this study and known to interact with each 
miRNA for each disease phenotype were also found.  Downregulated miR-143 
may result in upregulated ITGAM, LPIN1,and MMP9 in UC, FSCN1, MYC, TP53 
and VEGFA in CRC and  MMP3, TAGLN and VCAN in both UC and CRC 
phenotypes.  Significant upregualted genes known to interact with miR-145 
include BNIP3, CBFB, KRT7, MCL1, MUC1, SOD2, STAT1, SWAP70 and 
ALCAM for UC, CCND1, CDK4, EIF2C2, FSCN1, MYC, SOX4, TP53 and VEGFA 
for CRC and CDH11 for both UC and CRC.  Downregulation of miR-192 may 
result in the upregulation of ALCAM, APOE, CD79A, ITK, MCL1 and NOS2 in 
UC, CCND1, EIF2C2 and TP53 in CRC and COL1A1, COL1A2, COL4A1, CTGF 
and TGFB1 in UC and CRC.   
 Upregulated miRNA were also found to have known interactions with a 
number of significant downregulated genes for UC, CD and CRC.  Upregulated 
miR-21 was shown to downregulate CNTN3, ENPP3, FGFR3, PDCD4, SMAD7, 
THRB, FZD5, CDKN2B, FGFR3, SATB2 and TRIM36 across UC, CD and CRC 
patients.  Upregulated miR-155 and miR 29b were shown to downregulate 
HMOX1 in UC and CD, while upregulated miR-29b was found to downregulate 
CEBPA and CDKN2B in UC and CD.  While the coregulation of mRNA has been 
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shown for shared miRNA, there are a number of miRNA that are known to 
interact with commonly regulated genes that are not innervated by shared 
miRNA and these complex redundant interactions warrant further research and 
discovery in order to map the complex genetic regulation involved in IBD and 
CRC.   
 There were found to be a total of 53 significant upregulated transcription 
factors innervated by downregualted miRNA and 28 significant downregulated 
transcription factor genes innervated by upregulated miRNA suggesting 
complex interactions and feedback loops between miRNA and various 
transcription factors.  SMAD7, PPARG, CDKN2B and THRB are all significant 
transcription factor genes known to be downregulated in UC, CD and CRC.  
MiR-21 has been shown to be significantly upregulated in UC, CD and CRC and 
is known to interact with the upregulated transcription factors SMAD7 and 
THRB, while miR-31 is known to interact with CDKN2B.  SMAD7 is a nuclear 
protein that binds the E3 ubiquitin ligase SMURF2, which interacts with TGF-
beta receptor type-1 (TGFBR1).  Variations in SMAD7 have been shown to confer 
susceptibility to colorectal cancer type 3 and several transcriptional variants 
encoding different isoforms of this protein have been found.  Similarily, 
polymorphisms in PPARG have been shown to confer susceptibility to IBD [121, 
122].  The downregulation of these transcription factors in the presence of 
upregualted miRNA suggest a crucial role in the post-transcriptional regulation 
of these specific transcription factors by miRNA.   
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CHAPTER 4 
 
MICROFABRICATED QLISA BIOSENSOR FOR MEASURING FECAL 
BIOMARKER CONCENTRATIONS IN IBD PATIENTS 
 
 
 
4.1 ABSTRACT:   
 
 Microfluidic immunosensors have several advantages over standard 
microtiter based techniques including reduced regent consumption due to their 
reduced dimensionality, controllable surface properties, integration of electro-
optical components and potential for high throughput sample handling and 
automation.  Working towards the realization of a compact microfluidic 
immunoassay system, our group has developed a platform for the detection of 
quantum dot conjugated proteins within a capillary based immunoassay device 
[123].  This first generation device was further improved through two major 
design improvements including optimized antibody conjugation to PMMA 
substrates and microfluidic device integration.  The device was validated using 
human samples spiked with lactoferrin, an IBD biomarker.  This chapter 
highlights my contributions to one submitted manuscripts, two patents and one 
conference paper related to the realization of a second-generation microfluidic 
QLISA platform.   
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4.2 INTRODUCTION 
 
Immunoassay Technology 
 
 Immunoassays are routinely used to identify and quantitatively evaluate 
the concentration of an analyte contained within a test sample through the 
exploitation of selective and reversible antigen-antibody interactions (eq. 1.1) and 
have been employed in a variety of clinical, pharmaceutical, defense and 
environmental applications.  The specificity of this reaction in combination with 
characteristically high association constants make them an ideal biosensing 
modality and are the basis behind the gold standard of in vitro diagnostics; the 
enzyme linked immunosorbent assay (ELISA).   
   (1.1) 
 In the ELISA method, antibodies are used to detect specific antigens 
contained within a biological sample. Traditional heterogeneous solid-phase 
immunoassays, such as an ELISA are carried out on the solid substrate of a 
standard microtiter plate, which is typically manufactured from polystyrene and 
may have 6, 24, 96, 384 or 1536 sample wells.  In this format, proteins are 
passively adsorbed onto the microtiter plate surface through noncovalent 
hydrophobic interactions between the non-polar or aromatic amino acid residues 
present within the protein and the hydrophobic polymer chains present on the 
substrate, resulting in randomly oriented antibodies.  Some of the adsorbed 
antibodies are denatured in this process, leaving as few as 10% of the total 
adsorbed antibodies available for an affinity reaction [124, 125].  Furthermore, 
passive adsorption of antibodies onto the substrate results in low, 
inhomogeneous surface coverage with concentrations of approximately 
400ng/cm2 on PMMA [125].  Alternatively, homogeneous immunoassays may be 
! 
Ag+ Ab" Ag • Ab (Complex)
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carried out in the liquid phase of the wells of a microtiter plate, with no 
biomolecules adsorbed onto the substrate.  Overall, the ELISA method is very 
sensitive due to the high specificity of antibody binding and the amplification of 
the binding signal by means of enzymatically catalyzed fluorescence (often 
accomplished using horseradish peroxidase), which may be detected by 
measuring the absorbance or transmittance of light using a standard microtiter 
plate reader.   
 While microtiter plate based immunoassays offer sufficient automation 
and throughput, they often require the excessive consumption of expensive 
reagents and require the oversight of a trained technician as well as a significant 
amount of analysis time to perform. In order to circumvent these issues 
microfluidic immunosensors have been investigated as an alternative 
immunoassay platform, allowing for increased throughput and automation, 
lower reagent and sample consumption as well as decreased analysis time.  The 
advantages that microfluidic immunosensor platforms have over standard 
microtiter plate based assays arises from their reduced, micron scale features, 
which effectively increases their surface area to volume ratio over that of 
standard microtiter plates while decreasing working volumes and the 
characteristic diffusion length for biomolecules.  As a result, heterogeneous 
assays are particularly amenable to a microfluidic platform since they may 
exploit the increased surface area to volume ratio uniquely inherent to such 
microscale devices, allowing for comparable sensitivity, specificity and limit of 
detection as microtiter plate based assays in only a fraction of the time and with 
decreased sample and reagent consumption.  Furthermore, microfluidic 
immunosensors may be integrated with various components including 
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micromixers, valves, micropumps, electrical and optical components to facilitate 
the design and development of highly automated, precise and portable micro 
total analysis system capable of multianalyte detection as a point-of-care 
diagnostic platform [126-128].   
 Microfluidic immunosensors may be fabricated from a variety of materials 
depending upon the final application and the desired chemical, material and 
optical properties of the substrate.  The selection of an appropriate substrate 
often depends heavily upon the signal transduction mechanism employed by the 
sensor, the desired surface chemistry and the available fabrication techniques. 
Most immunosensors that rely on optical excitation and/or detection 
mechanisms are fabricated from materials with a high optical transmittance 
within the visible and near UV wavelengths and low autofluorescence.  For this 
reason, glass [129, 130] and various polymeric materials including PMMA [131-
136], PDMS [137-139], polycarbonate [140-142] and more recently the cycloolefin 
Zeonor [143, 144] have all been successfully used as immunosensor substrates in 
applications where an optical signal transduction and detection mechanism is 
employed.  In addition to their superior optical properties, polymers may also be 
manufactured on a commercial scale using existing techniques such as hot 
embossing and injection molding to inexpensively mass-produce disposable and 
highly reproducible immunosensor platforms.  Lastly, the surface of polymeric 
materials such as PMMA may be easily functionalized and modified to facilitate 
the covalent immobilization of properly oriented antibodies directly onto the 
substrate effectively enhancing assay sensitivity and allowing for decreased 
limits of detection while reducing non-specific binding [131, 145, 146].  
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 Capillary sensors have found extensive application in numerous 
disciplines of science, ranging from electronics and semiconductors to chemical 
and biological sampling & detection methods, like chromatography [147].  The 
versatility of a capillary comes from its geometry, its high surface area to volume 
ratio, the possibility to create a surface with perfect adhesion and use transparent 
construction materials [148].  A sturdy minute capillary construction allows the 
immunosensor device to be compact and portable.  The small size ensures easy, 
cost effective and accurate detection for small sample sizes.  A larger surface to 
volume ratio in a capillary compared to the geometry of wells in well-plates 
(currently used as standards), can facilitate detection reactions and increase 
sensitivity, by reducing diffusion[149].  Capillary based biosensors can eliminate 
the complex process of microfabrication required for microfluidic 
immunosensors.  Capillary tubes can act as both optical waveguides and 
sampling chambers.  The cylindrical shape facilitates easy and uninterrupted 
flow-in and flow-out of samples and the inner surface can be used for 
immobilization of probing molecules such as antibodies [150]. 
 Both glass and polymer based capillaries have been used to carry out 
immunoassays.  Specifically glass or fused silica[151-154], polystyrene [155], 
polymethylpentene [156], polymethylmethacrylate [157], poly-vinyl 
chloride[158] have been used in fabricating capillary biosensors.  Polymeric tubes 
may pose a manufacturing challenge and glass capillary tubes need additional 
processing steps of surface activation for successful fixation and immobilization 
of probes.  The inert nature of glass makes it necessary to perform additional 
chemical modification to form covalent bonds between a glass surface and a 
biomolecule.  Chemicals used for such modification / functionalization comprise 
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of silinazing agents like 3-mercaptopropyl trimethoxysilane.  These silanizing 
agents bind simultaneously to the hydroxy groups on the glass silicate surface 
and to various groups on the probe surface ranging from the amino terminal to, 
thiol groups, based upon the specific silanizing agent [154].  Therefore, the choice 
of these silinazing agents depends upon the type of immunoassay that they are 
going to be used in and the probes that they need to attach to.  On the other 
hand, polymeric capillaries, such as the ones we are proposing to use, are of 
particular interest due to readily available functional groups on their surface 
offering an appropriate substrate for immobilizing antibodies or antigens, 
without special modification steps.  Furthermore, recent developments in 
photochemical methods of functionalizing polymeric materials provide 
compelling reasons to choose polymeric capillaries over fused silica or glass 
capillaries [159].  Several strategies have been reported in the literature to detect 
low concentrations of antigens by solid phase immunoassay in capillaries, 
primarily focusing on excitation of fluorophores followed by collection of the 
emitted photons. One such approach takes advantage of the evanescent field at 
the interface of the polymer/liquid interface for collecting the emitted signal; 
however this method requires the material of the capillary to function as a 
waveguide [147], restricting the choice of material among those having very low 
scattering coefficient. Fused silica or glass, though meet the requirements, are 
fragile and require additional cladding layers to protect the capillaries from 
mechanical damage. This method is further challenged by issues related to 
optical alignment and coupling efficiency often resulting in reduced 
performance. 
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 The first capillary waveguide application for a sensor was reported by 
Weigl and Wolfbeis in 1994 [160], for carbon dioxide measurement.  In this case 
optical fibers perpendicular to the capillary were used for both excitation and 
collection.  Ligler et al in 2002 provided a summary on four different potential 
excitation and collection methods for integrating waveguide capillaries [161].  
Several biosensors utilize the integrating waveguide capillary biosensor design 
with data collection from the ends of the capillary.  Zhu et al reported 
development of a capillary based waveguide sensor for detection of E.  coli O157 
[162].  The method described utilized a capillary based sandwich immunoassay 
for detecting the presence of E.  coli O157.  Recently, Stringer et al reported a 
capillary biosensor based on Forster Resonance Energy Transfer (FRET) [163].  
The sensor utilized the superior properties of Qdot fluorescent particles and a 
Teflon AF capillary as a Liquid Core Waveguide to detect the presence of 
Troponin I in solution as well as in biological samples.  The limit of detection of 
the sensor was 32nM for troponin I in solution and 55nM in spiked human 
plasma. 
 Working to improve the current limitations of ELISA technology, our lab’s 
predicate QLISA platform exhibited comparable sensitivity with current 
methods while using 1/100th of the reagent volume and requiring less than half 
the operating time required of current ELISA methods [123].  Our preliminary 
data collected from a proof-of-concept device which includes UV LED as the 
excitation source indicate that it is indeed possible to design and fabricate a 
prototype capable of detection MPO and Lf with LDL at 10pg/ml.  Building 
upon this technology to further increase assay performance and throughput, a 
second generation QLISA technology was developed.  An overview of the first 
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and second-generation devices is shown in Figure 12.  The developed 
microfluidic platform allows for more precise fluidic control, site-specific 
antibody immobilization and integration with other components.  
 
 
 
 
 
 
 
 
 
 
Figure 14.  Capillary based first generation QLISA optical setup and surface 
chemistry using zero-length crosslinking (top) and microfluidic QLISA platform 
with integrated electrodes for electrothermally driven enhancement of reaction 
kinetics (bottom).  
 
Biosensor Surface Functionalization 
Maintaining the native physiological conformation of an antibody 
following its immobilization on a substrate is critical in determining the 
efficiency of any subsequent affinity reaction and thereby influencing important 
biosensor parameters such as selectivity and sensitivity [164-167].  Therefore, the 
selection of an antibody immobilization procedure is a key factor in determining 
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the performance parameters of any immunosensor.  Achieving proper antibody 
orientation following immobilization allows for higher signal to noise ratios, 
enhanced reaction rates and assay sensitivity while effectively reducing an 
immunosensor’s limit of detection [168, 169].   
In order to increase antibody surface coverage for biosensor applications, 
numerous covalent immobilization strategies have been developed using both 
zero and non-zero length crosslinkers.  Perhaps the most ubiquitous technique 
used to immobilize antibodies onto a polymeric substrate is through the 
formation of a covalent amide linkage between any reactive amine present 
within an antibody and a carboxylate moiety on the substrate using the zero-
length crosslinker 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) [170].  
EDC facilitates the formation of a permanent covalent amide bond between the 
antibody and substrate by first activating the carboxylate groups present on the 
substrate to form an intermediate ester, which then reacts directly with the 
amines present on the antibody to form a covalent linkage.  Sulfo-NHS is often 
used in conjunction with EDC in order to increase the solubility and stability of 
the active intermediate, resulting in an increased yield of immobilized antibodies 
onto the substrate.  However, since the covalent bond can be formed between 
any reactive amine on the antibody surface, this technique results in the random 
orientation of antibodies on the surface.  Although this antibody immobilization 
strategy has been shown to increase antibody surface coverage when compared 
to passive adsorption, these randomly oriented antibodies may have a 2-3 fold 
lower antigen binding capacity when compared to properly oriented antibodies, 
as a result of their limited mobility and increased steric hindrances at the antigen 
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binding site [171].  As a result of the reduced antigen binding capacity of 
antibodies immobilized using zero length crosslinkers, long flexible polymeric 
linkers such as diamino poly(ethylene glycol) – amino–PEG and 
poly(ethyleneimine) – PEI – have been investigated as spacers in an attempt to 
increase the mobility of the immobilized antibodies while maintaining their 
active binding sites.  The use of non-zero length crosslinkers offers several 
advantages over traditional antibody immobilization methods by allowing a 
high density of physiologically active antibodies to be immobilized onto a 
polymeric substrate.  Using the amine bearing polymer PEI as a spacer to 
immobilize an antibody onto a PMMA substrate effectively increases the antigen 
capture tenfold as compared to passively adsorbed antibodies [145] by limiting 
steric hindrance and antibody denaturation following immobilization, effectively 
enhancing assay sensitivity for the detection of an IgG analyte [145, 146].  
Amino–PEG spacers have also been used with great success to covalently bind 
physiologically active antibodies onto PMMA substrates.  Amino–PEG spacers 
have all of the benefits associated with PEI in addition to reducing non-specific 
interactions with the substrate by creating a hydrophilic polymer brush coating 
on top of the polymer substrate [172].  Both amino–PEG and PEI also come in a 
variety of molecular weights allowing for further optimization of chain density 
and flexibility.  Although the effect that the spacer length has on antibody 
density, non-specific adsorption and the functionality of the immobilized 
antibodies has not yet been fully elucidated, it has been shown that the length of 
the spacer is a critical determinant of the spacer coil conformation, which in turn 
alters the antigen binding capacity of the immobilized antibodies  [173].  Protein 
A, a cell wall component of Staphylococcus aureus, has been known for its 
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specificity in binding to the Fc portion of immunoglobulin G (IgG).  This 
specificity has found several applications in optical [174, 175] and flow injection 
[176, 177] immunosensor fabrication.  It has been postulated that this specificity 
results in orientation of the antibody [178, 179] rendering the binding sites 
readily available for the antigen particularly in a sandwich assay 
 
Quantum Dots 
Quantum dots are semiconductor nanocrystals that emit photons when 
excited by light. They do not photobleach and are useful for a variety of imaging 
applications[180-184]. Commercial QDs are environmentally harmful and toxic 
to humans due to the organic solvents and heavy metal elements. Many groups 
have studied the synthesis of water soluble QDs by adding silica coatings using 
3-(mercaptoprpyl) trimethoxysilane (MPS) and other polymeric as well as non-
toxic surfactants[183].  
Quantum dots exhibit a florescence emission based on their physical size 
(Figure 1). This has to do with the energy gap between the conduction and 
valence energy bands on these semiconductor metals when arranged as a 
nanocrystal at sizes smaller than ~10 nm [185, 186]. When a semiconductor gets 
excited, there is a gap between the excited electron and the hole it leaves behind. 
The Bohr energy radius is the distance between the excited electron and the gap 
formed. Therefore, when the size of the semiconductor is on the nanoscale the 
diameter is close to the Bohr energy radius, which forms a QD with distinct 
energy levels at these band gaps[187]. The energy spectra is modified at these 
sizes leading to quantum confinement. As the size decreases the energy gap 
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increases, which will lead to a blue shift in the emission wavelengths of these 
nanocrystals[187, 188].  
The wide range of biosensor applications using QDs is encouraging. 
Given their unique and advantageous photophysical properties, biosensing 
developers attempt to harness and maximize the potential of QDs, which has 
created a rapidly growing field. Perhaps no potential is greater than the 
multiplexing capabilities of QDs in biosensor development. Broad overlapping 
excitation spectra of different sized QDs allow simultaneous excitation with 
multiple distinct emission spectra correlating to specific QDs. This paves the way 
for multiple biomarker detection in a single sample and has significant 
advantages in translational medical applications, like our QLISA system shown 
in figure 12 and described in further detail in the following sections. 
 
Inflammatory Bowel Disease Diagnostic Biomarkers 
Inflammatory bowel disease (IBD) is an autoimmune, chronic 
inflammatory condition of the proximal most portions of the gastrointestinal (GI) 
tract, which is characterized by two distinct phenotypes: ulcerative colitis (UC) 
and Crohn’s disease (CD).   It is estimated that nearly 780,000 and 630,000 people 
suffer from UC and CD respectively within the United States alone [2], although 
these numbers are believed to be an underestimate since IBD is often 
misdiagnosed and clinical reporting varies significantly due to the presentation 
of a variety of common symptoms shared by other gastroenterological disorders. 
Consequently, gastroenterologists mainly rely on colonoscopies and histological 
examination before prescribing any particular diagnosis. While colonoscopies 
and subsequent biopsies allow the gastroenterologist to definitively diagnose 
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IBD from other gastrointestinal disorders, they are highly invasive, time 
consuming and costly procedures that only provide a qualitative assessment of 
intestinal inflammation. Alternatively, biomarkers have been studied extensively 
as a means to non-invasively diagnose and monitor disease activity. While the 
measurement of serological biomarkers may seem like a feasible measurement of 
inflammatory related disease indices, these inflammation biomarkers may often 
be elevated as an artifact of some other systemic inflammatory condition.  
Consequently, many researchers are actively investigating the presence and 
concentration of various fecal biomarkers present in patients with IBD.  
 As a result of elevated intestinal inflammation, IBD patients excrete an 
elevated quantity of leukocytes within their stool.  Traditionally, these leukocytes 
have been measured via radioactive labeling, which is often coupled to an 
abdominal scintigraphy procedure to identify inflamed segments of the intestine.   
111Indium labeled granulocyte scintigraphy has been validated as a highly 
sensitive (97% sensitivity) and specific quantitiative assessment of both the extent 
and severity of intestinal inflammation as compared to traditional endoscopic 
and histopathological indices [106].  Although this technique is an invaluable 
measure of the intestinal inflammatory response, the technique requires 
specialized facilities, subjects the patient to radiation exposure.  As a result, this 
technique is primarily used by researchers and is limited in routine clinical 
practice.  As an alternative to measuring leukocytes directly, leukocyte derived 
proteins may also be measured and have shown great promise as indicators of 
disease severity.  
 Although numerous leukocyte derived biomarkers have been investigated 
[111, 113, 189, 190], lactoferrin and calprotectin have been shown to be the most 
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sensitive and specific in discriminating IBD patients from a population of healthy 
patients [111].  Accordingly, our group has developed a QLISA based assay for 
lactoferrin and assessed the concentration of lactoferrin within a spiked human 
sample both within the new microfluidic system and in the first generation 
capillary based system.   
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4.3 METHODS 
Device Fabrication 
Microfluidic devices can be manufactured from thermoplastics using a 
variety of techniques including direct micromachining, laser ablation, injection 
molding and hot embossing.  In order to develop our prototype 
polymethylmethacrylate (PMMA) microchannel design, we opted to use a hot 
embossing technique since a single mold insert may be rapidly manufactured 
and used to create many pmma microchannels, allowing us to rapidly create 
microchannels in pmma that are consistently reproducible.  In working towards 
this goal, we first developed a 2.5” square copper mold insert with raised 
microstructures using the techniques of photolithography and electroplating 
(apapted from [191]).  The raised microstructures are then transferred to the 
pmma substrate via hot embossing to create microstructures within the pmma 
substrate.  Lastly, the device is sealed using a solvent assisted bonding technique 
(adapted from [192]).  An overview of this process is presented in Figure 13 and a 
more detailed description of this process is provided in the following sections.  
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Figure 15.  Profile view of the PMMA microchannel fabrication processs.  First, 
the copper is cleaned and patterned with 250µm thick negative photoresist (SU-8 
2150), allowing for an active site for copper electroplating in the subsequent step, 
producing raised microchannel features on a copper substrate (mold insert).  The 
mold insert is then used as a die in the subsequent hot embossing process to 
produce a microchannel in the desired PMMA substrate.  The device is then 
sealed with a pmma cover, effectively creating an array of sealed microchannels. 
 
The fabrication process begins with a photomask, which in this case is a 
clear field mask.  A simple photomask was first designed in order to optimize the 
fabrication procedure and demonstrate proof of concept for subsequent 
immunoassay reactions.  The photomask consists of microchannels of various 
widths (50, 100 and 250 µm) and pitches (5, 7.5 and 10mm) between 
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microchannels.  The photomask was first designed using AutoCAD 2010 and 
sent to Advanced Reproductions for printing.  Upon receipt, the thin film 
photomask was replicated to create a more durable chrome mask  Once the 
photomask pattern was transferred to a chrome photomask, photolithography 
was performed on a cleaned (acetone followed by DI water) 1mm thick 2.5” 
copper substrate (McMaster Carr, catalog# 9821K12). SU-8 2150 photoresist 
(Microchem) was then spun onto the substrate at 500rpm (100r/s acceleration) 
for 10 seconds followed by spinning at 17000rpm (300r/s acceleration) for 30 
seconds to produce a final thickness of approximately 200um.  The copper plate 
was then placed onto a hot plate and baked at 60°C for 20 minutes followed by a 
40 minute bake at 90°C (softbake).  The coated substrate is then cooled to room 
temperature and exposed at 28mW/cm2 for 17 seconds (476mJ/cm2).  Following 
exposure, the photoresist patterned substrate was placed onto a hot plate and 
baked at 65°C for one hour (a latent image of the pattern should not be visible 
until minutes into the post exposure bake, if a latent image is seen the pattern 
was likely overexposed).  The patterned substrate is then cooled to room 
temperature and developed for ten minutes in SU-8 developer under manual 
agitation.  The end product (micropatterned SU-8 on copper substrate) is shown 
below in Figure 14. 
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Figure 16.  SU-8 patterned copper substrate (left).  The raised SU-8 may be seen 
on top of the copper substrate.  The final width of the microchannel is shown to 
be approximately 260um.  The exposed (developed) regions of the SU-8 serve as 
a substrate for the adhesion of copper during the subsequent electroplating 
process.  Profilometry measurements of the raised copper microchannel structure 
demonstrated the height of the microchannel is approximately 150µm (right).   
 
Once the SU-8 micropatterned copper substrate has been manufactured 
copper electroplating is performed to create raised microchannel structures on 
the copper substrate.  First, the patterned substrate is cleaned extensively with 
acetone followed by a rinse in DI water and air-dried.  The patterned copper 
plate is then placed into a holder 35cm from a bare copper plate (cleaned with 
acetone & DI water).  The apparatus is then submerged in a copper electroplating 
solution (200g copper (II) sulfate pentahydrate, 25ml of concentrated H2SO4 in 
1mL of deionized water) with an applied DC current of 0.2A for 1 hour under stir 
bar agitation.  This was found to produce uniform raised microchannel 
structures of 150µm in height as measured using surface profilometry (figure 16).   
Following fabrication of the micropatterned copper mold insert, hot 
embossing was performed to create microchannel grooves on a PMMA substrate.  
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In order to accomplish this, 1cm thick PMMA sheets were cut into 2” squares and 
cleaned with soap and water and allowed to air dry.  Once clean a piece of 
PMMA is sandwiched between a glass plate and the copper mold insert and 
loaded into a Carver heat press.  Both the top and bottom platens were then 
brought into contact with the copper mold insert and glass plate respectively and 
set to 140°C.  Once the temperature of the platens reached 110°C a pressure of 
250psi is applied to the pmma sheet for a period of 5 minutes and then the 
platens are cooled to room temperature within the press.  The molded pmma is 
then removed from the mold insert.  A second 2” wide, 1cm thick pmma sheet is 
soaked in ethanol for 5 minutes, then brought into contact with the molded 
pmma piece and loaded into the carver heat press between two pieces of glass 
and the platens are heated to 75°C under a pressure of 250psi for 5 minutes.  The 
sealed microchannel coupon is then immediately removed from the press and 
the lumen of the channels is rinsed thoroughly with DI water. 
 
Surface Modification 
 Surface activation is carried out by circulating 1N NaOH through the 
microcahnnels for 60 minutes at 60oC using a peristaltic pump at 0.05ml/min.  
The microchannel is then washed with 2ml of 1X PBS pH 6.0 buffer.  A 0.2% 
diamino PEG (MW 25,000 branched) solution (1X PBS pH 11.5) is then circulated 
thorugh the microchannels at 0.05ml/min using the peristaltic pump for one 
hour at room temperature.  The microchannel is then rinsed for 5 minutes with 
deionized water at 3%.  A 1% w/v gluteraldehyde solution (1X PBS pH 7.2) is 
then incubated within the microchannel for 40 minutes at room temperature.  
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The microchannels are then rinsed for 5 minutes with deionized water at 
0.05ml/min.  The capture antibody solution (100nM lactoferrin or 
myeloperoxidase antibodies in 1X PBS pH 7.2) is then circulated through the 
capillary at 0.02ml/min using a peristaltic pump for one hour at room 
temperature.  The device is then rinsed with 0.05% tween for 2 minutes at 
0.05ml/min using the peristaltic pump followed by a rinse with 1X PBS for 2 
minutes at 0.05ml/min using the peristaltic pump.  The microchannels are then 
blocked by incubating the channels with 2% FBS for one hour at room 
temperature followed by a wash with 0.05% tween (1X PBS pH 7.4) for 2 minutes 
using the peristaltic pump at 0.05ml/min.  The microchannel device is then 
washed with 1X PBS pH 7.4 for 2 minutes using the peristaltic pump at 
0.05ml/min and stored at 4°C until needed.  An overview of the surface 
modified biosensor surface is presented in Figure 15. 
 96 
 
Figure 17.  Optimized chemical modification procedure for antibody 
immobilization within microfluidic QLISA device.   
 
Numerical Simulation 
 In order to investigate the influence of enhanced surface functionalization 
on antigen capture and time to equilibrium, a numerical simulation was 
performed using COMSOL.  The geometry for our analysis is presented below in 
Figure 16 and represents the typical dimensions and volume present within a 
standard 96-well microtiter plate immunoassay. 
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Figure 18.  A 96-well microtiter plate geometry.  The base of each well is 9mm 
with a liquid height of 125um within the well.  Immobilized antibody is 
present at the bottom of the plate and represents the reaction surface.  The 
boundary conditions used for the simulation are also shown.  
 
 In a typical microtiter plate immunoassay, an antigen solution is 
introduced into the well and allowed to react with an antibody present on the 
surface of the bottom of the well under static incubation.  This situation results in 
a diffusion, reaction system in which the antigen species diffuses towards the 
surface where it reacts with an immobilized antibody.  The reaction at the surface 
proceeds according to Equation 1, in which Ag, Ab and C are the antigen, 
antibody and antigen-antibody complex, respectively.  The association and 
dissociation constants are represented by ka and kd, respectively. 
 
[!"]+ !" !!⇄!![!]        (Equation 1) 
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From Equation 1, three differential equations may be formulated to represent the 
rate of change in the concentration of antigen, antibody and antigen-antibody 
complex.  Since we are interested in the rate of change in antigen-antibody 
complex concentration, the differential equation representing the formation of 
antigen-antibody complex is provided in Equation 2. 
 !"!" = !! !" !" − !![!]      (Equation 2) 
 
The equilibrium concentration of antigen-antibody complex (Ceq) may be 
found by finding the analytical solution to Equation 3 at equilibrium in which 
Ab0 represents the initial concentration of antibodies available for binding.  
 !!" = !! !"! !!! ! !!!        (Equation 3) 
  
Since the total number of free antibodies available for binding at any 
given time (Ab) is equal to the difference between the initial antibody 
concentration (Ab0) and the concentration of bound antigen-antibody complex 
(C), Equation 2 may be simplified to be expressed in terms of antigen-antibody 
complex and free antigen (Equation 4). 
 !"!" = !! !" !"! − ! − !![!]     (Equation 4) 
 !"#!" = !∇!!"        (Equation 5) 
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 The bulk concentration of antigen is given by the general diffusion 
equation (Equation 5) and may be coupled to concentration of antigen at the 
surface by establishing appropriate boundary conditions for the system in which 
the three walls of the liquid interface are treated as insulating boundaries and 
establishing a flux boundary at the reaction surface at the bottom of the 
microtiter plate (Figure 2) by imposing a weak form boundary in COMSOL.  
Constants were chosen to reflect actual immunoassay working conditions with ka 
= 1*105 1/M*s, kd = 1*10-3 1/s, C0 = 100nM and D = 1*10-11 m/s2.  
 
Immunoassay Protocol 
Approximately 1g of human stool samples were weighed and diluted 5 
times (v/w) with an extraction buffer (8.359mg of ethylenediaminetetraacetic 
acid, 250µL of FBS, 5mL of glycerol, 12.5µL of tween, 250µL protease inhibitor 
cocktail and 25mL of 1X PBS pH 7.4). Diluted samples were then incubated at 
4oC for 15 minutes. The solution was then homogenized and incubated again at 
4oC for 15 minutes.  To this solution an amount of lactoferrin was added to a final 
concentration of 100ng/ml.  The solution is then centrifuged at 14,000RPM for 30 
minutes at 4oC. All samples are diluted 1:10, 1:100, 1:1000, and 1:10,000 in 1X PBS 
pH 7.4.  
To generate standard curves, standard dilutions of lactoferrin were then 
introduced into the microchannel using a syringe and allowed to incubate for 60 
minutes followed by a wash with 0.05% tween20 in 1X PBS pH 7.4 at a flow rate 
of 0.05ml/min.  100nM biotinylated secondary antibody to lactoferrin is then 
incubated within the microchannel for 60 minutes followed by a wash with 
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0.05% tween20 in 1X PBS pH 7.4 at a flow rate of 0.05ml/min. Next, a 100nM 
solution of streptavidin conjugated quantum dots is incubated for 60 minutes 
and then washed with 0.05% tween20 in 1X PBS pH 7.4 at a flow rate of 
0.05ml/min.  
The microchannel device is then loaded into a holder where quantum dots 
conjugates are excited with an ultraviolet light emitting diode (385nm 
wavelength) with an output power of 80mW (Nichia Corporation). Fluorescence 
is captured with a charge-coupled device (CCD) camera (Stingray, AVT-FS-033B) 
through the computer software program AVT SmartView.  Images are gathered 
at a variety of integration times and calibration curves Raw images are processed 
within MATLAB.  Image fluorescence intensity is quantified through comparison 
to a standard calibration curve to determine the lactoferrin concentration.  The 
data acquisition setup is presented in Figure 17.  An overview of the entire 
QLISA workflow is presented in Figure 18.  A raw image of the illuminated 
capillary and the output from the image processing algorithm (Appendix H) is 
presented in Figure 19.   
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Figure 19.  QLISA optical setup used for data acquisition.   
 Figure 20.  Overview of the immunoassay and data acquisition steps for QLISA. 
 
 
 102 
 
 
Figure 21.  Image analysis performed within Matlab.  The function presented in 
Appendix H was used to determine the intensity of the region of interest (ROI) 
within the original image at various integration times.  
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4.4 RESULTS & DISCUSSION 
 
 
 
Figure 22: Numerical simulation showing time to equilibration as a function of 
primary antibody surface concentration. 
 
The results from our simulations indicate that equilibrium time is reduced 
as the density of primary immobilized antibody is increased. This can be 
expected, because as the surface concentration of primary antibody is increased, 
there are increased opportunities for the antigen to bind the antibody and form 
an antigen-antibody complex at the reaction surface. Our experimental results 
show a primary antibody concentration of approximately 2ng/cm2 and 8ng/cm2 
for passive adsorption and PEG with glutaraldehyde antibody immobilization 
strategies, respectively. When comparing these experimental concentrations with 
our numerical simulations (Figure 20) we see that equilibrium time for the PEG 
with glutaraldehyde chemistry is over 20% faster than passive adsorption. 
Further, our simulations support the need for approximately 1 hour of 
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incubation of primary antibody when using the PEG with glutaraldehyde 
chemistry.  This is demonstrated in Figure 20, where 10ng/cm2 of primary 
antibody requires just over 3600 seconds to reach equilibrium with its antigen.  It 
was also observed that as the antibody surface concentration is increased above 
about 100ng/cm2, we see limited reduction in equilibrium time.  This is due to 
the saturation of the antibody-antigen reaction given our initial conditions 
discussed in the Methods section, and thus there is limited benefit to improving 
equilibrium binding time through increasing primary antibody concentration 
beyond 100ng/cm2.  Therefore, if possible, increasing primary antibody 
concentration from 10 to 100ng/cm2 could further reduce equilibrium binding 
time by another 20-25%.   
 Linear or branched PEG has many secondary and primary amino groups 
available for conjugation with capture antibodies within a heterogeneous 
immunoassay. It is known that non-zero length crosslinkers like polyethylene 
glycol or polyethylene imine (PEI) can result in increased sensitivity of an assay 
when used as the bridge between the primary antibody and the substrate [193]. 
PEI in particular has been used to covalently bind antibodies onto the surface of 
PMMA microchannels for ELISA applications [146, 194] and has shown 
increased antigen binding due to increased mobility of the antibody while 
maintaining the antigen binding capacity of the epitope [145, 146].  By adapting 
the length of the antibody crosslinker (di-amino PEG) a nearly 16 fold increase in 
signal to noise ratio was realized over traditional zero-length crosslinking 
methods as shown in figure 21.  The reduced steric hinderance of the capture 
antibody in combination with the reduced non-specific protein adsorption was 
demonstrated with a previously developed capillary based MPO assay [123]. 
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Figure 23  Raw intensity values of negative control  sample compared to 1nm 
MPO on capillary immunoassay with enhanced surface chemistry (a) and signal 
to noise ratio using enhanced antibody immobilization for 1nm MPO taken at 
50us integration time (b).   
 
The increased sensitivity of the microfluidic platform was observed in 
measuring the IBD biomarker lactoferrin within a spiked human sample (Figure 
22).  There was a noticeable increase in signal generated from the human samples 
as a result of non-specific adsorption of extraneous proteins contained within the 
sample.  Limit of detections for the microfluidic lactoferrin assay were calculated 
as being the concentration of analyte necessary to generate a signal that is equal 
to the standard deviation plus three times the standard deviation of the 
background (background noise) as interpolated using the standard curves for 
each platform (Figure 22) The limit of detection for the microfluidic lactoferrin 
assay was calculated to be 6.4ng/ml and 39.4ng/ml for the capillary based assay.   
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Figure 24.  Standard curves for lactoferrin generated using both the microfluidic 
and capillary immunoassay platforms.  Spiked human samples and negative 
controls were assessed using both platforms for comparison.  Images were 
collected at an integration time of 50us.   
 
  
y	  =	  1.5583x	  +	  16.112	  R²	  =	  0.98866	  
y	  =	  0.6126x	  +	  7.8947	  R²	  =	  0.95482	  0	  50	  
100	  150	  
200	  250	  
300	  350	  
0	   50	   100	   150	   200	   250	  
In
te
ns
it
y	  
9A
U
)	  
Lactoferrin	  Concentration	  (ng/ml)	  
QLIDA	  Human	  Sample	  Comparison	  
Microchannel	  Calibration	  Curve	  Capillary	  Calibration	  Curve	  
Spiked	  Human	  Sample	  (microchannel)	  Spiked	  Human	  Sample	  (capillary)	  
 107 
CHAPTER 5 
CONCLUSION 
 
 The pathophysiology of Infammatory bowel disease and the progression 
to colorectal cancer remains to be fully elucidated.  The objective of this work is 
to integrate computational genomic data including miRNA and mRNA gene 
expression signatures and various knowledgebases to 1) Better define 
transcriptional regulation in IBD phenotypes, identify therapeutic targets 
currently available for other autoimmune diseases for drug repositioning; 2) 
Identify discrete genetic classifiers that can be used to differentiate between 
disease phenotypes; 3) Develop a proof of concept highly scalable microfluidic 
QLISA platform for the detection of the IBD biomarker lactoferrin within human 
stool samples.   
 Gene signatures as well as pathway analysis of the IBD and CRC 
transcriptome reveals significant overlap between the two diseases as well as 
with IBD and other autoimmune diseases including lupus, type 1 diabetes and 
rheumatoid arthritis.  Our study is the first to map genetic links between 
enteropathic arthritic symptoms in patients with IBD and gene signatures 
expressed within the colon.  Our integrated analysis of transcriptional regulation 
maps the involvement of miRNA in IBD as well as other autoimmune diseases 
and colorectal cancer, while identifying therapeutic targets for the repositioning 
of existing therapeutics in the treatment of IBD.  Unique biomarker sets were 
found to accurately differentiate between IBD phenotypes and the four Dukes 
stages of CRC. 
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 The second generation microfluidic QLISA platform with enhanced 
antibody conjugation strategies using a diamino PEG crosslinker was found to 
improve signal to noise ratios and increase assay sensitivity while lowering the 
limit of detection for lactoferrin to 6.4ng/ml.  The device was shown to detect 
lactoferrin within spike dhuman stool samples and demonstrates transitional 
clinical potential beyond the gastrointestinal biomarker space and is currently 
being licensed by Net Scientific.   
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5.1 CONTRIBUTIONS 
 Throughout my time at Drexel University I have had the opportunity to 
collaborate on a variety of research projects with many spectacularly talented 
colleagues and mentors.  My work with Dr. Aydin Tozeren has led to the 
preparation of two manuscripts (chapters 2 & 3) as well as many other research 
ideas and ongoing collaborations.  The manuscript presented in chapter 2 was 
submitted to the journal of Inflammatory Bowel Disease in February 2012 and is 
currently under review for publication.  The third chapter is a manuscript draft 
which is intended for submission to a computational or clinical journal related to 
cancer.  The final chapter is composed of work performed under Dr. Elisabth 
Papazoglou and Dr. Moses Noh has led to the development of two patents (PCT 
International Patent Application No.PCT/US11/36290 and U.S. Patent 
Application No.61/334,056) two manuscripts and a book chapter.  I co-atuthored 
one manuscript with David Hansberry regarding the optimization of antibody 
conjugation methods onto PMMA substrates was submitted to the journal of 
Biomedical Microdevices and is currently under editorial review.  The methods 
presented within the paper are also currently protected under provisional patent 
applications.  The microfluidic immunoassay platform developed under Dr. 
Noh’s guidance with integrated electrothermal mixing electrodes was prepared 
in collaboration with Chengjie Yu and was presented at MicroTAS 2011 in Seatlle 
Washington [195].  I am also a co-author of a book chapter within, “Quantum 
Dots: Applications, Synthesis and Characterization” entitled, “Quantum Dots for 
Bioimaging, Cellular Labeling, and Diagnostics,” which is currently in press.  I 
am also a coauthor on a paper written with Dr. John Fitzpatrick and Dr. Franco 
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Capaldi entitled, “Effect of Decellularization Protocol on the Mechanical 
Behavior of Porcine Descending Aorta,” [196].    
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5.2 FUTURE WORK 
 Biomarkers in addition to lactoferrin identified though computational 
analysis for the stratification of colonic disease phenotypes must be validated on 
a clinically relevant cohort for validation of both the efficacy of patient 
classification using identified biomarker sets in terms of assay panel sensitivity 
and specificity and clinical performance of the multiplexed microfluidic 
immunoassay platform alongside standard ELISA methods.  This research 
requires IBR approval, large sample sizes, extensive assay development and is 
outside of the scope of this thesis. 
 Ongoing bioinformatics projects related to this work involve studying the 
interaction of the intestinal microbiome to model host-pathogen itneractions and 
their involvement in driving the pathogenesis of IBD and CRC.  Microbial 
species may be identified through 16S rRNA gene sequencing, while the host 
response may be measured through microarray analysis.  Statistically enriched 
human receptors may be mapped to interacting proteins using the Human 
Protein Database (HPRD) and homologous proteins or enriched protein domains 
and conserved eukaryotic binding motifs may then be found within enriched 
bacterial species to identify unique host-pathogen interactions and better 
understand this complex phenomena and identify potential therapeutic 
pathways to limit the mucosal immune response.   
 The QLISA platform is currently licensed by Net Scientific and being 
transitioned into the cardiac biomarker market as a bedside diagnostic panel and 
associated device..  The assay has extended to a micro bead based immunoassay 
to further increase assay sensitivity and decrease the limit of detection, required 
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by cardiac immunoassays which need to detect picomolar concentrations of 
analytes within serum.   
 There are other means of performing micromixing, particularly related to 
the manipulation of microparticles within luquids including AC electrokinetic 
mixing and dielectrophoresis .  These methods require extensive characterization 
within biological systems to determine their efficacy in the enhancement of 
immunoassay kinetics.  Although these methods are not readily transferable to 
the PMMA substrate, other surface activation techniques may be applied to glass 
substrates and integrated with electrokinetic mixing components within a 
particle based assay and microfluidic liquid handling device to develop the next 
generation microfluidic QLISA platform for clinical use and validation.  This 
work also requires extensive study of the complex interactions between electrical 
fields and antigen-antibody binding kinetics and affinity.  
 113 
References 1.	   Molodecky,	   N.A.,	   et	   al.,	   Increasing	   incidence	   and	   prevalence	   of	   the	  
inflammatory	   bowel	   diseases	   with	   time,	   based	   on	   systematic	   review.	  Gastroenterology,	  2012.	  142(1):	  p.	  46-­‐54	  e42;	  quiz	  e30.	  2.	   Loftus,	   E.V.,	   Clinical	   epidemiology	   of	   inflammatory	   bowel	   disease:	   Incidence,	  
prevalence,	  and	  environmental	  influences.	  Gastroenterology,	  2004.	  126(6):	  p.	  1504-­‐1517.	  3.	   Assche,	   G.V.,	   Fecal	   biomarkers	   for	   the	   diagnosis	   and	   management	   of	  
inflammatory	  bowel	  disease.	  Gastroenterol	  Hepatol	  (N	  Y),	  2011.	  7(6):	  p.	  396-­‐8.	  4.	   Cho,	   J.H.,	   The	   genetics	   and	   immunopathogenesis	   of	   inflammatory	   bowel	  
disease.	  Nature	  Reviews	  Immunology,	  2008.	  8:	  p.	  458-­‐466.	  5.	   Zhang,	  H.,	  et	  al.,	  Genetics	  of	  inflammatory	  bowel	  disease:	  clues	  to	  pathogenesis.	  British	  Medical	  Bulletin,	  2008.	  87(1):	  p.	  17-­‐30.	  6.	   Xavier,	   R.J.	   and	  D.K.	   Podolsky,	  Unravelling	   the	  pathogenesis	  of	   inflammatory	  
bowel	  disease.	  Nature,	  2007.	  448(7152):	  p.	  427-­‐434.	  7.	   Gassler,	   N.,	   et	   al.,	   Inflammatory	   bowel	   disease	   is	   associated	  with	   changes	   of	  
enterocytic	   junctions.	   American	   Journal	   of	   Physiology-­‐Gastrointestinal	   and	  Liver	  Physiology,	  2001.	  281(1):	  p.	  G216-­‐G228.	  8.	   Holden,	  W.,	  T.	  Orchard,	  and	  P.	  Wordsworth,	  Enteropathic	  arthritis.	  Rheum	  Dis	  Clin	  North	  Am,	  2003.	  29(3):	  p.	  513-­‐30,	  viii.	  9.	   Rodriguez-­‐Reyna,	   T.S.,	   C.	   Martinez-­‐Reyes,	   and	   J.K.	   Yamamoto-­‐Furusho,	  
Rheumatic	   manifestations	   of	   inflammatory	   bowel	   disease.	   World	   J	  Gastroenterol,	  2009.	  15(44):	  p.	  5517-­‐24.	  10.	   Ha,	   T.Y.,	  MicroRNAs	   in	  Human	  Diseases:	   From	  Autoimmune	  Diseases	   to	   Skin,	  
Psychiatric	   and	  Neurodegenerative	  Diseases.	   Immune	   Netw,	   2011.	   11(5):	   p.	  227-­‐44.	  11.	   Frank,	  D.N.,	  et	  al.,	  Disease	  Phenotype	  and	  Genotype	  Are	  Associated	  with	  Shifts	  
in	   Intestinal-­‐associated	   Microbiota	   in	   Inflammatory	   Bowel	   Diseases.	  Inflammatory	  Bowel	  Diseases,	  2011.	  17(1):	  p.	  179-­‐184.	  12.	   Fava,	   F.	   and	   S.	   Danese,	   Intestinal	  microbiota	   in	   inflammatory	  bowel	  disease:	  
Friend	  of	  foe?	  World	  J	  Gastroenterol,	  2011.	  17(5):	  p.	  557-­‐66.	  13.	   Vanderploeg,	   R.,	   et	   al.,	   Influences	   of	   Intestinal	   Bacteria	   in	   Human	  
Inflammatory	   Bowel	   Disease.	   Infectious	   Disease	   Clinics	   of	   North	   America,	  2010.	  24(4):	  p.	  977-­‐+.	  14.	   Sartor,	   R.B.,	   Genetics	   and	   Environmental	   Interactions	   Shape	   the	   Intestinal	  
Microbiome	   to	   Promote	   Inflammatory	   Bowel	   Disease	   Versus	   Mucosal	  
Homeostasis.	  Gastroenterology,	  2010.	  139(6):	  p.	  1816-­‐1819.	  15.	   Friswell,	   M.,	   B.	   Campbell,	   and	   J.	   Rhodes,	   The	   Role	   of	   Bacteria	   in	   the	  
Pathogenesis	   of	   Inflammatory	   Bowel	   Disease.	   Gut	   and	   Liver,	   2010.	   4(3):	   p.	  295-­‐306.	  16.	   Chichlowski,	  M.	  and	  L.P.	  Hale,	  Bacterial-­‐mucosal	  interactions	  in	  inflammatory	  
bowel	   disease-­‐an	   alliance	   gone	   bad.	   American	   Journal	   of	   Physiology-­‐Gastrointestinal	  and	  Liver	  Physiology,	  2008.	  295(6):	  p.	  G1139-­‐G1149.	  
 114 
17.	   Gill,	   S.R.,	   et	   al.,	  Metagenomic	   analysis	   of	   the	   human	   distal	   gut	   microbiome.	  Science,	  2006.	  312(5778):	  p.	  1355-­‐1359.	  18.	   Mahida,	  Y.R.	  and	  V.E.	  Rolfe,	  Host-­‐bacterial	  interactions	  in	  inflammatory	  bowel	  
disease.	  Clinical	  Science,	  2004.	  107(4):	  p.	  331-­‐341.	  19.	   Goh,	  K.I.,	   et	   al.,	  The	  human	  disease	  network.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2007.	  
104(21):	  p.	  8685-­‐90.	  20.	   Xu,	   J.	   and	   Y.	   Li,	   Discovering	   disease-­‐genes	   by	   topological	   features	   in	   human	  
protein-­‐protein	  interaction	  network.	  Bioinformatics,	  2006.	  22(22):	  p.	  2800-­‐5.	  21.	   Dudley,	   J.T.	   and	   A.J.	   Butte,	   Identification	   of	   discriminating	   biomarkers	   for	  
human	  disease	  using	  integrative	  network	  biology.	  Pac	  Symp	  Biocomput,	  2009:	  p.	  27-­‐38.	  22.	   Zanzoni,	   A.,	   M.	   Soler-­‐Lopez,	   and	   P.	   Aloy,	   A	   network	   medicine	   approach	   to	  
human	  disease.	  FEBS	  Lett,	  2009.	  583(11):	  p.	  1759-­‐65.	  23.	   Linghu,	  B.,	  et	  al.,	  Genome-­‐wide	  prioritization	  of	  disease	  genes	  and	  identification	  
of	   disease-­‐disease	   associations	   from	   an	   integrated	   human	   functional	   linkage	  
network.	  Genome	  Biol,	  2009.	  10(9):	  p.	  R91.	  24.	   Barrenas,	   F.,	   et	   al.,	   Network	   properties	   of	   complex	   human	   disease	   genes	  
identified	  through	  genome-­‐wide	  association	  studies.	  Plos	  One,	  2009.	  4(11):	  p.	  e8090.	  25.	   Suthram,	   S.,	   et	   al.,	   Network-­‐based	   elucidation	   of	   human	   disease	   similarities	  
reveals	   common	   functional	   modules	   enriched	   for	   pluripotent	   drug	   targets.	  PLoS	  Comput	  Biol,	  2010.	  6(2):	  p.	  e1000662.	  26.	   Zhang,	   S.H.,	   et	   al.,	   From	   phenotype	   to	   gene:	   detecting	   disease-­‐specific	   gene	  
functional	   modules	   via	   a	   text-­‐based	   human	   disease	   phenotype	   network	  
construction.	  FEBS	  Lett,	  2010.	  584(16):	  p.	  3635-­‐43.	  27.	   Zhang,	   Y.,	   et	   al.,	   Systematic	   analysis,	   comparison,	   and	   integration	   of	   disease	  
based	   human	   genetic	   association	   data	   and	   mouse	   genetic	   phenotypic	  
information.	  BMC	  Med	  Genomics,	  2010.	  3:	  p.	  1.	  28.	   Nguyen,	   T.P.	   and	   F.	   Jordan,	  A	  quantitative	  approach	   to	   study	   indirect	  effects	  
among	  disease	  proteins	   in	   the	  human	  protein	   interaction	  network.	   BMC	   Syst	  Biol,	  2010.	  4:	  p.	  103.	  29.	   Zhang,	   X.,	   et	   al.,	   The	   expanded	   human	   disease	   network	   combining	   protein-­‐
protein	  interaction	  information.	  Eur	  J	  Hum	  Genet,	  2011.	  19(7):	  p.	  783-­‐8.	  30.	   Hu,	   G.	   and	   P.	   Agarwal,	   Human	   disease-­‐drug	   network	   based	   on	   genomic	  
expression	  profiles.	  Plos	  One,	  2009.	  4(8):	  p.	  e6536.	  31.	   Dawany,	   N.B.,	   W.N.	   Dampier,	   and	   A.	   Tozeren,	   Large-­‐scale	   integration	   of	  
microarray	  data	  reveals	  genes	  and	  pathways	  common	  to	  multiple	  cancer	  types.	  Int	  J	  Cancer,	  2011.	  128(12):	  p.	  2881-­‐91.	  32.	   Noble,	  C.L.,	  et	  al.,	  Regional	  variation	  in	  gene	  expression	  in	  the	  healthy	  colon	  is	  
dysregulated	  in	  ulcerative	  colitis.	  Gut,	  2008.	  57(10):	  p.	  1398-­‐405.	  33.	   Noble,	   C.L.,	   et	   al.,	   Characterization	   of	   Intestinal	   Gene	   Expression	   Profiles	   in	  
Crohn's	   Disease	   by	   Genome-­‐wide	   Microarray	   Analysis.	   Inflammatory	   Bowel	  Diseases,	  2010.	  16(10):	  p.	  1717-­‐1728.	  34.	   Barrett,	   T.,	   et	   al.,	   NCBI	   GEO:	   mining	   tens	   of	   millions	   of	   expression	   profiles	   -­‐	  
database	  and	  tools	  update.	  Nucleic	  Acids	  Research,	  2007.	  35:	  p.	  D760-­‐D765.	  
 115 
35.	   Edgar,	  R.,	  M.	  Domrachev,	  and	  A.E.	  Lash,	  Gene	  Expression	  Omnibus:	  NCBI	  gene	  
expression	   and	   hybridization	   array	   data	   repository.	   Nucleic	   Acids	   Research,	  2002.	  30(1):	  p.	  207-­‐210.	  36.	   Shieh,	  A.D.	   and	  Y.S.	  Hung,	  Detecting	  outlier	  samples	   in	  microarray	  data.	   Stat	  Appl	  Genet	  Mol	  Biol,	  2009.	  8(1):	  p.	  Article	  13.	  37.	   Olsen,	   J.,	   et	   al.,	  Diagnosis	  of	  ulcerative	  colitis	  before	  onset	  of	   inflammation	  by	  
multivariate	  modeling	  of	  genome-­‐wide	  gene	  expression	  data.	   Inflamm	  Bowel	  Dis,	  2009.	  15(7):	  p.	  1032-­‐8.	  38.	   Carey,	   R.,	   et	   al.,	   Activation	   of	   an	   IL-­‐6:STAT3-­‐dependent	   transcriptome	   in	  
pediatric-­‐onset	  inflammatory	  bowel	  disease.	  Inflamm	  Bowel	  Dis,	  2008.	  14(4):	  p.	  446-­‐57.	  39.	   Ahrens,	  R.,	  et	  al.,	  Intestinal	  macrophage/epithelial	  cell-­‐derived	  CCL11/eotaxin-­‐
1	  mediates	  eosinophil	  recruitment	  and	  function	  in	  pediatric	  ulcerative	  colitis.	   J	  Immunol,	  2008.	  181(10):	  p.	  7390-­‐9.	  40.	   Kugathasan,	  S.,	  et	  al.,	  Loci	  on	  20q13	  and	  21q22	  are	  associated	  with	  pediatric-­‐
onset	   inflammatory	   bowel	   disease.	   Nature	   Genetics,	   2008.	   40(10):	   p.	   1211-­‐1215.	  41.	   Bjerrum,	   J.T.,	   et	   al.,	  Genome-­‐wide	  gene	  expression	  analysis	  of	  mucosal	  colonic	  
biopsies	  and	  isolated	  colonocytes	  suggests	  a	  continuous	  inflammatory	  state	  in	  
the	  lamina	  propria	  of	  patients	  with	  quiescent	  ulcerative	  colitis.	  Inflamm	  Bowel	  Dis,	  2010.	  16(6):	  p.	  999-­‐1007.	  42.	   Arijs,	   I.,	   et	   al.,	   Mucosal	   Gene	   Expression	   of	   Antimicrobial	   Peptides	   in	  
Inflammatory	  Bowel	  Disease	  Before	  and	  After	  First	  Infliximab	  Treatment.	  Plos	  One,	  2009.	  4(11).	  43.	   Irizarry,	  R.A.,	  et	  al.,	  Exploration,	  normalization,	  and	  summaries	  of	  high	  density	  
oligonucleotide	  array	  probe	  level	  data.	  Biostatistics,	  2003.	  4(2):	  p.	  249-­‐264.	  44.	   Irizarry,	   R.A.,	   et	   al.,	   Summaries	   of	   affymetrix	   GeneChip	   probe	   level	   data.	  Nucleic	  Acids	  Research,	  2003.	  31(4).	  45.	   Bolstad,	   B.M.,	   et	   al.,	  A	  comparison	  of	  normalization	  methods	   for	  high	  density	  
oligonucleotide	  array	  data	  based	  on	  variance	  and	  bias.	  Bioinformatics,	   2003.	  
19(2):	  p.	  185-­‐193.	  46.	   Dai,	   M.H.,	   et	   al.,	   Evolving	   gene/transcript	   definitions	   significantly	   alter	   the	  
interpretation	  of	  GeneChip	  data.	  Nucleic	  Acids	  Research,	  2005.	  33(20).	  47.	   Sandberg,	  R.	  and	  O.	  Larsson,	  Improved	  precision	  and	  accuracy	  for	  microarrays	  
using	  updated	  probe	  set	  definitions.	  Bmc	  Bioinformatics,	  2007.	  8.	  48.	   Johnson,	  W.E.,	   C.	   Li,	   and	   A.	   Rabinovic,	  Adjusting	  batch	   effects	   in	  microarray	  
expression	   data	   using	   empirical	   Bayes	  methods.	   Biostatistics,	   2007.	   8(1):	   p.	  118-­‐27.	  49.	   Tusher,	   V.G.,	   R.	   Tibshirani,	   and	   G.	   Chu,	   Significance	   analysis	   of	  microarrays	  
applied	   to	   the	   ionizing	   radiation	   response.	   Proceedings	   of	   the	   National	  Academy	  of	  Sciences	  of	   the	  United	  States	  of	  America,	  2001.	  98(9):	  p.	  5116-­‐5121.	  50.	   Hong,	  F.,	   et	   al.,	  RankProd:	  a	  bioconductor	  package	  for	  detecting	  differentially	  
expressed	  genes	  in	  meta-­‐analysis.	  Bioinformatics,	  2006.	  22(22):	  p.	  2825-­‐7.	  
 116 
51.	   Breitling,	  R.,	  et	  al.,	  Rank	  products:	  a	  simple,	  yet	  powerful,	  new	  method	  to	  detect	  
differentially	  regulated	  genes	  in	  replicated	  microarray	  experiments.	  FEBS	  Lett,	  2004.	  573(1-­‐3):	  p.	  83-­‐92.	  52.	   Dennis,	  G.,	  et	  al.,	  DAVID:	  Database	  for	  annotation,	  visualization,	  and	  integrated	  
discovery.	  Genome	  Biology,	  2003.	  4(9).	  53.	   Huang,	   D.W.,	   B.T.	   Sherman,	   and	   R.A.	   Lempicki,	   Systematic	   and	   integrative	  
analysis	   of	   large	   gene	   lists	   using	   DAVID	   bioinformatics	   resources.	   Nature	  Protocols,	  2009.	  4(1):	  p.	  44-­‐57.	  54.	   Alibes,	  A.,	  et	  al.,	   IDconverter	  and	  IDClight:	  Conversion	  and	  annotation	  of	  gene	  
and	  protein	  IDs.	  Bmc	  Bioinformatics,	  2007.	  8.	  55.	   Diehn,	  M.,	  et	  al.,	  SOURCE:	  a	  unified	  genomic	  resource	  of	  functional	  annotations,	  
ontologies,	  and	  gene	  expression	  data.	  Nucleic	  Acids	  Research,	  2003.	  31(1):	  p.	  219-­‐223.	  56.	   Dawany,	  N.B.	  and	  A.	  Tozeren,	  Asymmetric	  microarray	  data	  produces	  gene	  lists	  
highly	   predictive	   of	   research	   literature	   on	   multiple	   cancer	   types.	   Bmc	  Bioinformatics,	  2010.	  11.	  57.	   Kanehisa,	  M.,	  et	  al.,	  From	  genomics	  to	  chemical	  genomics:	  new	  developments	  in	  
KEGG.	  Nucleic	  Acids	  Research,	  2006.	  34:	  p.	  D354-­‐D357.	  58.	   Gaulton,	   A.,	   et	   al.,	   ChEMBL:	   a	   large-­‐scale	   bioactivity	   database	   for	   drug	  
discovery.	  Nucleic	  Acids	  Res,	  2011.	  59.	   Wu,	   F.,	   et	   al.,	   Identification	   of	   microRNAs	   associated	   with	   ileal	   and	   colonic	  
Crohn's	  disease.	  Inflamm	  Bowel	  Dis,	  2010.	  16(10):	  p.	  1729-­‐38.	  60.	   Wu,	   F.,	   et	   al.,	  MicroRNAs	  are	  differentially	   expressed	   in	  ulcerative	   colitis	   and	  
alter	   expression	   of	   macrophage	   inflammatory	   peptide-­‐2	   alpha.	  Gastroenterology,	  2008.	  135(5):	  p.	  1624-­‐1635	  e24.	  61.	   Pekow,	   J.R.,	   et	   al.,	   miR-­‐143	   and	   miR-­‐145	   are	   downregulated	   in	   ulcerative	  
colitis:	   putative	   regulators	   of	   inflammation	   and	   protooncogenes.	   Inflamm	  Bowel	  Dis,	  2012.	  18(1):	  p.	  94-­‐100.	  62.	   Fasseu,	   M.,	   et	   al.,	   Identification	   of	   restricted	   subsets	   of	   mature	   microRNA	  
abnormally	  expressed	  in	  inactive	  colonic	  mucosa	  of	  patients	  with	  inflammatory	  
bowel	  disease.	  Plos	  One,	  2010.	  5(10).	  63.	   Takagi,	   T.,	   et	   al.,	   Increased	   expression	   of	   microRNA	   in	   the	   inflamed	   colonic	  
mucosa	  of	  patients	  with	  active	  ulcerative	  colitis.	  J	  Gastroenterol	  Hepatol,	  2010.	  
25	  Suppl	  1:	  p.	  S129-­‐33.	  64.	   Dweep,	   H.,	   et	   al.,	  miRWalk-­‐-­‐database:	   prediction	   of	   possible	   miRNA	   binding	  
sites	  by	  "walking"	  the	  genes	  of	  three	  genomes.	   J	  Biomed	  Inform,	  2011.	  44(5):	  p.	  839-­‐47.	  65.	   Park,	   J.Y.,	  et	  al.,	  Proteomic	  analysis	  of	  pancreatic	  juice	  for	  the	  identification	  of	  
biomarkers	   of	   pancreatic	   cancer.	   J	   Cancer	   Res	   Clin	   Oncol,	   2011.	  137(8):	   p.	  1229-­‐38.	  66.	   Planas,	   R.,	   et	   al.,	  Regenerating	   gene	   Ialpha	   is	   a	   biomarker	   for	   diagnosis	   and	  
monitoring	  of	  celiac	  disease:	  a	  preliminary	  study.	  Transl	  Res,	  2011.	  158(3):	  p.	  140-­‐5.	  67.	   Astorri,	   E.,	   et	   al.,	   Circulating	   Reg1alpha	   proteins	   and	   autoantibodies	   to	  
Reg1alpha	   proteins	   as	   biomarkers	   of	   beta-­‐cell	   regeneration	   and	   damage	   in	  
type	  1	  diabetes.	  Horm	  Metab	  Res,	  2010.	  42(13):	  p.	  955-­‐60.	  
 117 
68.	   Usami,	   S.,	   et	   al.,	   Regenerating	   gene	   I	   regulates	   interleukin-­‐6	   production	   in	  
squamous	   esophageal	   cancer	   cells.	   Biochem	   Biophys	   Res	   Commun,	   2010.	  
392(1):	  p.	  4-­‐8.	  69.	   Ezzat,	   M.,	   et	   al.,	   Elevated	   production	   of	   serum	  B-­‐cell-­‐attracting	   chemokine-­‐1	  
(BCA-­‐1/CXCL13)	   is	   correlated	   with	   childhood-­‐onset	   lupus	   disease	   activity,	  
severity,	  and	  renal	  involvement.	  Lupus,	  2011.	  20(8):	  p.	  845-­‐54.	  70.	   El-­‐Haibi,	  C.P.,	  et	  al.,	  CXCL13	  mediates	  prostate	  cancer	  cell	  proliferation	  through	  
JNK	  signalling	  and	  invasion	  through	  ERK	  activation.	  Cell	  Prolif,	  2011.	  44(4):	  p.	  311-­‐9.	  71.	   Meeuwisse,	   C.M.,	   et	   al.,	   Identification	  of	  CXCL13	  as	  a	  marker	   for	   rheumatoid	  
arthritis	   outcome	   using	   an	   in	   silico	   model	   of	   the	   rheumatic	   joint.	   Arthritis	  Rheum,	  2011.	  63(5):	  p.	  1265-­‐73.	  72.	   Chung-­‐Faye,	   G.,	   et	   al.,	   Fecal	  M2-­‐pyruvate	   kinase	   (M2-­‐PK):	   a	   novel	  marker	   of	  
intestinal	  inflammation.	  Inflamm	  Bowel	  Dis,	  2007.	  13(11):	  p.	  1374-­‐8.	  73.	   Joishy,	  M.,	  et	  al.,	  Fecal	  Calprotectin	  and	  Lactoferrin	  as	  Noninvasive	  Markers	  of	  
Pediatric	  Inflammatory	  Bowel	  Disease.	   Journal	   of	  Pediatric	  Gastroenterology	  and	  Nutrition,	  2009.	  48(1):	  p.	  48-­‐54.	  74.	   D'Inca,	   R.,	   et	   al.,	   Calprotectin	   and	   lactoferrin	   in	   the	   assessment	   of	   intestinal	  
inflammation	  and	  organic	  disease.	  International	  Journal	  of	  Colorectal	  Disease,	  2007.	  22(4):	  p.	  429-­‐437.	  75.	   Noss,	   E.H.,	   et	   al.,	   Modulation	   of	   matrix	   metalloproteinase	   production	   by	  
rheumatoid	   arthritis	   synovial	   fibroblasts	   after	   cadherin	   11	   engagement.	  Arthritis	  Rheum,	  2011.	  63(12):	  p.	  3768-­‐78.	  76.	   Werlin,	   S.L.,	   et	   al.,	  Evidence	  of	   intestinal	   inflammation	   in	  patients	  with	  cystic	  
fibrosis.	  J	  Pediatr	  Gastroenterol	  Nutr,	  2010.	  51(3):	  p.	  304-­‐8.	  77.	   Zhang,	   C.,	   et	   al.,	   Dieckol	   from	   Ecklonia	   cava	   Regulates	   Invasion	   of	   Human	  
Fibrosarcoma	   Cells	   and	   Modulates	   MMP-­‐2	   and	   MMP-­‐9	   Expression	   via	   NF-­‐
kappaB	   Pathway.	   Evid	   Based	   Complement	   Alternat	   Med,	   2011.	   2011:	   p.	  140462.	  78.	   Garamszegi,	   N.,	   S.P.	   Garamszegi,	   and	   S.P.	   Scully,	  Matrix	  metalloproteinase-­‐1	  
contribution	  to	  sarcoma	  cell	  invasion.	  J	  Cell	  Mol	  Med,	  2011.	  79.	   Ouban,	   A.	   and	   A.A.	   Ahmed,	   Claudins	   in	   human	   cancer:	   a	   review.	   Histol	  Histopathol,	  2010.	  25(1):	  p.	  83-­‐90.	  80.	   Salzman,	   N.H.,	   et	   al.,	   Enteric	   defensins	   are	   essential	   regulators	   of	   intestinal	  
microbial	  ecology.	  Nat	  Immunol,	  2010.	  11(1):	  p.	  76-­‐83.	  81.	   Te	  Velde,	  A.A.,	  et	  al.,	  Glutathione	  peroxidase	  2	  and	  aquaporin	  8	  as	  new	  markers	  
for	   colonic	   inflammation	   in	   experimental	   colitis	   and	   inflammatory	   bowel	  
diseases:	   an	   important	   role	   for	   H2O2?	   Eur	   J	   Gastroenterol	   Hepatol,	   2008.	  
20(6):	  p.	  555-­‐60.	  82.	   Schejbel,	   L.,	   et	   al.,	   Molecular	   basis	   of	   hereditary	   C1q	   deficiency-­‐-­‐revisited:	  
identification	  of	  several	  novel	  disease-­‐causing	  mutations.	  Genes	  Immun,	  2011.	  
12(8):	  p.	  626-­‐34.	  83.	   Sparano,	  J.A.,	  et	  al.,	  Randomized	  phase	  III	  trial	  of	  marimastat	  versus	  placebo	  in	  
patients	  with	  metastatic	  breast	  cancer	  who	  have	  responding	  or	  stable	  disease	  
after	  first-­‐line	  chemotherapy:	  Eastern	  Cooperative	  Oncology	  Group	  trial	  E2196.	  J	  Clin	  Oncol,	  2004.	  22(23):	  p.	  4683-­‐90.	  
 118 
84.	   Skov,	   L.,	   et	   al.,	   IL-­‐8	  as	  antibody	   therapeutic	   target	   in	   inflammatory	  diseases:	  
reduction	   of	   clinical	   activity	   in	   palmoplantar	   pustulosis.	   J	   Immunol,	   2008.	  
181(1):	  p.	  669-­‐79.	  85.	   Bocca,	   C.,	   et	   al.,	   Celecoxib	   inactivates	   epithelial-­‐mesenchymal	   transition	  
stimulated	   by	   hypoxia	   and/or	   epidermal	   growth	   factor	   in	   colon	   cancer	   cells.	  Mol	  Carcinog,	  2011.	  86.	   Shiraishi,	   T.,	   S.	   Matsuyama,	   and	   H.	   Kitano,	   Large-­‐scale	   analysis	   of	   network	  
bistability	  for	  human	  cancers.	  PLoS	  Comput	  Biol,	  2010.	  6(7):	  p.	  e1000851.	  87.	   Burger,	   J.A.,	   et	   al.,	   Potential	   of	   CXCR4	   antagonists	   for	   the	   treatment	   of	  
metastatic	  lung	  cancer.	  Expert	  Rev	  Anticancer	  Ther,	  2011.	  11(4):	  p.	  621-­‐30.	  88.	   Kong,	   Y.W.,	   et	   al.,	   The	   mechanism	   of	   micro-­‐RNA-­‐mediated	   translation	  
repression	  is	  determined	  by	  the	  promoter	  of	  the	  target	  gene.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2008.	  105(26):	  p.	  8866-­‐71.	  89.	   Wang,	   J.,	   et	   al.,	   Polymorphisms	   of	   matrix	   metalloproteinases	   in	   myocardial	  
infarction:	  a	  meta-­‐analysis.	  Heart,	  2011.	  97(19):	  p.	  1542-­‐6.	  90.	   Lennard-­‐Jones,	  J.E.	  and	  J.	  Powell-­‐Tuck,	  Drug	  treatment	  of	  inflammatory	  bowel	  
disease.	  Clin	  Gastroenterol,	  1979.	  8(1):	  p.	  187-­‐217.	  91.	   El-­‐Tawil,	   A.M.,	   Oestrogens	   and	   Crohn's	   disease:	   the	   missed	   link.	   Andrologia,	  2008.	  40(3):	  p.	  141-­‐5.	  92.	   Kappelman,	  M.D.,	  et	  al.,	  Association	  of	  paediatric	  inflammatory	  bowel	  disease	  
with	  other	  immune-­‐mediated	  diseases.	  Arch	  Dis	  Child,	  2011.	  96(11):	  p.	  1042-­‐6.	  93.	   Willcocks,	   L.C.,	   et	   al.,	  A	  defunctioning	  polymorphism	   in	  FCGR2B	   is	  associated	  
with	   protection	   against	   malaria	   but	   susceptibility	   to	   systemic	   lupus	  
erythematosus.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2010.	  107(17):	  p.	  7881-­‐5.	  94.	   Ververis,	   K.	   and	   T.C.	   Karagiannis,	   Potential	   non-­‐oncological	   applications	   of	  
histone	  deacetylase	  inhibitors.	  Am	  J	  Transl	  Res,	  2011.	  3(5):	  p.	  454-­‐67.	  95.	   Ben-­‐Zvi,	   I.,	   et	   al.,	   Hydroxychloroquine:	   From	  Malaria	   to	   Autoimmunity.	   Clin	  Rev	  Allergy	  Immunol,	  2011.	  96.	   Wang,	   H.,	   et	   al.,	   Platelet-­‐activating	   factor	   and	   endotoxin	   activate	  
CCAAT/enhancer	  binding	  protein	  in	  rat	  small	  intestine.	  Br	  J	  Pharmacol,	  2001.	  
133(5):	  p.	  713-­‐21.	  97.	   Shulzhenko,	   N.,	   et	   al.,	   Crosstalk	   between	   B	   lymphocytes,	  microbiota	   and	   the	  
intestinal	  epithelium	  governs	  immunity	  versus	  metabolism	  in	  the	  gut.	  Nat	  Med,	  2011.	  17(12):	  p.	  1585-­‐93.	  98.	   Jemal,	  A.,	  et	  al.,	  Global	  cancer	  statistics.	  CA	  Cancer	  J	  Clin,	  2011.	  61(2):	  p.	  69-­‐90.	  99.	   Triantafillidis,	   J.K.,	   G.	   Nasioulas,	   and	   P.A.	   Kosmidis,	   Colorectal	   Cancer	   and	  
Inflammatory	   Bowel	   Disease:	   Epidemiology,	   Risk	   Factors,	   Mechanisms	   of	  
Carcinogenesis	  and	  Prevention	  Strategies.	   Anticancer	  Research,	   2009.	  29(7):	  p.	  2727-­‐2737.	  100.	   Eaden,	   J.A.,	   K.R.	   Abrams,	   and	   J.F.	   Mayberry,	  The	   risk	   of	   colorectal	   cancer	   in	  
ulcerative	  colitis:	  a	  meta-­‐analysis.	  Gut,	  2001.	  48(4):	  p.	  526-­‐35.	  101.	   Canavan,	  C.,	  K.R.	  Abrams,	  and	  J.	  Mayberry,	  Meta-­‐analysis:	  colorectal	  and	  small	  
bowel	   cancer	   risk	   in	  patients	  with	  Crohn's	   disease.	   Aliment	   Pharmacol	   Ther,	  2006.	  23(8):	  p.	  1097-­‐104.	  
 119 
102.	   Smith,	   J.J.,	   et	   al.,	   Experimentally	   derived	   metastasis	   gene	   expression	   profile	  
predicts	  recurrence	  and	  death	  in	  patients	  with	  colon	  cancer.	  Gastroenterology,	  2010.	  138(3):	  p.	  958-­‐68.	  103.	   Jorissen,	   R.N.,	   et	   al.,	  Metastasis-­‐Associated	   Gene	   Expression	   Changes	   Predict	  
Poor	  Outcomes	   in	   Patients	  with	  Dukes	   Stage	  B	   and	  C	   Colorectal	   Cancer.	   Clin	  Cancer	  Res,	  2009.	  15(24):	  p.	  7642-­‐7651.	  104.	   Galamb,	  O.,	  et	  al.,	  Reversal	  of	  gene	  expression	  changes	  in	  the	  colorectal	  normal-­‐
adenoma	   pathway	   by	   NS398	   selective	   COX2	   inhibitor.	   Br	   J	   Cancer,	   2010.	  
102(4):	  p.	  765-­‐73.	  105.	   Galamb,	   O.,	   et	   al.,	  Diagnostic	  mRNA	   expression	   patterns	   of	   inflamed,	   benign,	  
and	   malignant	   colorectal	   biopsy	   specimen	   and	   their	   correlation	   with	  
peripheral	  blood	  results.	  Cancer	  Epidemiol	  Biomarkers	  Prev,	  2008.	  17(10):	  p.	  2835-­‐45.	  106.	   Saverymuttu,	   S.H.,	   et	   al.,	   in-­‐111	  autologous	   leukocyte	   scanning	   -­‐	   comparison	  
with	   radiology	   for	   imaging	   the	   colon	   in	   inflammatory	   bowel-­‐disease.	   British	  Medical	  Journal,	  1982.	  285(6337):	  p.	  255-­‐257.	  107.	   Saverymuttu,	  S.H.,	  et	  al.,	  indium-­‐111-­‐granulocyte	  scanning	  in	  the	  assessment	  of	  
disease	   extent	   and	   disease-­‐activity	   in	   inflammatory	   bowel-­‐disease	   -­‐	   a	  
comparison	   with	   colonoscopy,	   histology,	   and	   fecal	   indium-­‐111-­‐granulocyte	  
excretion.	  Gastroenterology,	  1986.	  90(5):	  p.	  1121-­‐1128.	  108.	   Kane,	   S.V.,	   et	   al.,	   Fecal	   lactoferrin	   is	   a	   sensitive	   and	   specific	   marker	   in	  
identifying	   intestinal	   inflammation.	   American	   Journal	   of	   Gastroenterology,	  2003.	  98(6):	  p.	  1309-­‐1314.	  109.	   Sugi,	  K.,	  et	  al.,	  Fecal	  lactoferrin	  as	  a	  marker	  for	  disease	  activity	  in	  inflammatory	  
bowel	   disease:	   Comparison	  with	   other	   neutrophil-­‐derived	   proteins.	   American	  Journal	  of	  Gastroenterology,	  1996.	  91(5):	  p.	  927-­‐934.	  110.	   Roseth,	   A.G.,	   et	   al.,	   Assessment	   Of	   The	   Neutrophil	   Dominating	   Protein	  
Calprotectin	   In	   Feces	   -­‐	   A	   Methodologic	   Study.	   Scandinavian	   Journal	   of	  Gastroenterology,	  1992.	  27(9):	  p.	  793-­‐798.	  111.	   Langhorst,	   J.,	   et	   al.,	   Noninvasive	   markers	   in	   the	   assessment	   of	   intestinal	  
inflammation	  in	  inflammatory	  bowel	  diseases:	  Performance	  of	  fecal	  lactoferrin,	  
calprotectin,	  and	  PMN-­‐Elastase,	  CRP,	  and	  clinical	  indices.	  American	  Journal	  of	  Gastroenterology,	  2008.	  103(1):	  p.	  162-­‐169.	  112.	   Quinton,	   J.F.,	   et	   al.,	   Anti-­‐Saccharomyces	   cerevisiae	   mannan	   antibodies	  
combined	   with	   antineutrophil	   cytoplasmic	   autoantibodies	   in	   inflammatory	  
bowel	  disease:	  prevalence	  and	  diagnostic	  role.	  Gut,	  1998.	  42(6):	  p.	  788-­‐791.	  113.	   Schoepfer,	   A.M.,	   et	   al.	   Discriminating	   IBD	   from	   IBS:	   Comparison	   of	   the	   test	  
performance	  of	  fecal	  markers,	  blood	  leukocytes,	  CRP,	  and	  IBD	  antibodies.	  2008.	  John	  Wiley	  &	  Sons	  Inc.	  114.	   Kanehisa,	   M.	   and	   S.	   Goto,	   KEGG:	   kyoto	   encyclopedia	   of	   genes	   and	   genomes.	  Nucleic	  Acids	  Res,	  2000.	  28(1):	  p.	  27-­‐30.	  115.	   Hanley,	   J.A.	   and	   B.J.	   McNeil,	   The	   Meaning	   And	   Use	   Of	   The	   Area	   Under	   A	  
Receiver	   Operating	   Characteristic	   (ROC)	   Curve.	   Radiology,	   1982.	   143(1):	   p.	  29-­‐36.	  
 120 
116.	   Lasko,	   T.A.,	   et	   al.,	   The	   use	   of	   receiver	   operating	   characteristic	   curves	   in	  
biomedical	   informatics.	   Journal	   of	   Biomedical	   Informatics,	   2005.	   38(5):	   p.	  404-­‐415.	  117.	   Smoot,	   M.E.,	   et	   al.,	   Cytoscape	   2.8:	   new	   features	   for	   data	   integration	   and	  
network	  visualization.	  Bioinformatics,	  2011.	  27(3):	  p.	  431-­‐2.	  118.	   Essaghir,	  A.,	  et	  al.,	  Transcription	  factor	  regulation	  can	  be	  accurately	  predicted	  
from	   the	   presence	   of	   target	   gene	   signatures	   in	   microarray	   gene	   expression	  
data.	  Nucleic	  Acids	  Res,	  2010.	  38(11):	  p.	  e120.	  119.	   Luo,	   X.,	   et	   al.,	  MicroRNA	   signatures:	   novel	   biomarker	   for	   colorectal	   cancer?	  Cancer	  Epidemiol	  Biomarkers	  Prev,	  2011.	  20(7):	  p.	  1272-­‐86.	  120.	   Pekow,	  J.R.	  and	  J.H.	  Kwon,	  MicroRNAs	  in	  inflammatory	  bowel	  disease.	  Inflamm	  Bowel	  Dis,	  2012.	  18(1):	  p.	  187-­‐93.	  121.	   Andersen,	  V.,	  et	  al.,	  Polymorphisms	  in	  NF-­‐kappaB,	  PXR,	  LXR,	  PPARgamma	  and	  
risk	   of	   inflammatory	   bowel	   disease.	   World	   J	   Gastroenterol,	   2011.	   17(2):	   p.	  197-­‐206.	  122.	   Glas,	   J.,	   et	   al.,	   Role	   of	   PPARG	   gene	   variants	   in	   inflammatory	   bowel	   disease.	  Inflamm	  Bowel	  Dis,	  2011.	  17(4):	  p.	  1057-­‐8.	  123.	   Babu,	   S.,	   et	   al.,	   A	   PMMA	  microcapillary	   quantum	   dot	   linked	   immunosorbent	  
assay	  (QLISA).	  Biosensors	  &	  Bioelectronics,	  2009.	  24(12):	  p.	  3467-­‐3474.	  124.	   Butler,	   J.E.,	   et	   al.,	  The	   immunochemistry	   of	   sandwich	   elisas-­‐-­‐VI.	   Greater	   than	  
90%	  of	  monoclonal	   and	   75%	  of	   polyclonal	   anti-­‐fluorescyl	   capture	   antibodies	  
(CAbs)	   are	   denatured	   by	   passive	   adsorption.	   Molecular	   Immunology,	   1993.	  
30(13):	  p.	  1165-­‐1175.	  125.	   Butler,	   J.E.,	  et	  al.,	  The	  Physical	  and	  Functional-­‐Behavior	  of	  Capture	  Antibodies	  
Adsorbed	  on	  Polystyrene.	  Journal	  of	  Immunological	  Methods,	  1992.	  150(1-­‐2):	  p.	  77-­‐90.	  126.	   Christodoulides,	  N.,	  et	  al.,	  A	  microchip-­‐based	  multianalyte	  assay	  system	  for	  the	  
assessment	  of	  cardiac	  risk.	  Analytical	  Chemistry,	  2002.	  74(13):	  p.	  3030-­‐3036.	  127.	   Henares,	   T.G.,	   et	   al.,	   Integration	   of	   multianalyte	   sensing	   functions	   on	   a	  
capillary-­‐assembled	   microchip:	   Simultaneous	   determination	   of	   ion	  
concentrations	   and	   enzymatic	   activities	   by	   a	   "drop-­‐and-­‐sip"	   technique.	  Analytical	  Chemistry,	  2007.	  79(3):	  p.	  908-­‐915.	  128.	   Kricka,	  L.J.,	  Prospects	  for	  microchips	  in	  immunoassays	  and	  immunoassay	  tests	  
at	  the	  point-­‐of-­‐care.	  Journal	  of	  Clinical	  Ligand	  Assay,	  2002.	  25(4):	  p.	  317-­‐324.	  129.	   Mendoza,	   L.G.,	   et	   al.,	   High-­‐throughput	   microarray-­‐based	   enzyme-­‐linked	  
immunosorbent	  assay	  (ELISA).	  Biotechniques,	  1999.	  27(4):	  p.	  778-­‐+.	  130.	   Akkoyun,	   A.	   and	   U.	   Bilitewski,	   Optimisation	   of	   glass	   surfaces	   for	   optical	  
immunosensors.	  Biosensors	  &	  Bioelectronics,	  2002.	  17(8):	  p.	  655-­‐664.	  131.	   Yuan,	   Y.,	   H.Y.	   He,	   and	   J.	   Lee,	   Protein	  A-­‐Based	  Antibody	   Immobilization	  Onto	  
Polymeric	   Microdevices	   for	   Enhanced	   Sensitivity	   of	   Enzyme-­‐Linked	  
Immunosorbent	   Assay.	   Biotechnology	   and	   Bioengineering,	   2009.	   102(3):	   p.	  891-­‐901.	  132.	   Qi,	   S.Z.,	   et	   al.,	  Microfluidic	   devices	   fabricated	   in	   poly(	   methyl	   methacrylate)	  
using	   hot-­‐embossing	   with	   integrated	   sampling	   capillary	   and	   fiber	   optics	   for	  
fluorescence	  detection.	  Lab	  on	  a	  Chip,	  2002.	  2(2):	  p.	  88-­‐95.	  
 121 
133.	   Irawan,	  R.,	  et	  al.,	  Integration	  of	  optical	  fiber	  light	  guide,	  fluorescence	  detection	  
system,	   and	   multichannel	   disposable	   microfluidic	   chip.	   Biomedical	  Microdevices,	  2007.	  9(3):	  p.	  413-­‐419.	  134.	   Charles,	   P.T.,	   et	   al.,	   TNT	   displacement	   immunoassay	   with	   integrated	  
microfluidic	  micromixer	  components.	  Sensor	  Letters,	  2008.	  6(3):	  p.	  417-­‐420.	  135.	   Baldini,	   F.,	   et	   al.,	  Optical	  PMMA	  chip	  suitable	   for	  multianalyte	  detection.	   Ieee	  Sensors	  Journal,	  2008.	  8(7-­‐8):	  p.	  1305-­‐1309.	  136.	   Baldini,	   F.,	   et	   al.,	   A	   new	   procalcitonin	   optical	   immunosensor	   for	   POCT	  
applications.	  Analytical	  and	  Bioanalytical	  Chemistry,	  2009.	  393(4):	  p.	  1183-­‐1190.	  137.	   Park,	  H.,	  et	  al.,	  Open	  sandwich	  FRET	  immunoassay	  of	  estrogen	  receptor	  beta	  in	  
a	  PDMS	  microfluidic	  channel.	  Bulletin	  of	   the	  Korean	  Chemical	  Society,	  2008.	  
29(7):	  p.	  1297-­‐1298.	  138.	   Luo,	   C.X.,	   et	   al.,	   PDMS	   microfludic	   device	   for	   optical	   detection	   of	   protein	  
immunoassay	  using	  gold	  nanoparticles.	  Lab	  on	  a	  Chip,	  2005.	  5(7):	  p.	  726-­‐729.	  139.	   Eteshola,	  E.	   and	  D.	  Leckband,	  Development	  and	  characterization	  of	  an	  ELISA	  
assay	  in	  PDMS	  microfluidic	  channels.	  Sensors	  and	  Actuators	  B-­‐Chemical,	  2001.	  
72(2):	  p.	  129-­‐133.	  140.	   Morais,	   S.,	   et	   al.,	  Multiplexed	  Microimmunoassays	  on	  a	  Digital	  Versatile	  Disk.	  Analytical	  Chemistry,	  2009.	  81(14):	  p.	  5646-­‐5654.	  141.	   Kido,	   H.,	   A.	   Maquieira,	   and	   B.D.	   Hammock,	   Disc-­‐based	   immunoassay	  
microarrays.	  Analytica	  Chimica	  Acta,	  2000.	  411(1-­‐2):	  p.	  1-­‐11.	  142.	   Han,	   S.M.,	   et	   al.,	   Plastic	   enzyme-­‐linked	   immunosorbent	   assays	   (ELISA)-­‐on-­‐a-­‐
chip	   biosensor	   for	   botulinum	   neurotoxin	   A.	   Analytica	   Chimica	   Acta,	   2007.	  
587(1):	  p.	  1-­‐8.	  143.	   Raj,	   J.,	  et	  al.,	  Surface	  immobilisation	  of	  antibody	  on	  cyclic	  olefin	  copolymer	  for	  
sandwich	   immunoassay.	   Biosensors	   &	   Bioelectronics,	   2009.	  24(8):	   p.	   2654-­‐2658.	  144.	   Jonsson,	   C.,	   et	   al.,	   Silane-­‐dextran	   chemistry	  on	   lateral	   flow	  polymer	   chips	   for	  
immunoassays.	  Lab	  on	  a	  Chip,	  2008.	  8(7):	  p.	  1191-­‐1197.	  145.	   Bai,	   Y.L.,	   et	   al.,	   Surface	   modification	   for	   enhancing	   antibody	   binding	   on	  
polymer-­‐based	   microfluidic	   device	   for	   enzyme-­‐linked	   immunosorbent	   assay.	  Langmuir,	  2006.	  22(22):	  p.	  9458-­‐9467.	  146.	   Bai,	   Y.L.,	  W.C.	  Huang,	   and	   S.T.	   Yang,	  Enzyme-­‐linked	   Immunosorbent	  assay	  of	  
Escherichia	   coli	   O157	   :	   H7	   in	   surface	   enhanced	   Poly(Methyl	   methacrylate)	  
microchannels.	  Biotechnology	  and	  Bioengineering,	  2007.	  98(2):	  p.	  328-­‐339.	  147.	   Mastichiadis,	   C.,	   et	   al.,	   Capillary-­‐based	   immunoassays,	   immunosensors	   and	  
DNA	   sensors	   -­‐	   steps	   towards	   integration	   and	   multi-­‐analysis.	   Trac-­‐Trends	   in	  Analytical	  Chemistry,	  2008.	  27(9):	  p.	  771-­‐784.	  148.	   Lee,	  M.	  and	  R.A.	  Durst,	  Determination	  of	  imazethapyr	  using	  capillary	  column	  
flow	   injection	   liposome	   immunoanalysis.	   Journal	   of	   Agricultural	   and	   Food	  Chemistry,	  1996.	  44(12):	  p.	  4032-­‐4036.	  149.	   Kaneki,	   N.,	   et	   al.,	   Electrochemical	   Enzyme-­‐Immunoassay	   Using	   Sequential	  
Saturation	   Technique	   in	   a	   20-­‐Mul	   Capillary	   -­‐	   Digoxin	   as	   a	   Model	   Analyte.	  Analytica	  Chimica	  Acta,	  1994.	  287(3):	  p.	  253-­‐258.	  
 122 
150.	   Thomas,	   T.,	   et	   al.,	   Development	   of	   a	   capillary	   biosensor	   for	   Helicobacter	  
hepaticus.	  Sensor	  Letters,	  2007.	  5(2):	  p.	  398-­‐404.	  151.	   Torabi,	   F.,	   et	   al.,	  Development	  of	  a	  plasma	  panel	   test	   for	  detection	  of	  human	  
myocardial	   proteins	   by	   capillary	   immunoassay.	   Biosensors	   &	   Bioelectronics,	  2007.	  22(7):	  p.	  1218-­‐1223.	  152.	   Surugiu,	   L.,	   et	   al.,	   Dextran-­‐modified	   surface	   for	   highly	   sensitive	  
chemiluminescent	  ELISA.	  Analyst,	  2001.	  126(10):	  p.	  1633-­‐1635.	  153.	   Bange,	   A.,	   H.B.	   Halsall,	   and	   W.R.	   Heineman,	   Microfluidic	   immunosensor	  
systems.	  Biosens	  Bioelectron,	  2005.	  20(12):	  p.	  2488-­‐503.	  154.	   Yacoub-­‐George,	  E.,	  et	  al.,	  A	  miniaturized	  ISFET-­‐ELISA	  system	  with	  a	  pretreated	  
fused	  silica	  capillary	  as	  reaction	  cartridge.	  Sensors	  and	  Actuators	  B:	  Chemical,	  1996.	  34(1-­‐3):	  p.	  429-­‐434.	  155.	   Misiakos,	   K.	   and	   S.E.	   Kakabakos,	   A	   multi-­‐band	   capillary	   immunosensor.	  Biosensors	  &	  Bioelectronics,	  1998.	  13(7-­‐8):	  p.	  825-­‐830.	  156.	   Mastichiadis,	  C.,	   et	   al.,	  Simultaneous	  determination	  of	  pesticides	  using	  a	  four-­‐
band	  disposable	  optical	  capillary	   immunosensor.	   Analytical	   Chemistry,	   2002.	  
74(23):	  p.	  6064-­‐6072.	  157.	   Petrou,	  P.S.,	  et	  al.,	  Multi-­‐analyte	  capillary	  immunosensor	  for	  the	  determination	  
of	   hormones	   in	   human	   serum	   samples.	   Biosensors	   &	   Bioelectronics,	   2002.	  
17(4):	  p.	  261-­‐268.	  158.	   Rose,	   A.,	   et	   al.,	   GDH	   biosensor	   based	   off-­‐line	   capillary	   immunoassay	   for	  
alkylphenols	  and	  their	  ethoxylates.	  Biosensors	  &	  Bioelectronics,	  2002.	  17(11-­‐12):	  p.	  1033-­‐1043.	  159.	   McCarley,	  R.L.,	  et	  al.,	  Resist-­‐free	  patterning	  of	  surface	  architectures	  in	  polymer-­‐
based	   microanalytical	   devices.	   Journal	   of	   the	   American	   Chemical	   Society,	  2005.	  127(3):	  p.	  842-­‐843.	  160.	   Weigl,	   B.H.	   and	   O.S.	   Wolfbeis,	   CAPILLARY	   OPTICAL	   SENSORS.	   Analytical	  Chemistry,	  1994.	  66(20):	  p.	  3323-­‐3327.	  161.	   Ligler,	   F.S.,	   et	   al.,	   Integrating	   waveguide	   biosensor.	   Analytical	   Chemistry,	  2002.	  74(3):	  p.	  713-­‐719.	  162.	   Zhu,	   P.X.,	   et	   al.,	   Detection	   of	   water-­‐borne	   E-­‐coli	   O157	   using	   the	   integrating	  
waveguide	  biosensor.	  Biosensors	  &	  Bioelectronics,	  2005.	  21(4):	  p.	  678-­‐683.	  163.	   Stringer,	   R.C.,	   D.	   Hoehn,	   and	   S.A.	   Grant,	   Quantum	   dot-­‐based	   biosensor	   for	  
detection	   of	   human	   cardiac	   Troponin	   I	   using	   a	   liquid-­‐core	   waveguide.	   Ieee	  Sensors	  Journal,	  2008.	  8(3-­‐4):	  p.	  295-­‐300.	  164.	   Danczyk,	   R.,	   et	   al.,	   Comparison	   of	   antibody	   functionality	   using	   different	  
immobilization	  methods.	   Biotechnology	   and	  Bioengineering,	   2003.	  84(2):	   p.	  215-­‐223.	  165.	   Saphire,	  E.O.,	  et	  al.,	  Contrasting	  IgG	  structures	  reveal	  extreme	  asymmetry	  and	  
flexibility.	  Journal	  of	  Molecular	  Biology,	  2002.	  319(1):	  p.	  9-­‐18.	  166.	   Kang,	   J.H.,	   et	   al.,	   Improving	   immunobinding	  using	  oriented	   immobilization	  of	  
an	  oxidized	  antibody.	  Journal	  of	  Chromatography	  A,	  2007.	  1161(1-­‐2):	  p.	  9-­‐14.	  167.	   Schramm,	   W.,	   S.-­‐H.	   Paek,	   and	   G.	   Voss,	   Strategies	   for	   the	   Immobilization	   of	  
Antibodies.	  ImmunoMethods,	  1993.	  3(2):	  p.	  93-­‐103.	  
 123 
168.	   Cho,	  I.H.,	  et	  al.,	  Site-­‐directed	  immobilization	  of	  antibody	  onto	  solid	  surfaces	  for	  
the	  construction	  of	   immunochip.	   Biotechnology	   and	  Bioprocess	   Engineering,	  2004.	  9(2):	  p.	  112-­‐117.	  169.	   Sok,	  D.,	  et	  al.,	  Novel	  fluoroimmunoassay	  for	  ovarian	  cancer	  biomarker	  CA-­‐125.	  Analytical	  and	  Bioanalytical	  Chemistry,	  2009.	  393(5):	  p.	  1521-­‐1523.	  170.	   Staros,	   J.V.,	   R.W.	   Wright,	   and	   D.M.	   Swingle,	   Enhancement	   by	   N-­‐
Hydroxysulfosuccinimide	   of	   Water-­‐Soluble	   Carbodiimide-­‐Mediated	   Coupling	  
Reactions.	  Analytical	  Biochemistry,	  1986.	  156(1):	  p.	  220-­‐222.	  171.	   Bonroy,	   K.,	   et	   al.,	   Comparison	   of	   random	   and	   oriented	   immobilisation	   of	  
antibody	   fragments	   on	   mixed	   self-­‐assembled	   monolayers.	   Journal	   of	  Immunological	  Methods,	  2006.	  312(1-­‐2):	  p.	  167-­‐181.	  172.	   Patel,	   S.,	   et	   al.,	   Control	   of	   cell	   adhesion	   on	   poly(methyl	   methacrylate).	  Biomaterials,	  2006.	  27(14):	  p.	  2890-­‐2897.	  173.	   Ting	   Cao,	   A.W.,	   Xuemei	   Liang,	   Haiying	   Tang,	   Gregory	   W.	   Auner,	   Steven	   O.	  Salley,	   K.Y.	   Simon	   Ng,,	   Investigation	   of	   spacer	   length	   effect	   on	   immobilized	  
<I>Escherichia	   coli</I>	   pili-­‐antibody	   molecular	   recognition	   by	   AFM.	  Biotechnology	  and	  Bioengineering,	  2007.	  98(6):	  p.	  1109-­‐1122.	  174.	   Anderson,	  G.P.,	  et	  al.,	  Effectiveness	  of	  protein	  A	  for	  antibody	  immobilization	  for	  
a	   fiber	   optic	   biosensor.	   Biosensors	   and	   Bioelectronics,	   1997.	  12(4):	   p.	   329-­‐336.	  175.	   Owaku,	   K.,	   et	   al.,	   Protein	   A	   Langmuir-­‐Blodgett	   Film	   for	   Antibody	  
Immobilization	   and	   Its	   Use	   in	   Optical	   Immunosensing.	   Analytical	   Chemistry,	  1995.	  67(9):	  p.	  1613-­‐1616.	  176.	   Palmer,	   D.A.,	   et	   al.,	  Rapid	   Fluorescence	   Flow-­‐Injection	   Immunoassay	  Using	   a	  
Novel	   Perfusion	   Chromatographic	   Material.	   Analyst,	   1994.	   119(5):	   p.	   943-­‐947.	  177.	   Ren,	   X.Z.	   and	   J.N.	   Miller,	   Flow-­‐Injection	   Fluoroimmunoassay	   for	   Human	  
Transferrin	  Using	  a	  Protein-­‐a	  Immunoreactor.	  Analytical	  Letters,	  1994.	  27(6):	  p.	  1067-­‐1074.	  178.	   Jagannath,	   C.	   and	   S.	   Sehgal,	  Enhancement	  of	   the	  antigen-­‐binding	   capacity	  of	  
incomplete	  IgG	  antibodies	  to	  Brucella	  melitensis	  through	  Fc	  region	  interactions	  
with	  staphylococcal	  protein	  A.	  J	  Immunol	  Methods,	  1989.	  124(2):	  p.	  251-­‐7.	  179.	   Chung,	  J.W.,	  et	  al.,	  Immunosensor	  with	  a	  controlled	  orientation	  of	  antibodies	  by	  
using	   NeutrAvidin-­‐protein	   A	   complex	   at	   immunoaffinity	   layer.	   J	   Biotechnol,	  2006.	  126(3):	  p.	  325-­‐33.	  180.	   Michalet,	  X.,	  et	  al.,	  Quantum	  dots	  for	  live	  cells,	  in	  vivo	  imaging,	  and	  diagnostics.	  Science,	  2005.	  307(5709):	  p.	  538-­‐44.	  181.	   Chan,	   W.C.	   and	   S.	   Nie,	   Quantum	   dot	   bioconjugates	   for	   ultrasensitive	  
nonisotopic	  detection.	  Science,	  1998.	  281(5385):	  p.	  2016-­‐8.	  182.	   Bruchez,	   M.,	   Jr.,	   et	   al.,	   Semiconductor	   nanocrystals	   as	   fluorescent	   biological	  
labels.	  Science,	  1998.	  281(5385):	  p.	  2013-­‐6.	  183.	   Medintz,	   I.L.,	   et	   al.,	   Quantum	   dot	   bioconjugates	   for	   imaging,	   labelling	   and	  
sensing.	  Nature	  Materials,	  2005.	  4(6):	  p.	  435-­‐46.	  184.	   Ghasemi,	   Y.,	   P.	   Peymani,	   and	   S.	   Afifi,	   Quantum	   dot:	   magic	   nanoparticle	   for	  
imaging,	  detection	  and	  targeting.	  Acta	  bio-­‐medica	   :	  Atenei	  Parmensis,	  2009.	  
80(2):	  p.	  156-­‐65.	  
 124 
185.	   Klimov,	   V.I.,	   et	   al.,	   Optical	   gain	   and	   stimulated	   emission	   in	   nanocrystal	  
quantum	  dots.	  Science,	  2000.	  290(5490):	  p.	  314-­‐7.	  186.	   Htoon,	   H.,	   et	   al.,	   Highly	   emissive	   multiexcitons	   in	   steady-­‐state	  
photoluminescence	   of	   individual	   "giant"	   CdSe/CdS	   Core/Shell	   nanocrystals.	  Nano	  letters,	  2010.	  10(7):	  p.	  2401-­‐7.	  187.	   Rogach,	   A.L.,	   Semiconductor	   nanocrystal	   quantum	   dots:	   synthesis,	   assembly,	  
spectroscopy	  and	  applications2008:	  Springer.	  188.	   Klimov,	   V.I.,	   Nanocrystal	   Quantum	   Dots,	   Second	   Edition2009:	   Taylor	   and	  Francis.	  189.	   Sutherland,	  A.D.,	  R.B.	  Gearry,	  and	  F.A.	  Frizelle,	  Review	  of	  fecal	  biomarkers	  in	  
inflammatory	  bowel	  disease.	  Diseases	  of	  the	  Colon	  &	  Rectum,	  2008.	  51(8):	  p.	  1283-­‐1291.	  190.	   Tibbe,	  J.A.	  and	  I.	  Bjarnason,	  Non-­‐invasive	  investigation	  of	  inflammatory	  bowel	  
disease.	  World	  Journal	  of	  Gastroenterology,	  2001.	  7(4):	  p.	  460-­‐465.	  191.	   Nugen,	   S.R.,	   P.J.	   Asiello,	   and	   A.J.	   Baeumner,	   Design	   and	   fabrication	   of	   a	  
microfluidic	   device	   for	   near-­‐single	   cell	   mRNA	   isolation	   using	   a	   copper	   hot	  
embossing	   master.	   Microsystem	   Technologies-­‐Micro-­‐and	   Nanosystems-­‐Information	  Storage	  and	  Processing	  Systems,	  2009.	  15(3):	  p.	  477-­‐483.	  192.	   Hsu,	  Y.C.	  and	  T.Y.	  Chen,	  Applying	  Taguchi	  methods	  for	  solvent-­‐assisted	  PMMA	  
bonding	   technique	   for	   static	   and	   dynamic	   mu-­‐TAS	   devices.	   Biomedical	  Microdevices,	  2007.	  9(4):	  p.	  513-­‐522.	  193.	   Hermanson,	   G.T.,	   Bioconjugate	   Techniques.	   Second	   ed2008,	   New	   York:	  Academic	  Press.	  194.	   Naruishi,	  N.,	  et	  al.,	  Highly	  efficient	  dynamic	  modification	  of	  plastic	  microfluidic	  
devices	   using	   proteins	   in	   microchip	   capillary	   electrophoresis.	   Journal	   of	  Chromatography	  A,	  2006.	  1130(2):	  p.	  169-­‐174.	  195.	   Clark,	  P.,	  et	  al.,	  MICROFABRICATED	  QLISA	  BIOSENSORS	  WITH	  AN	  EMBEDDED	  
MIXING	  ELEMENT.	  uTAS,	  2011.	  196.	   Fitzpatrick,	   J.C.,	   P.M.	   Clark,	   and	   F.M.	   Capaldi,	   Effect	   of	   decellularization	  
protocol	   on	   the	   mechanical	   behavior	   of	   porcine	   descending	   aorta.	   Int	   J	  Biomater,	  2010.	  2010.	  	  
  
 125 
Appendix A: Principal Component Analysis m-file 
 
function [cumvar, outliers,z] = PCA(data, k, IDcutoff) 
%data is an expression matrix or probestructure as returned by the celintensityread function 
%k is an integer multiplier of the standard deviaiton 
%IDcutoff is an integer representing the  character length to be associated with each sample as 
returned within ProbeStructure.CELNames 
                                                                    
if isobject(data) 
    CELNames = data.colnames'; 
    data = data.Matrix; 
    n = 0.1*length(data.rownames); 
elseif isstruct(data) 
    CELNames = data.CELNames; 
    data = data.PMIntensities; 
    n = 0.1*length(data.ProbeSetIDs); 
else CELNames = CELNames; 
    data = data;  
end 
names = cellfun(@(x)(x(1:IDcutoff)), CELNames, 'uniformoutput', false); 
[r, ~, J] = unique(names);                                                  %J is sample a numeric sample vector 
  
%Variance Filter and PCA 
variance = var(data,[],2); 
[~, inds] = sort(variance, 'descend'); 
[~, zscores, pcvars] = princomp(data(inds(1:n),:)'); 
cumvar = cumsum(pcvars./sum(pcvars) * 100);                                 %cumulative sum of the 
variances 
  
%find the centroid of each diseae classification 
figure 
gscatter(zscores(:,1),zscores(:,2),names); 
hold on 
z = zeros(length(CELNames),1); 
clear('n'); 
for n = 1:1:length(r)                                                       %for each phenotype 
    points = zscores(:,1:2); 
    xmean = mean(zscores(J==n,1)); 
    ymean = mean(zscores(J==n,2)); 
    stdev_x = std(zscores(J==n,1)); 
    stdev_y = std(zscores(J==n,2)); 
    scatter(xmean,ymean,[],'black')                                         %plot centroid 
    [x y] = CalculateEllipse(xmean, ymean, k*stdev_x, k*stdev_y, 0,100); 
    plot(x,y); 
    for c = 1:1:size(points,1)                                           %for all pca points 
        x2 = points(c,1); 
        y2 = points(c,2); 
        xc = xmean; 
        yc = ymean; 
        t = 0; 
        a = k*stdev_x; 
        b = k*stdev_y; 
        TF = strcmpi(names(c,1),r(n,1)); 
        if TF==1 && ((x2-xc)*cos(t)-(y2-yc)*sin(t)).^2/a^2 + ((x2-xc)*sin(t)+(y2-yc)*cos(t)).^2/b^2 >= 
1 
            z(c)=1; 
        end 
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    end  
end 
outliers = CELNames(z==1,1); 
outliers = sort(outliers); 
xlabel('First Principal Component'); 
ylabel('Second Principal Component'); 
title('Principal Component Scatter Plot'); 
hold off 
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Appendix B:  GAD Gene-Disease Interaction m-file 
function [output2,output4]=GAD_genes(genelist) 
%genelist is a cell array of gene symbols (all letters must be capitalized) 
%run in folder containing raw Gene Association Database data 
  
f1 = fopen('genelist.txt'); 
gad_genes = textscan(f1, '%s','HeaderLines',2,'Delimiter','\t','EndOfLine','\r'); 
fclose(f1); 
gad_genes = gad_genes{1,1}; 
  
f2 = fopen('all.txt'); 
all = textscan(f2, '%*s %*s %*s %*s %*s %s %*s %*s %s 
%*[^\r]','HeaderLines',3,'Delimiter','\t','EndOfLine','\r'); 
fclose(f2); 
  
%Find GAD Annotated Genes within Genelist 
tf = ismember(all{1,2},genelist); 
output(:,1) = all{1,2}(tf); 
output(:,2) = all{1,1}(tf); 
  
for n=1:length(output) 
    tf2(n) = isempty(output{n,2}); 
    tf2 = tf2'; 
end 
output2 = output(tf2==0,:); 
  
%Delimit Diseases 
for n=1:size(output2,1) 
    str = output2{n,2}; 
    C = textscan(str,'%s','Delimiter','|'); 
    out = repmat(output2(n,1),length(C{1,1}),1); 
    out(:,2) = C{1,1}; 
    if n==1 
        output3 = out; 
    else 
    output3 = vertcat(output3,out); 
    end 
end 
  
%find unique interactions 
unique_genes = unique(output3(:,1)); 
for n=1:length(unique_genes) 
    tf = ismember(output3(:,1),unique_genes(n)); 
    unique_mesh = unique(output3(tf,2)); 
    out2 = repmat(unique_genes(n),length(unique_mesh),1); 
    out2(:,2) = unique_mesh; 
    if n==1 
        output4 = out2; 
    else 
        output4 = vertcat(output4,out2); 
    end 
end 
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Appendix C:  ROC Sample classification by logistic regression 
 
function [AUC,x,y] = ROC_genes(Expression,probes,classifiers) 
  
tf = ismember(probes,classifiers); 
filtered_data = Expression.Matrix(tf,:); 
  
names = cellfun(@(x)(x(1:3)), Expression.colnames, 'uniformoutput', false); 
[~, ~, J] = unique(names); 
  
IBD_data = filtered_data(:,J==3); 
CRC_data = filtered_data(:,J==1); 
HC_data = filtered_data(:,J==2); 
data1 = IBD_data; 
data2 = CRC_data; 
data = [data1, data2]; 
ids = [zeros(1,size(data1,2)) ones(1,size(data2,2))]; 
  
b = glmfit(data', ids'==1, 'binomial'); 
guesses = glmval(b, data', 'logit'); 
[x, y, ~, AUC]=perfcurve(ids, guesses, 1); 
plot(x,y) 
xlabel('False positive rate'); ylabel('True positive rate') 
title('ROC for classification by logistic regression') 
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APPENDIX D 
 
Ulcerative	  Colitis	  
Up-­‐regulated	  
	  
Down-­‐regulated	  
Gene	  Symbol	   FC	   p-­‐value	  
	  
Gene	  Symbol	   FC	   p-­‐value	  
REG1A	   50.7	   2.23E-­‐04	  
	  
Cldn8	   -­‐22.5	   3.97E-­‐04	  
S100A8	   35.2	   3.14E-­‐04	  
	  
Ostalpha	   -­‐9.6	   1.52E-­‐05	  
REG1B	   26.6	   1.53E-­‐05	  
	  
CA1	   -­‐8.3	   2.88E-­‐04	  
MMP3	   22.6	   2.98E-­‐04	  
	  
GUCA2B	   -­‐7.9	   7.89E-­‐04	  
DEFA5	   20.8	   2.22E-­‐04	  
	  
MT1M	   -­‐7.5	   4.69E-­‐05	  
CHI3L1	   19.1	   4.52E-­‐04	  
	  
Adh1c	   -­‐6.8	   4.95E-­‐04	  
Mmp1	   17.8	   5.75E-­‐05	  
	  
GHR	   -­‐6.6	   3.16E-­‐04	  
Lcn2	   15.5	   9.05E-­‐04	  
	  
SLC16A9	   -­‐6.5	   5.01E-­‐04	  
Mmp12	   13.1	   3.93E-­‐04	  
	  
slc30a10	   -­‐5.9	   4.86E-­‐04	  
IDO1	   12.1	   3.96E-­‐04	  
	  
CNTN3	   -­‐5.6	   5.91E-­‐04	  
PI3	   11.5	   5.10E-­‐04	  
	  
Gba3	   -­‐5.4	   1.66E-­‐04	  
CXCL13	   11.4	   1.02E-­‐05	  
	  
ANPEP	   -­‐5.1	   7.57E-­‐06	  
ANXA1	   11.2	   6.82E-­‐04	  
	  
BEST4	   -­‐5.1	   1.57E-­‐04	  
IL8	   11.1	   1.18E-­‐04	  
	  
mep1b	   -­‐5.0	   6.19E-­‐07	  
FCGR3B	   11.1	   3.18E-­‐04	  
	  
Slc3a1	   -­‐4.9	   8.38E-­‐05	  
TNIP3	   10.3	   5.04E-­‐04	  
	  
pnliprp2	   -­‐4.9	   9.09E-­‐08	  
REG4	   9.9	   8.57E-­‐04	  
	  
vldlr	   -­‐4.8	   9.07E-­‐04	  
MMP10	   9.6	   5.99E-­‐04	  
	  
Npy1r	   -­‐4.8	   7.51E-­‐05	  
IGHV1-­‐69	   9.6	   6.10E-­‐04	  
	  
CWH43	   -­‐4.8	   3.38E-­‐04	  
Cxcl6	   9.3	   1.05E-­‐04	  
	  
UGT1A7	   -­‐4.6	   1.19E-­‐04	  
UBD	   9.1	   8.10E-­‐04	  
	  
SLC16A1	   -­‐4.2	   4.64E-­‐04	  
mmp7	   8.7	   9.27E-­‐04	  
	  
HSD17B2	   -­‐4.2	   5.57E-­‐04	  
SERPINB5	   8.6	   2.47E-­‐04	  
	  
MT1G	   -­‐4.1	   9.32E-­‐05	  
IGKV4-­‐1	   8.3	   1.49E-­‐04	  
	  
Prap1	   -­‐4.0	   5.24E-­‐05	  
IGLV3-­‐1	   7.6	   1.41E-­‐04	  
	  
TRHDE	   -­‐4.0	   1.01E-­‐04	  
Spink4	   6.9	   4.20E-­‐04	  
	  
Pkib	   -­‐4.0	   6.82E-­‐04	  
C4orf7	   6.8	   1.14E-­‐07	  
	  
Cd177	   -­‐4.0	   7.57E-­‐05	  
LOC651536	   6.8	   5.33E-­‐05	  
	  
FLJ32063	   -­‐4.0	   8.25E-­‐04	  
ighv1-­‐2	   6.8	   3.25E-­‐04	  
	  
EXPH5	   -­‐4.0	   5.86E-­‐04	  
TNC	   6.4	   1.51E-­‐04	  
	  
Ostbeta	   -­‐3.9	   3.70E-­‐04	  
CXCL11	   6.4	   1.26E-­‐05	  
	  
Ms4a12	   -­‐3.9	   3.70E-­‐06	  
DMBT1	   6.4	   6.41E-­‐05	  
	  
SLC17A4	   -­‐3.8	   3.21E-­‐04	  
C2CD4A	   6.3	   2.26E-­‐04	  
	  
ISX	   -­‐3.7	   4.04E-­‐05	  
IGLV3-­‐25	   6.3	   7.52E-­‐05	  
	  
SELENBP1	   -­‐3.7	   4.60E-­‐04	  
IGHV3-­‐9	   6.2	   9.45E-­‐05	  
	  
CA7	   -­‐3.7	   2.40E-­‐04	  
BCL2A1	   6.2	   3.68E-­‐05	  
	  
C10orf116	   -­‐3.7	   5.25E-­‐04	  
LY96	   6.1	   3.10E-­‐04	  
	  
PPARGC1A	   -­‐3.6	   8.12E-­‐04	  
IL1B	   6.1	   5.15E-­‐04	  
	  
MT1F	   -­‐3.5	   1.28E-­‐04	  
 130 
CTHRC1	   6.1	   9.70E-­‐05	  
	  
ANKRD43	   -­‐3.5	   7.46E-­‐04	  
GREM1	   5.8	   1.40E-­‐05	  
	  
ptprr	   -­‐3.5	   2.92E-­‐05	  
C4BPB	   5.8	   3.72E-­‐04	  
	  
cdkn2b	   -­‐3.4	   7.83E-­‐04	  
IGHV@	   5.8	   1.81E-­‐04	  
	  
FAM55D	   -­‐3.4	   1.04E-­‐04	  
IGLV2-­‐14	   5.8	   9.76E-­‐05	  
	  
MT1X	   -­‐3.4	   5.17E-­‐05	  
DEFA6	   5.8	   1.97E-­‐05	  
	  
SULT1A2	   -­‐3.4	   5.76E-­‐04	  
IGLV3-­‐19	   5.8	   6.90E-­‐05	  
	  
TRPM6	   -­‐3.4	   2.83E-­‐04	  
MNDA	   5.8	   5.53E-­‐05	  
	  
Mep1a	   -­‐3.4	   6.85E-­‐04	  
IGLV2-­‐11	   5.7	   1.72E-­‐04	  
	  
PADI2	   -­‐3.3	   9.42E-­‐04	  
S100A9	   5.7	   1.77E-­‐04	  
	  
pitx2	   -­‐3.3	   9.40E-­‐06	  
SELL	   5.6	   1.91E-­‐05	  
	  
Entpd5	   -­‐3.3	   8.48E-­‐04	  
IGLL3	   5.6	   2.58E-­‐05	  
	  
DPP10	   -­‐3.3	   5.84E-­‐04	  
HLA-­‐DQB1	   5.5	   7.22E-­‐04	  
	  
Hsd3b2	   -­‐3.3	   3.83E-­‐07	  
IGHV4-­‐34	   5.5	   1.29E-­‐04	  
	  
PBLD	   -­‐3.3	   1.71E-­‐04	  
CXCL5	   5.4	   2.25E-­‐06	  
	  
DEFB1	   -­‐3.2	   6.37E-­‐05	  
OLFM4	   5.4	   1.51E-­‐04	  
	  
Slc38a4	   -­‐3.2	   1.25E-­‐06	  
srgn	   5.3	   1.73E-­‐04	  
	  
HEPACAM2	   -­‐3.2	   2.20E-­‐05	  
Col6a3	   5.3	   4.96E-­‐04	  
	  
NEURL1B	   -­‐3.2	   3.80E-­‐04	  
IL13RA2	   5.2	   6.02E-­‐05	  
	  
Nr1h4	   -­‐3.2	   1.01E-­‐06	  
Cfi	   5.2	   4.79E-­‐05	  
	  
BEST2	   -­‐3.2	   2.29E-­‐05	  
LOC100133678	   5.1	   3.46E-­‐06	  
	  
VIPR1	   -­‐3.1	   4.28E-­‐04	  
HLA-­‐DRB4	   5.0	   8.10E-­‐04	  
	  
LOC100507594	   -­‐3.1	   4.47E-­‐04	  
IGHV3-­‐11	   5.0	   1.08E-­‐05	  
	  
C2orf88	   -­‐3.1	   3.62E-­‐04	  
c13orf15	   5.0	   2.05E-­‐04	  
	  
C1qtnf3	   -­‐3.0	   9.10E-­‐04	  
POU2AF1	   4.9	   7.43E-­‐06	  
	  
METTL7B	   -­‐3.0	   3.24E-­‐04	  
Prok2	   4.9	   7.08E-­‐05	  
	  
ACSF2	   -­‐3.0	   3.88E-­‐04	  
PCSK1	   4.8	   3.42E-­‐04	  
	  
Paqr5	   -­‐3.0	   6.74E-­‐04	  
Aldob	   4.8	   2.93E-­‐05	  
	  
Mcoln2	   -­‐2.9	   4.03E-­‐05	  
CXCR2	   4.8	   2.39E-­‐04	  
	  
FAM5C	   -­‐2.9	   2.01E-­‐04	  
FOXQ1	   4.8	   2.18E-­‐04	  
	  
sult1a1	   -­‐2.9	   5.03E-­‐04	  
Ccl11	   4.8	   2.85E-­‐04	  
	  
TMEM56	   -­‐2.9	   3.14E-­‐04	  
Cxcl9	   4.7	   1.13E-­‐06	  
	  
SLC4A4	   -­‐2.9	   1.95E-­‐04	  
Col15a1	   4.7	   7.64E-­‐05	  
	  
TSPAN7	   -­‐2.8	   7.08E-­‐04	  
SPP1	   4.7	   1.35E-­‐05	  
	  
Slc23a1	   -­‐2.8	   1.42E-­‐04	  
SERPINB7	   4.7	   5.68E-­‐07	  
	  
CKB	   -­‐2.8	   3.97E-­‐06	  
hla-­‐dpa1	   4.7	   2.85E-­‐04	  
	  
Mier3	   -­‐2.8	   6.37E-­‐04	  
MGC29506	   4.6	   2.14E-­‐04	  
	  
Pde6a	   -­‐2.8	   5.21E-­‐04	  
Mmp9	   4.6	   4.74E-­‐05	  
	  
ST6GAL2	   -­‐2.8	   5.24E-­‐08	  
COL1A2	   4.6	   2.12E-­‐04	  
	  
FLJ22763	   -­‐2.8	   7.00E-­‐05	  
serpina3	   4.6	   7.31E-­‐05	  
	  
C7orf10	   -­‐2.8	   1.14E-­‐04	  
S100P	   4.5	   4.46E-­‐04	  
	  
Tmed6	   -­‐2.8	   5.74E-­‐05	  
Ncf2	   4.5	   2.80E-­‐04	  
	  
abca8	   -­‐2.8	   1.45E-­‐05	  
C4BPA	   4.5	   3.82E-­‐05	  
	  
aifm3	   -­‐2.8	   1.44E-­‐04	  
 131 
CCL18	   4.4	   5.63E-­‐05	  
	  
aqp11	   -­‐2.7	   2.95E-­‐04	  
LYZ	   4.4	   8.38E-­‐05	  
	  
Ces2	   -­‐2.7	   8.02E-­‐04	  
CSF2RB	   4.3	   1.20E-­‐05	  
	  
PRR15	   -­‐2.7	   6.05E-­‐04	  
fam26f	   4.3	   3.98E-­‐05	  
	  
PIGZ	   -­‐2.7	   3.79E-­‐05	  
VNN2	   4.3	   1.01E-­‐04	  
	  
KCNJ2	   -­‐2.7	   1.81E-­‐04	  
PF4	   4.2	   1.66E-­‐04	  
	  
Tmem37	   -­‐2.7	   6.77E-­‐05	  
GBP1	   4.2	   8.71E-­‐05	  
	  
SCNN1B	   -­‐2.7	   1.66E-­‐07	  
tgfbi	   4.2	   1.86E-­‐04	  
	  
CDHR1	   -­‐2.7	   1.53E-­‐05	  
MS4A1	   4.2	   9.66E-­‐08	  
	  
MAOA	   -­‐2.7	   6.42E-­‐04	  
TRIM22	   4.1	   1.18E-­‐04	  
	  
SATB2	   -­‐2.7	   3.56E-­‐04	  
CD74	   4.1	   5.45E-­‐04	  
	  
ZNF575	   -­‐2.6	   5.20E-­‐04	  
FLJ40330	   4.1	   5.15E-­‐05	  
	  
HSD11B2	   -­‐2.6	   1.53E-­‐04	  
TNFRSF17	   4.1	   4.22E-­‐07	  
	  
C5orf35	   -­‐2.6	   1.48E-­‐04	  
nnmt	   4.1	   3.64E-­‐05	  
	  
SGK2	   -­‐2.6	   1.62E-­‐04	  
SAMSN1	   4.1	   4.92E-­‐05	  
	  
KIAA1737	   -­‐2.6	   5.24E-­‐04	  
CCL20	   4.1	   7.00E-­‐05	  
	  
ACOX1	   -­‐2.6	   2.58E-­‐04	  
MGP	   4.1	   1.20E-­‐04	  
	  
Tex11	   -­‐2.6	   2.00E-­‐04	  
CXCL10	   4.0	   4.38E-­‐08	  
	  
RAVER2	   -­‐2.6	   4.95E-­‐04	  
WNT5A	   4.0	   2.33E-­‐05	  
	  
FMO5	   -­‐2.6	   4.95E-­‐04	  
SELE	   4.0	   5.17E-­‐05	  
	  
Samd13	   -­‐2.6	   1.29E-­‐04	  
PLAU	   4.0	   3.15E-­‐04	  
	  
Tmem171	   -­‐2.5	   2.37E-­‐04	  
EVI2B	   4.0	   3.72E-­‐05	  
	  
Slc25a34	   -­‐2.5	   3.65E-­‐04	  
FPR1	   4.0	   1.06E-­‐04	  
	  
C10orf58	   -­‐2.5	   1.49E-­‐04	  
LOC91316	   4.0	   1.57E-­‐06	  
	  
IGSF9	   -­‐2.5	   2.38E-­‐04	  
psmb9	   4.0	   7.40E-­‐04	  
	  
WDR78	   -­‐2.5	   1.93E-­‐04	  
Ctsk	   3.9	   3.99E-­‐04	  
	  
CA2	   -­‐2.5	   6.40E-­‐04	  
CHST15	   3.9	   1.50E-­‐04	  
	  
PLCE1	   -­‐2.5	   3.61E-­‐04	  
PTGS2	   3.9	   8.93E-­‐06	  
	  
gxylt2	   -­‐2.5	   4.12E-­‐07	  
Basp1	   3.9	   2.37E-­‐05	  
	  
NAAA	   -­‐2.5	   2.96E-­‐04	  
CDH3	   3.9	   3.37E-­‐04	  
	  
MAGI1	   -­‐2.5	   3.82E-­‐04	  
LUM	   3.9	   2.73E-­‐06	  
	  
xrcc6bp1	   -­‐2.5	   3.52E-­‐04	  
Ifitm2	   3.9	   4.12E-­‐04	  
	  
RICH2	   -­‐2.5	   2.45E-­‐04	  
HLA-­‐DMB	   3.8	   4.59E-­‐04	  
	  
ABAT	   -­‐2.5	   9.27E-­‐04	  
MXRA5	   3.8	   5.81E-­‐05	  
	  
Ephx2	   -­‐2.5	   4.46E-­‐04	  
Igkc	   3.8	   1.16E-­‐04	  
	  
HPGD	   -­‐2.5	   6.00E-­‐05	  
ROBO1	   3.8	   1.15E-­‐04	  
	  
ITPKA	   -­‐2.5	   6.18E-­‐04	  
Pde4b	   3.8	   9.58E-­‐05	  
	  
tmem38b	   -­‐2.4	   6.52E-­‐04	  
LTF	   3.8	   1.66E-­‐07	  
	  
retsat	   -­‐2.4	   9.21E-­‐04	  
AIM2	   3.8	   8.89E-­‐05	  
	  
phyH	   -­‐2.4	   8.85E-­‐04	  
HCLS1	   3.8	   2.94E-­‐05	  
	  
C7orf31	   -­‐2.4	   8.95E-­‐05	  
arhgdib	   3.8	   2.81E-­‐04	  
	  
LOC100128893	   -­‐2.4	   1.18E-­‐04	  
CR2	   3.8	   4.33E-­‐07	  
	  
LOC100505633	   -­‐2.4	   1.04E-­‐04	  
PECAM1	   3.7	   5.31E-­‐04	  
	  
STBD1	   -­‐2.4	   1.47E-­‐04	  
 132 
TMEM158	   3.7	   2.32E-­‐04	  
	  
MYO1D	   -­‐2.4	   8.59E-­‐04	  
CYTIP	   3.7	   5.10E-­‐06	  
	  
EFNA1	   -­‐2.4	   3.46E-­‐05	  
SERPINA1	   3.7	   6.88E-­‐04	  
	  
VAV3	   -­‐2.4	   7.67E-­‐05	  
LAMP3	   3.7	   4.44E-­‐06	  
	  
GIPC2	   -­‐2.4	   1.03E-­‐04	  
cstA	   3.7	   3.50E-­‐05	  
	  
ACVR1C	   -­‐2.4	   5.63E-­‐05	  
CCL19	   3.7	   8.76E-­‐08	  
	  
OSBPL1A	   -­‐2.4	   3.58E-­‐05	  
CXCR4	   3.7	   5.48E-­‐06	  
	  
PLEKHG6	   -­‐2.4	   2.90E-­‐04	  
AG2	   3.7	   1.78E-­‐05	  
	  
PPARG	   -­‐2.4	   2.54E-­‐05	  
pfkfb3	   3.7	   2.80E-­‐04	  
	  
SLC20A2	   -­‐2.4	   5.48E-­‐04	  
CASP1	   3.7	   6.00E-­‐04	  
	  
PDCD4	   -­‐2.4	   1.80E-­‐04	  
SDR16C5	   3.7	   1.20E-­‐04	  
	  
MTMR11	   -­‐2.3	   5.00E-­‐04	  
Col4a1	   3.7	   2.47E-­‐04	  
	  
C1orf210	   -­‐2.3	   1.92E-­‐04	  
AZGP1P1	   3.6	   1.56E-­‐04	  
	  
ANK3	   -­‐2.3	   8.36E-­‐05	  
Col5a2	   3.6	   6.56E-­‐05	  
	  
Scin	   -­‐2.3	   4.67E-­‐05	  
wars	   3.6	   1.89E-­‐04	  
	  
PDK4	   -­‐2.3	   4.76E-­‐06	  
cyr61	   3.6	   2.61E-­‐05	  
	  
FLJ35024	   -­‐2.3	   2.68E-­‐05	  
TNFSF13B	   3.6	   3.89E-­‐05	  
	  
Eya2	   -­‐2.3	   5.66E-­‐08	  
RGS2	   3.5	   1.17E-­‐04	  
	  
LRRC31	   -­‐2.3	   1.59E-­‐05	  
PLA2G7	   3.5	   4.32E-­‐06	  
	  
UGDH	   -­‐2.3	   9.58E-­‐04	  
Pla2g2a	   3.5	   1.22E-­‐07	  
	  
rab40b	   -­‐2.3	   1.61E-­‐04	  
LAPTM5	   3.5	   2.96E-­‐05	  
	  
FGFR2	   -­‐2.3	   2.64E-­‐05	  
dapp1	   3.5	   6.54E-­‐04	  
	  
fam82a1	   -­‐2.3	   9.56E-­‐04	  
IGLV6-­‐57	   3.5	   5.56E-­‐05	  
	  
pAG1	   -­‐2.3	   2.20E-­‐04	  
cd38	   3.5	   1.71E-­‐04	  
	  
CNGA1	   -­‐2.3	   3.25E-­‐05	  
Rgs5	   3.5	   1.60E-­‐04	  
	  
AMN	   -­‐2.3	   1.18E-­‐04	  
GJA1	   3.5	   1.56E-­‐06	  
	  
gramd1c	   -­‐2.3	   2.02E-­‐05	  
KRT6B	   3.4	   3.41E-­‐05	  
	  
CLCN2	   -­‐2.3	   1.19E-­‐04	  
rab31	   3.4	   1.93E-­‐04	  
	  
SVOPL	   -­‐2.3	   3.38E-­‐08	  
LAX1	   3.4	   2.43E-­‐04	  
	  
Camk2n1	   -­‐2.3	   5.27E-­‐04	  
Rftn1	   3.4	   2.22E-­‐05	  
	  
Etfdh	   -­‐2.3	   1.62E-­‐04	  
clu	   3.4	   6.97E-­‐06	  
	  
scube2	   -­‐2.3	   3.04E-­‐05	  
tdo2	   3.4	   3.19E-­‐07	  
	  
PTPRO	   -­‐2.3	   4.93E-­‐07	  
LOC643733	   3.4	   3.18E-­‐04	  
	  
PTGDR	   -­‐2.2	   4.56E-­‐05	  
Kynu	   3.4	   9.27E-­‐04	  
	  
PANK1	   -­‐2.2	   1.11E-­‐05	  
EGR3	   3.4	   3.50E-­‐05	  
	  
CYP4F2	   -­‐2.2	   2.78E-­‐06	  
Igsf6	   3.4	   4.59E-­‐05	  
	  
tmcc3	   -­‐2.2	   1.90E-­‐04	  
Abca12	   3.4	   4.16E-­‐04	  
	  
Golt1a	   -­‐2.2	   2.96E-­‐04	  
Ccl2	   3.3	   6.32E-­‐07	  
	  
GLB1L2	   -­‐2.2	   2.33E-­‐04	  
TNFRSF6B	   3.3	   6.47E-­‐04	  
	  
fxyd3	   -­‐2.2	   1.78E-­‐04	  
TRIB2	   3.3	   2.14E-­‐04	  
	  
Matn2	   -­‐2.2	   7.39E-­‐05	  
Cd53	   3.3	   6.08E-­‐06	  
	  
CA4	   -­‐2.2	   8.77E-­‐08	  
ELTD1	   3.3	   1.42E-­‐04	  
	  
C2orf89	   -­‐2.2	   8.47E-­‐05	  
PECAM1	   3.3	   6.90E-­‐04	  
	  
PDZD3	   -­‐2.2	   2.35E-­‐04	  
 133 
COL3A1	   3.3	   2.51E-­‐05	  
	  
HOXA5	   -­‐2.2	   1.13E-­‐05	  
plek	   3.3	   5.01E-­‐05	  
	  
Pla2g12b	   -­‐2.2	   5.09E-­‐05	  
Vcam1	   3.3	   1.45E-­‐07	  
	  
ZDHHC23	   -­‐2.2	   1.74E-­‐04	  
FSTL1	   3.3	   1.86E-­‐04	  
	  
Nhej1	   -­‐2.2	   2.72E-­‐04	  
Ube2l6	   3.3	   6.77E-­‐04	  
	  
LOC100132815	   -­‐2.2	   1.14E-­‐04	  
CSRP2	   3.3	   2.30E-­‐04	  
	  
hsdl2	   -­‐2.2	   5.97E-­‐04	  
APOL1	   3.3	   2.78E-­‐04	  
	  
RAPGEFL1	   -­‐2.2	   1.26E-­‐04	  
F2R	   3.3	   7.98E-­‐05	  
	  
Acads	   -­‐2.2	   3.13E-­‐04	  
LOC646057	   3.3	   5.15E-­‐05	  
	  
SRI	   -­‐2.2	   1.91E-­‐04	  
CD44	   3.3	   5.56E-­‐04	  
	  
AGMAT	   -­‐2.2	   1.13E-­‐04	  
LOC653879	   3.3	   1.62E-­‐05	  
	  
ZNF57	   -­‐2.2	   4.79E-­‐04	  
msn	   3.3	   1.43E-­‐04	  
	  
ACVR2A	   -­‐2.2	   5.59E-­‐04	  
Evi2a	   3.2	   1.22E-­‐06	  
	  
fam101a	   -­‐2.2	   2.39E-­‐04	  
IL7R	   3.2	   1.62E-­‐05	  
	  
ca12	   -­‐2.2	   1.33E-­‐04	  
Nptx2	   3.2	   1.13E-­‐06	  
	  
bsg	   -­‐2.2	   1.41E-­‐05	  
TMEM163	   3.2	   4.62E-­‐05	  
	  
KIAA1239	   -­‐2.2	   7.00E-­‐06	  
FCER1G	   3.2	   2.24E-­‐05	  
	  
ap3s2	   -­‐2.2	   9.94E-­‐04	  
CD93	   3.2	   1.30E-­‐04	  
	  
LEAP2	   -­‐2.2	   4.99E-­‐05	  
ptgds	   3.2	   6.67E-­‐06	  
	  
SGK223	   -­‐2.1	   4.54E-­‐04	  
GNA15	   3.2	   8.26E-­‐04	  
	  
Edn3	   -­‐2.1	   2.25E-­‐04	  
Egr2	   3.2	   2.68E-­‐05	  
	  
XK	   -­‐2.1	   1.55E-­‐04	  
BIRC3	   3.2	   7.98E-­‐05	  
	  
CYCS	   -­‐2.1	   6.35E-­‐05	  
AQP9	   3.2	   5.81E-­‐06	  
	  
thrB	   -­‐2.1	   2.68E-­‐05	  
COL1A1	   3.2	   1.54E-­‐04	  
	  
Cited2	   -­‐2.1	   1.65E-­‐04	  
C1s	   3.2	   3.67E-­‐05	  
	  
CDX2	   -­‐2.1	   5.82E-­‐05	  
ART3	   3.2	   2.07E-­‐04	  
	  
a1cf	   -­‐2.1	   3.25E-­‐06	  
TMEM45A	   3.2	   1.92E-­‐05	  
	  
Adh1c	   -­‐2.1	   2.75E-­‐04	  
HLA-­‐DPB1	   3.1	   2.87E-­‐06	  
	  
FABP1	   -­‐2.1	   4.25E-­‐04	  
gem	   3.1	   2.35E-­‐04	  
	  
Ccnjl	   -­‐2.1	   5.96E-­‐04	  
loxl1	   3.1	   2.17E-­‐04	  
	  
gsta1	   -­‐2.1	   1.23E-­‐07	  
FCRL5	   3.1	   1.79E-­‐04	  
	  
fam189a1	   -­‐2.1	   6.38E-­‐04	  
Btn3a3	   3.1	   3.75E-­‐04	  
	  
P2RY1	   -­‐2.1	   6.59E-­‐04	  
Cd52	   3.1	   4.57E-­‐06	  
	  
GCNT2	   -­‐2.1	   4.83E-­‐06	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Crohn's	  Disease	  
Up-­‐regulated	  
	  
Down-­‐regulated	  
Gene	  Symbol	   FC	   p-­‐value	  
	  
Gene	  Symbol	   FC	   p-­‐value	  
REG1A	   46.3	   3.52E-­‐04	  
	  
AQP8	   -­‐12.0	   7.89E-­‐04	  
REG1B	   40.3	   9.94E-­‐05	  
	  
Cldn8	   -­‐9.0	   7.99E-­‐07	  
S100A8	   26.5	   2.53E-­‐04	  
	  
Ostalpha	   -­‐7.5	   4.22E-­‐08	  
MMP3	   19.1	   2.25E-­‐04	  
	  
PCK1	   -­‐6.9	   1.13E-­‐04	  
Mmp1	   16.6	   2.88E-­‐05	  
	  
SLC16A9	   -­‐6.0	   9.69E-­‐04	  
CHI3L1	   15.7	   6.15E-­‐04	  
	  
UGT2A3	   -­‐5.8	   1.41E-­‐05	  
IDO1	   12.4	   3.91E-­‐04	  
	  
GUCA2B	   -­‐5.3	   3.34E-­‐04	  
Duox2	   12.1	   2.88E-­‐04	  
	  
LOC100506782	   -­‐5.2	   4.36E-­‐04	  
CXCL13	   10.8	   1.61E-­‐06	  
	  
MT1M	   -­‐4.9	   7.64E-­‐08	  
FCGR3B	   10.2	   2.10E-­‐04	  
	  
GUCA2A	   -­‐4.8	   5.27E-­‐05	  
Mmp12	   10.1	   1.49E-­‐04	  
	  
slc30a10	   -­‐4.5	   2.19E-­‐04	  
DEFA6	   9.8	   3.30E-­‐04	  
	  
vldlr	   -­‐4.5	   9.68E-­‐04	  
IL8	   9.1	   3.36E-­‐05	  
	  
HSD17B2	   -­‐4.2	   8.97E-­‐04	  
Cxcl6	   8.5	   3.70E-­‐05	  
	  
ANPEP	   -­‐4.1	   4.36E-­‐08	  
BCL2A1	   7.1	   3.72E-­‐05	  
	  
LAMA1	   -­‐3.9	   3.81E-­‐04	  
IGHV3-­‐11	   6.6	   1.06E-­‐04	  
	  
Prap1	   -­‐3.9	   8.18E-­‐05	  
IL1B	   6.5	   5.32E-­‐04	  
	  
GHR	   -­‐3.9	   3.79E-­‐06	  
Cxcl9	   6.5	   3.50E-­‐07	  
	  
Slc3a1	   -­‐3.8	   1.49E-­‐05	  
CXCL11	   6.3	   3.16E-­‐07	  
	  
mep1b	   -­‐3.8	   2.13E-­‐06	  
MMP10	   6.3	   3.64E-­‐04	  
	  
ptprr	   -­‐3.8	   6.78E-­‐05	  
Duoxa2	   6.2	   8.05E-­‐04	  
	  
SLC16A1	   -­‐3.7	   3.72E-­‐04	  
LOC651536	   6.2	   1.33E-­‐05	  
	  
Slc26a2	   -­‐3.7	   2.29E-­‐08	  
REG4	   5.9	   4.74E-­‐05	  
	  
chp2	   -­‐3.5	   3.28E-­‐05	  
PI3	   5.9	   2.80E-­‐05	  
	  
APOBEC3B	   -­‐3.4	   5.01E-­‐04	  
C4orf7	   5.7	   2.68E-­‐07	  
	  
pitx2	   -­‐3.4	   1.10E-­‐05	  
DMBT1	   5.7	   1.17E-­‐05	  
	  
MT1X	   -­‐3.3	   3.20E-­‐05	  
IGKV4-­‐1	   5.7	   2.62E-­‐05	  
	  
Ms4a12	   -­‐3.3	   1.33E-­‐07	  
TNIP3	   5.7	   1.70E-­‐04	  
	  
abca8	   -­‐3.2	   2.23E-­‐04	  
MNDA	   5.6	   4.96E-­‐06	  
	  
TUBAL3	   -­‐3.2	   2.86E-­‐04	  
LOC100133678	   5.6	   9.99E-­‐06	  
	  
Cd177	   -­‐3.1	   4.22E-­‐08	  
TIMP1	   5.5	   9.99E-­‐04	  
	  
pnliprp2	   -­‐3.0	   7.02E-­‐05	  
fam26f	   5.5	   6.52E-­‐05	  
	  
PHLPP2	   -­‐3.0	   8.14E-­‐04	  
CTHRC1	   5.4	   1.46E-­‐05	  
	  
UGT1A7	   -­‐3.0	   9.47E-­‐08	  
CCL18	   5.4	   1.18E-­‐04	  
	  
RUNDC3B	   -­‐3.0	   6.91E-­‐04	  
CXCL5	   5.3	   1.01E-­‐06	  
	  
MT1G	   -­‐2.9	   7.10E-­‐08	  
LY96	   5.3	   1.56E-­‐04	  
	  
Ostbeta	   -­‐2.9	   9.96E-­‐06	  
ANXA1	   5.3	   3.51E-­‐05	  
	  
BEST4	   -­‐2.8	   1.27E-­‐07	  
SELL	   5.2	   2.59E-­‐06	  
	  
Hsd3b2	   -­‐2.8	   1.82E-­‐05	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HLA-­‐DQB1	   5.2	   3.37E-­‐04	  
	  
LOC100507594	   -­‐2.8	   5.82E-­‐04	  
Spink4	   5.2	   9.68E-­‐05	  
	  
Mep1a	   -­‐2.8	   1.24E-­‐04	  
CXCL10	   5.1	   8.58E-­‐08	  
	  
SLC17A4	   -­‐2.8	   4.47E-­‐05	  
PCSK1	   5.0	   6.25E-­‐04	  
	  
C10orf116	   -­‐2.8	   1.60E-­‐04	  
CSF2RB	   4.9	   1.39E-­‐05	  
	  
cdkn2b	   -­‐2.8	   7.59E-­‐04	  
C2CD4A	   4.8	   1.58E-­‐04	  
	  
Npy1r	   -­‐2.8	   2.81E-­‐06	  
Mmp9	   4.8	   4.22E-­‐05	  
	  
MT1F	   -­‐2.8	   1.21E-­‐06	  
SPP1	   4.7	   6.43E-­‐06	  
	  
Adh1c	   -­‐2.8	   1.32E-­‐07	  
TRIM22	   4.7	   4.97E-­‐04	  
	  
Slc38a4	   -­‐2.7	   8.21E-­‐07	  
hla-­‐dpa1	   4.7	   3.22E-­‐04	  
	  
DHRS11	   -­‐2.7	   3.44E-­‐05	  
mmp7	   4.6	   5.56E-­‐05	  
	  
CA7	   -­‐2.7	   7.67E-­‐06	  
srgn	   4.6	   3.69E-­‐05	  
	  
TRHDE	   -­‐2.6	   2.98E-­‐07	  
LAMP3	   4.6	   1.48E-­‐05	  
	  
ST6GAL2	   -­‐2.6	   2.97E-­‐07	  
Ncf2	   4.6	   1.43E-­‐04	  
	  
TRPM6	   -­‐2.6	   4.83E-­‐05	  
HLA-­‐DRB4	   4.6	   7.23E-­‐04	  
	  
SLC1A1	   -­‐2.6	   1.13E-­‐05	  
OLFM4	   4.6	   7.26E-­‐05	  
	  
aqp11	   -­‐2.6	   4.75E-­‐04	  
GBP1	   4.5	   1.23E-­‐04	  
	  
PADI2	   -­‐2.6	   6.72E-­‐04	  
TNC	   4.4	   4.84E-­‐06	  
	  
LOC644246	   -­‐2.6	   2.78E-­‐05	  
GREM1	   4.4	   2.92E-­‐07	  
	  
SULT1A2	   -­‐2.6	   1.99E-­‐04	  
IGHV1-­‐69	   4.4	   2.43E-­‐05	  
	  
ANKRD43	   -­‐2.6	   5.73E-­‐05	  
SERPINB5	   4.3	   3.92E-­‐08	  
	  
C1qtnf3	   -­‐2.5	   6.81E-­‐04	  
MS4A1	   4.3	   7.97E-­‐08	  
	  
DEFB1	   -­‐2.5	   7.41E-­‐08	  
Cd55	   4.2	   8.70E-­‐04	  
	  
Pkib	   -­‐2.5	   6.07E-­‐09	  
TNFSF13B	   4.2	   1.12E-­‐04	  
	  
CNTN3	   -­‐2.5	   2.06E-­‐06	  
CCL20	   4.2	   2.35E-­‐04	  
	  
Entpd5	   -­‐2.5	   9.71E-­‐05	  
S100A9	   4.2	   8.85E-­‐07	  
	  
CA1	   -­‐2.5	   4.68E-­‐05	  
Col15a1	   4.2	   3.82E-­‐05	  
	  
DPP10	   -­‐2.4	   1.11E-­‐05	  
SAMSN1	   4.2	   2.60E-­‐05	  
	  
EFNA1	   -­‐2.4	   2.53E-­‐05	  
LYZ	   4.1	   2.77E-­‐05	  
	  
PDK4	   -­‐2.4	   9.69E-­‐06	  
IGLV2-­‐14	   4.1	   3.89E-­‐07	  
	  
sult1a1	   -­‐2.4	   1.70E-­‐04	  
HLA-­‐DMB	   4.1	   9.55E-­‐04	  
	  
STBD1	   -­‐2.4	   2.11E-­‐04	  
TCN1	   4.1	   6.74E-­‐05	  
	  
ACSF2	   -­‐2.3	   8.80E-­‐05	  
tdo2	   4.1	   3.32E-­‐07	  
	  
Gba3	   -­‐2.3	   9.18E-­‐05	  
COL1A2	   4.1	   1.26E-­‐05	  
	  
Mier3	   -­‐2.3	   1.62E-­‐04	  
cstA	   4.1	   1.03E-­‐04	  
	  
lrrc19	   -­‐2.3	   2.18E-­‐05	  
Col6a3	   3.9	   3.86E-­‐05	  
	  
FLJ35024	   -­‐2.3	   1.97E-­‐05	  
Cfi	   3.9	   5.69E-­‐06	  
	  
Paqr5	   -­‐2.3	   3.79E-­‐05	  
S100P	   3.9	   2.65E-­‐04	  
	  
VIPR1	   -­‐2.3	   1.39E-­‐05	  
IGHV3-­‐23	   3.8	   1.95E-­‐05	  
	  
FLJ32063	   -­‐2.3	   4.13E-­‐08	  
FPR1	   3.8	   9.39E-­‐06	  
	  
FLJ22763	   -­‐2.3	   1.42E-­‐07	  
nnmt	   3.8	   1.30E-­‐06	  
	  
MAGI1	   -­‐2.3	   5.14E-­‐04	  
CXCR2	   3.8	   1.48E-­‐06	  
	  
Tmem37	   -­‐2.3	   1.01E-­‐06	  
ROBO1	   3.8	   1.73E-­‐04	  
	  
Ces2	   -­‐2.3	   3.45E-­‐04	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Ccl11	   3.8	   5.55E-­‐05	  
	  
EXPH5	   -­‐2.3	   6.23E-­‐08	  
PLA2G7	   3.8	   3.72E-­‐08	  
	  
Cyp2s1	   -­‐2.2	   8.52E-­‐05	  
Basp1	   3.8	   5.68E-­‐06	  
	  
KIAA1737	   -­‐2.2	   2.36E-­‐04	  
Igsf6	   3.7	   3.41E-­‐05	  
	  
CWH43	   -­‐2.2	   7.51E-­‐06	  
c13orf15	   3.7	   1.54E-­‐05	  
	  
gsta1	   -­‐2.2	   1.42E-­‐07	  
C4BPB	   3.7	   7.07E-­‐05	  
	  
PPARGC1A	   -­‐2.2	   2.23E-­‐08	  
plek	   3.7	   2.66E-­‐05	  
	  
BEST2	   -­‐2.2	   6.64E-­‐07	  
Pde4b	   3.7	   2.60E-­‐05	  
	  
Mcoln2	   -­‐2.2	   5.34E-­‐07	  
Pla2g2a	   3.7	   2.99E-­‐07	  
	  
ITPKA	   -­‐2.2	   3.77E-­‐04	  
Ifitm2	   3.6	   2.65E-­‐04	  
	  
CKB	   -­‐2.2	   2.93E-­‐06	  
psmb9	   3.6	   6.71E-­‐04	  
	  
PRR15	   -­‐2.2	   4.83E-­‐05	  
Ccl2	   3.6	   2.32E-­‐08	  
	  
METTL7B	   -­‐2.2	   1.43E-­‐06	  
POU2AF1	   3.6	   2.89E-­‐07	  
	  
ACOX1	   -­‐2.2	   4.09E-­‐05	  
Vcam1	   3.6	   2.75E-­‐08	  
	  
ISX	   -­‐2.2	   3.70E-­‐05	  
IGLL3	   3.6	   5.32E-­‐07	  
	  
NEURL1B	   -­‐2.2	   3.01E-­‐06	  
ighv1-­‐2	   3.6	   7.06E-­‐06	  
	  
chrna1	   -­‐2.1	   4.02E-­‐04	  
Ctsk	   3.6	   1.33E-­‐04	  
	  
PIGZ	   -­‐2.1	   2.89E-­‐07	  
CCL19	   3.6	   2.92E-­‐06	  
	  
bsg	   -­‐2.1	   8.75E-­‐07	  
AIM2	   3.6	   9.07E-­‐05	  
	  
LOC100288092	   -­‐2.1	   3.16E-­‐06	  
VNN2	   3.5	   1.18E-­‐07	  
	  
Pde6a	   -­‐2.1	   2.57E-­‐05	  
CR2	   3.5	   2.79E-­‐06	  
	  
EDN1	   -­‐2.1	   2.83E-­‐04	  
WNT5A	   3.5	   2.85E-­‐08	  
	  
PDZD3	   -­‐2.1	   2.90E-­‐04	  
Vnn1	   3.5	   5.52E-­‐08	  
	  
Scin	   -­‐2.1	   1.13E-­‐07	  
IL7R	   3.5	   6.93E-­‐06	  
	  
Epdr1	   -­‐2.1	   3.02E-­‐08	  
Cd53	   3.5	   9.95E-­‐07	  
	  
RAVER2	   -­‐2.1	   2.04E-­‐05	  
HCLS1	   3.4	   8.50E-­‐07	  
	  
Tmem171	   -­‐2.1	   7.34E-­‐06	  
CHST15	   3.4	   2.18E-­‐05	  
	  
OSBPL1A	   -­‐2.1	   6.52E-­‐06	  
AQP9	   3.4	   8.08E-­‐08	  
	  
CDHR1	   -­‐2.1	   3.26E-­‐07	  
CASP1	   3.4	   6.41E-­‐04	  
	  
aifm3	   -­‐2.1	   4.50E-­‐08	  
lcp2	   3.4	   6.84E-­‐07	  
	  
phyH	   -­‐2.1	   2.23E-­‐04	  
FLJ40330	   3.4	   1.18E-­‐06	  
	  
HIGD1D	   -­‐2.1	   3.96E-­‐04	  
PLAU	   3.4	   5.39E-­‐05	  
	  
FMO5	   -­‐2.1	   1.14E-­‐04	  
IGLV3-­‐1	   3.4	   9.21E-­‐07	  
	  
PBLD	   -­‐2.1	   6.93E-­‐07	  
Elovl5	   3.3	   1.22E-­‐04	  
	  
LOC100505633	   -­‐2.1	   3.25E-­‐07	  
FKBP11	   3.3	   9.86E-­‐04	  
	  
SELENBP1	   -­‐2.1	   1.51E-­‐06	  
LUM	   3.3	   5.11E-­‐07	  
	  
SEMA5A	   -­‐2.1	   2.48E-­‐04	  
wars	   3.3	   5.11E-­‐05	  
	  
FAM5C	   -­‐2.1	   4.76E-­‐07	  
FCER1G	   3.3	   1.90E-­‐06	  
	  
tmem38b	   -­‐2.1	   7.99E-­‐05	  
TNFAIP6	   3.3	   3.56E-­‐05	  
	  
WSCD1	   -­‐2.1	   5.44E-­‐04	  
LOC643733	   3.3	   2.99E-­‐04	  
	  
SGK2	   -­‐2.1	   1.25E-­‐06	  
CXCR4	   3.3	   9.61E-­‐08	  
	  
HHLA2	   -­‐2.1	   3.01E-­‐08	  
IGLV2-­‐11	   3.3	   1.71E-­‐08	  
	  
Matn2	   -­‐2.0	   1.10E-­‐04	  
rab31	   3.3	   1.18E-­‐04	  
	  
C7orf10	   -­‐2.0	   2.33E-­‐07	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Evi2a	   3.2	   5.97E-­‐08	  
	  
KIAA1239	   -­‐2.0	   3.70E-­‐08	  
SELE	   3.2	   2.82E-­‐08	  
	  
emp1	   -­‐2.0	   7.80E-­‐06	  
FOXQ1	   3.2	   2.38E-­‐06	  
	  
Snx30	   -­‐2.0	   1.94E-­‐04	  
gbp5	   3.2	   5.08E-­‐08	  
	  
Slc23a1	   -­‐2.0	   2.39E-­‐07	  
dapp1	   3.2	   9.15E-­‐04	  
	  
Pla2g12b	   -­‐2.0	   9.45E-­‐06	  
ART3	   3.2	   5.61E-­‐04	  
	  
C1orf210	   -­‐2.0	   5.45E-­‐06	  
IFI44	   3.2	   6.41E-­‐05	  
	  
C2orf88	   -­‐2.0	   5.07E-­‐08	  
Ifit3	   3.2	   4.90E-­‐08	  
	  
IGSF9	   -­‐2.0	   2.41E-­‐06	  
Ube2l6	   3.2	   8.40E-­‐04	  
	  
TMEM56	   -­‐2.0	   8.29E-­‐09	  
Col5a2	   3.2	   3.08E-­‐08	  
	  
GLB1L2	   -­‐2.0	   1.61E-­‐05	  
tgfbi	   3.2	   3.49E-­‐06	  
	  
Slc25a34	   -­‐2.0	   1.78E-­‐05	  
Rftn1	   3.2	   2.52E-­‐06	  
	  
tmcc3	   -­‐2.0	   1.18E-­‐04	  
micB	   3.2	   3.90E-­‐04	  
	  
SLC20A2	   -­‐2.0	   2.12E-­‐04	  
CYTIP	   3.1	   9.63E-­‐08	  
	  
Cited2	   -­‐2.0	   7.89E-­‐05	  
Btn3a3	   3.1	   6.86E-­‐04	  
	  
C10orf58	   -­‐2.0	   4.58E-­‐08	  
PECAM1	   3.1	   1.33E-­‐04	  
	  
SLC39A5	   -­‐2.0	   2.81E-­‐04	  
Col4a1	   3.1	   1.74E-­‐05	  
	  
PDCD4	   -­‐2.0	   7.11E-­‐05	  
ptgds	   3.1	   3.88E-­‐08	  
	  
Golt1a	   -­‐2.0	   7.59E-­‐05	  
PDZK1IP1	   3.1	   2.16E-­‐05	  
	  
SVOPL	   -­‐2.0	   1.41E-­‐05	  
Prok2	   3.1	   2.78E-­‐06	  
	  
PLEKHG6	   -­‐2.0	   2.55E-­‐05	  
LAPTM5	   3.1	   1.04E-­‐08	  
	  
C5orf35	   -­‐2.0	   6.36E-­‐08	  
CD163	   3.1	   2.49E-­‐07	  
	  
smpdl3a	   -­‐2.0	   1.16E-­‐04	  
TNFRSF17	   3.1	   2.86E-­‐06	  
	  
PPP1R3B	   -­‐2.0	   5.22E-­‐04	  
LOC646057	   3.1	   3.09E-­‐05	  
	  
gxylt2	   -­‐2.0	   1.54E-­‐05	  
ELTD1	   3.1	   3.77E-­‐05	  
	  
MYO1D	   -­‐2.0	   9.63E-­‐05	  
C1s	   3.1	   1.92E-­‐06	  
	  
PXMP2	   -­‐2.0	   5.35E-­‐04	  
TMEM158	   3.1	   9.18E-­‐06	  
	  
CNGA1	   -­‐2.0	   4.16E-­‐08	  
MXRA5	   3.1	   2.71E-­‐08	  
	  
FABP1	   -­‐2.0	   2.99E-­‐07	  
arhgdib	   3.1	   5.93E-­‐05	  
	  
Samd13	   -­‐2.0	   6.57E-­‐08	  
FSTL1	   3.0	   2.40E-­‐05	  
	  
WDR78	   -­‐2.0	   2.46E-­‐08	  
DRAM1	   3.0	   1.23E-­‐04	  
	  
SLC4A4	   -­‐2.0	   1.71E-­‐07	  
ENPP2	   3.0	   3.95E-­‐05	  
	  
appl2	   -­‐2.0	   6.03E-­‐06	  
Ptprc	   3.0	   1.15E-­‐07	  
	  
CA4	   -­‐1.9	   8.83E-­‐05	  
HLA-­‐DPB1	   3.0	   7.93E-­‐08	  
	  
GIPC2	   -­‐1.9	   3.00E-­‐07	  
PTGS2	   3.0	   9.12E-­‐07	  
	  
FAM55D	   -­‐1.9	   2.77E-­‐06	  
EVI2B	   3.0	   2.20E-­‐07	  
	  
PRKG2	   -­‐1.9	   1.03E-­‐04	  
CCL4	   3.0	   6.83E-­‐08	  
	  
fam189a1	   -­‐1.9	   4.45E-­‐04	  
serpina3	   3.0	   9.23E-­‐07	  
	  
HPGD	   -­‐1.9	   1.00E-­‐07	  
Ifitm1	   3.0	   4.77E-­‐04	  
	  
MTMR11	   -­‐1.9	   6.77E-­‐05	  
IL13RA2	   3.0	   8.49E-­‐08	  
	  
VAV3	   -­‐1.9	   6.20E-­‐08	  
Rgs5	   2.9	   1.97E-­‐05	  
	  
C1orf115	   -­‐1.9	   1.04E-­‐04	  
SERPING1	   2.9	   4.84E-­‐05	  
	  
RNF128	   -­‐1.9	   1.23E-­‐06	  
LILRB2	   2.9	   6.44E-­‐08	  
	  
Etfdh	   -­‐1.9	   1.02E-­‐05	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Egr2	   2.9	   2.65E-­‐06	  
	  
UGDH	   -­‐1.9	   4.99E-­‐05	  
MGP	   2.9	   8.24E-­‐08	  
	  
NAAA	   -­‐1.9	   6.42E-­‐05	  
pfkfb3	   2.9	   6.91E-­‐05	  
	  
GCOM1	   -­‐1.9	   5.12E-­‐04	  
IGHV3-­‐9	   2.9	   2.28E-­‐06	  
	  
PLCE1	   -­‐1.9	   1.07E-­‐07	  
P2RY13	   2.9	   1.75E-­‐06	  
	  
CYP2B6	   -­‐1.9	   6.67E-­‐07	  
cd38	   2.9	   9.00E-­‐05	  
	  
GATA6	   -­‐1.9	   5.11E-­‐05	  
ITGB2	   2.9	   1.49E-­‐05	  
	  
Tmed6	   -­‐1.9	   6.69E-­‐06	  
Egfl6	   2.9	   9.92E-­‐07	  
	  
LOC100133772	   -­‐1.9	   1.02E-­‐04	  
PF4	   2.9	   2.39E-­‐05	  
	  
ABAT	   -­‐1.9	   1.14E-­‐04	  
CD93	   2.9	   1.58E-­‐05	  
	  
sh3bgrl2	   -­‐1.9	   1.65E-­‐04	  
Cd48	   2.9	   5.92E-­‐08	  
	  
ANK3	   -­‐1.9	   2.64E-­‐08	  
CLIC2	   2.9	   3.63E-­‐05	  
	  
TSPAN7	   -­‐1.9	   8.11E-­‐06	  
CPA3	   2.9	   5.40E-­‐07	  
	  
MAOA	   -­‐1.9	   1.68E-­‐06	  
LOC653879	   2.9	   4.15E-­‐08	  
	  
CLCN2	   -­‐1.9	   5.17E-­‐07	  
LCP1	   2.9	   5.38E-­‐08	  
	  
CYP4F2	   -­‐1.9	   9.36E-­‐07	  
AG2	   2.9	   2.93E-­‐07	  
	  
fxyd3	   -­‐1.9	   1.14E-­‐06	  
Cd52	   2.9	   7.86E-­‐08	  
	  
HSPB3	   -­‐1.9	   2.26E-­‐06	  
APOL1	   2.9	   1.53E-­‐04	  
	  
arrdc4	   -­‐1.9	   4.96E-­‐05	  
ifi30	   2.9	   1.21E-­‐04	  
	  
CNNM2	   -­‐1.9	   1.32E-­‐04	  
COL3A1	   2.8	   3.10E-­‐07	  
	  
cobL	   -­‐1.9	   1.55E-­‐04	  
COL1A1	   2.8	   1.19E-­‐06	  
	  
Cpt1a	   -­‐1.9	   9.89E-­‐04	  
Mafb	   2.8	   2.10E-­‐06	  
	  
ACVR2A	   -­‐1.9	   2.61E-­‐04	  
Rhoh	   2.8	   4.63E-­‐07	  
	  
Camk2n1	   -­‐1.9	   7.26E-­‐05	  
TMEM45A	   2.8	   1.21E-­‐06	  
	  
Ephx2	   -­‐1.9	   2.53E-­‐06	  
SNX10	   2.8	   4.69E-­‐09	  
	  
CDHR5	   -­‐1.9	   8.54E-­‐08	  
LOC91316	   2.8	   1.54E-­‐05	  
	  
Ppp1r14a	   -­‐1.9	   3.22E-­‐06	  
CSRP2	   2.8	   2.37E-­‐05	  
	  
pAG1	   -­‐1.9	   5.04E-­‐06	  
LIPG	   2.8	   2.80E-­‐04	  
	  
SLC9A3R1	   -­‐1.8	   3.28E-­‐05	  
SAMD9L	   2.8	   2.40E-­‐04	  
	  
Prdx6	   -­‐1.8	   4.60E-­‐04	  
dse	   2.8	   1.72E-­‐07	  
	  
LOC100506261	   -­‐1.8	   6.37E-­‐05	  
IGLV3-­‐19	   2.8	   4.61E-­‐06	  
	  
AHCYL2	   -­‐1.8	   3.64E-­‐07	  
MGC29506	   2.8	   3.56E-­‐08	  
	  
FCGRT	   -­‐1.8	   3.29E-­‐04	  
Rilpl2	   2.8	   6.07E-­‐04	  
	  
NR5A2	   -­‐1.8	   4.59E-­‐05	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UPREGULATED	  CRC	  GENES	  
Gene Symbol Dukes	  A	  FC	   Dukes	  B	  FC	   Dukes	  C	  FC	   Dukes	  D	  FC	  
CTHRC1	   11.7	   17.3	   19.8	   16.4	  
FOXQ1	   15.0	   15.3	   15.1	   16.1	  
IL8	   13.0	   18.1	   18.0	   12.1	  
THBS2	   9.1	  
	  
16.0	   14.4	  
SPP1	   5.6	   13.6	   15.1	   18.1	  
MMP7	   8.2	   10.6	   11.7	   10.1	  
CLDN2	   9.5	   8.3	   7.2	   8.8	  
SFRP2	   5.1	   8.2	   9.9	   10.2	  
CDH3	   7.2	  
	  
7.4	   7.1	  
TIMP1	   5.7	   7.3	   7.7	   7.7	  
KRT23	   6.8	   7.2	   5.9	   8.5	  
GDF15	   7.4	   6.8	   6.2	   6.8	  
SULF1	   4.8	   7.1	   7.7	   7.2	  
COL11A1	   4.4	  
	  
8.4	   7.1	  
CLDN1	   6.2	  
	  
6.9	   6.7	  
H19	   5.1	   5.9	   7.4	   7.1	  
COL1A1	   5.3	  
	  
6.9	   6.0	  
COL12A1	   5.3	  
	  
6.7	   6.0	  
CXCL2	   8.5	   6.2	   5.3	   3.9	  
TCN1	   6.5	   6.9	   4.8	   5.6	  
AZGP1P1	   5.6	   5.9	   5.6	   6.3	  
CXCL1	   7.5	   6.1	   5.9	   3.8	  
SNORA71A	   5.4	   6.2	   5.9	   5.5	  
CYR61	   4.7	   5.7	   6.0	   6.2	  
MMP1	   4.7	   6.7	   7.0	   4.0	  
CXCL3	   7.6	   5.6	   5.4	   3.5	  
MFAP2	   4.6	  
	  
6.0	   5.9	  
COL10A1	   3.2	   5.4	   7.3	   6.0	  
VCAN	   4.0	   5.1	   5.7	   5.3	  
FAP	   3.8	  
	  
6.1	   5.1	  
SFRP4	   3.9	   4.6	   6.0	   5.6	  
FLJ44450	   5.0	   5.3	   4.9	   4.8	  
SLC7A5	   4.6	   5.0	   5.2	   5.0	  
COL1A2	   3.9	   5.1	   5.5	   4.9	  
MGP	   3.4	   4.4	   5.2	   6.1	  
TESC	   4.3	   4.7	   5.1	   5.0	  
S100A8	   4.0	   5.7	   5.3	   4.0	  
C2ORF82	   4.8	   4.8	   4.8	   4.5	  
C2CD4A	   6.3	   4.7	   4.0	   3.8	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COL5A2	   3.8	   4.9	   5.3	   4.7	  
FAM165B	   4.5	   4.7	   4.8	   4.3	  
LCN2	   6.5	   4.3	   4.0	   3.3	  
CHI3L1	   4.9	   5.0	   4.7	   3.3	  
C8ORF62	   4.6	   4.3	   4.5	   4.5	  
DPEP1	   4.4	   4.5	   3.8	   4.8	  
F2R	   4.7	   4.0	   4.4	   4.5	  
RP9P	   4.2	  
	  
4.5	   4.4	  
EPHX4	   4.3	   4.3	   4.4	   4.3	  
NCRNA00164	   4.4	   4.9	   4.1	   3.8	  
TACSTD2	   3.3	   4.1	   4.6	   5.2	  
LY6G6D	   4.5	   4.0	   4.4	   4.2	  
TGFBI	   4.0	   4.3	   4.0	   4.7	  
CXCL11	   4.9	   4.7	   4.3	   3.0	  
MMP3	   4.1	   4.7	   4.8	   3.1	  
PHLDA1	   4.0	   4.4	   3.8	   4.2	  
UBD	   4.7	   4.1	   4.2	   3.3	  
LGR5	   4.3	   3.6	   3.7	   4.5	  
FXYD5	   3.8	   3.9	   4.2	   3.7	  
WNT2	   4.0	  
	  
3.9	   3.6	  
KIAA1199	   3.8	   4.0	   3.4	   4.1	  
ANLN	   3.9	   3.9	   4.0	   3.5	  
FOSL1	   3.5	   4.0	   4.2	   3.5	  
REG1A	   4.2	   4.3	   3.1	   3.6	  
FNDC1	   2.7	   3.7	   4.4	   4.3	  
COL6A3	   3.2	   3.9	   4.2	   3.8	  
COL15A1	   3.1	   4.0	   4.2	   3.7	  
CST1	   3.5	   3.6	   4.2	   3.7	  
GREM1	   2.6	   3.9	   4.7	   3.7	  
LUM	   3.4	   3.7	   4.2	   3.6	  
CRNDE	   3.8	   4.0	   3.4	   3.7	  
CDH11	   3.3	   3.7	   4.0	   3.9	  
OLFML2B	   2.9	   3.8	   4.1	   4.0	  
RPL18AP3	   3.8	   3.6	   3.7	   3.7	  
C13ORF37	   3.5	   3.7	   3.9	   3.7	  
INHBA	   2.8	   3.6	   4.2	   3.8	  
TTYH3	   3.7	  
	  
3.6	   3.5	  
ASPN	   2.2	   3.6	   4.1	   4.3	  
S100A2	   3.0	   3.7	   4.2	   3.5	  
PPBP	   3.0	   3.5	   4.0	   3.7	  
UBE2C	   3.6	  
	  
3.6	   3.5	  
NKAIN3	   3.6	   3.6	   3.5	   3.4	  
ESM1	   3.4	   3.1	   3.7	   3.8	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VSNL1	   3.4	   4.2	   3.3	   3.1	  
COL4A1	   3.2	   3.5	   3.7	   3.6	  
DUSP4	   3.4	   3.9	   3.8	   2.9	  
FOS	   3.3	   3.7	   3.3	   3.5	  
MAMSTR	   3.5	   3.4	   3.4	   3.4	  
SPON2	   2.7	   3.6	   3.7	   3.6	  
RHOB	   3.3	   3.5	   3.3	   3.6	  
SLC35D3	   3.5	   2.9	   3.7	   3.5	  
ETV4	   3.3	  
	  
3.2	   3.6	  
TPM4	   3.3	   3.4	   3.6	   3.1	  
EREG	   2.5	   3.4	   3.8	   3.7	  
MAD2L1	   3.5	   3.4	   3.3	   3.2	  
LOC652797	   3.1	   3.5	   3.5	   3.3	  
DUOX2	   3.3	  
	   	   	  GAL	   2.9	   3.3	   3.7	   3.3	  
PLS3	   3.1	   3.4	   3.3	   3.4	  
IFITM1	   3.6	   3.4	   3.3	   2.8	  
SERPINB5	   2.4	   3.6	   4.3	   2.8	  
FAM182B	   3.0	   3.4	   3.2	   3.4	  
LOC100505478	   3.2	   3.4	   3.3	   3.1	  
ASCL2	   3.5	   2.8	   2.9	   3.8	  
TIMP3	   2.5	   3.3	   3.6	   3.6	  
C13ORF33	   3.0	   3.3	   3.4	   3.2	  
S100A11	   3.0	   3.3	   3.3	   3.3	  
ZAK	   3.2	   3.2	   3.0	   3.5	  
CTGF	   2.8	   3.1	   3.5	   3.5	  
TAF1L	   3.2	   3.3	   3.2	   3.1	  
DUSP27	   4.1	   2.8	   2.6	   3.3	  
MMP2	   2.8	   3.3	   3.6	   3.2	  
APCDD1	   4.0	   3.4	   2.7	   2.8	  
THY1	   2.7	  
	  
3.5	   3.3	  
MYC	   3.5	   3.1	   3.1	   3.0	  
MYL9	   2.2	   3.4	   3.6	   3.4	  
SRPX2	   2.9	   3.1	   3.2	   3.3	  
SLC29A1	   3.0	  
	  
3.2	   3.2	  
COL5A1	   2.5	   3.2	   3.5	   3.3	  
S100P	   3.2	   3.2	   3.2	   2.9	  
SOX9	   3.3	   3.2	   3.0	   3.0	  
NID1	   3.1	   3.0	   3.2	   3.2	  
IL33	   3.9	   2.7	   2.9	   2.9	  
PRRX1	   2.6	   3.2	   3.7	   2.9	  
LY6E	   2.6	   3.2	   3.5	   2.9	  
ARNTL2	   3.3	  
	  
3.1	   2.8	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SERPINE1	   2.4	   3.2	   3.6	   3.1	  
JUB	   2.9	  
	  
3.3	   3.0	  
RGS1	   3.0	   3.0	   3.3	   2.9	  
CXCL5	  
	  
2.7	   3.5	   2.9	  
TRIM29	   2.9	   3.4	   3.1	   2.7	  
CEBPB	   2.7	   3.1	   3.2	   3.2	  
ECT2	   3.2	   3.1	   3.1	   2.8	  
TPX2	   3.2	   3.0	   3.0	   3.0	  
ACTB	   3.0	   3.0	   3.1	   3.0	  
BAG2	   2.4	   3.2	   3.3	   3.1	  
ODAM	   2.7	   3.1	   2.8	   3.4	  
IGHV1-­‐69	   3.0	  
	   	   	  SLCO4A1	   2.8	   3.2	   3.1	   2.9	  
KRT80	   2.5	   3.0	   3.1	   3.3	  
AGT	   3.5	   2.7	   2.5	   3.2	  
SPOCK1	  
	  
2.8	   3.0	   3.1	  
MSX1	   3.0	   2.9	   2.8	   3.1	  
TAGLN	   2.0	   3.1	   3.4	   3.2	  
OR10A5	   2.8	   3.2	   2.9	   3.0	  
IFI6	   2.9	   3.2	   3.0	   2.6	  
CCL20	   2.9	  
	   	   	  TG	   3.2	   2.9	   2.8	   2.9	  
CCND1	   2.9	   3.0	   3.0	   2.8	  
EDNRA	   2.5	   3.0	   3.1	   3.0	  
C9ORF16	   2.8	   3.0	   3.1	   2.8	  
SLCO1B3	   2.7	   3.1	   3.1	   2.8	  
SPARC	   2.4	   2.9	   3.3	   3.0	  
BGN	   2.3	   2.9	   3.3	   3.1	  
AMIGO2	   2.4	   2.7	   3.3	   3.1	  
SCD	   2.6	  
	  
2.8	   3.3	  
KLK6	   2.3	   3.2	   2.9	   3.2	  
CALU	   2.8	  
	  
3.0	   2.9	  
WNT5A	   3.1	   2.8	   3.1	   2.7	  
APOLD1	   3.1	   2.5	   2.5	   3.4	  
MACC1	   2.8	   2.8	   2.8	   3.1	  
BHLHE40	   2.7	   3.1	   3.1	   2.7	  
KAL1	   2.2	   2.9	   3.2	   3.2	  
LRRC25	   2.8	   2.9	   2.9	   2.8	  
ITGBL1	   2.4	   2.5	   3.1	   3.4	  
TAGLN2	   2.8	   3.0	   2.9	   2.7	  
KIR2DL3	   2.8	   2.8	   2.7	   3.0	  
C7ORF68	   2.8	   2.8	   2.8	   3.0	  
SERHL2	   2.7	   3.0	   2.7	   2.8	  
 143 
PCP4	   2.2	   3.2	   2.8	   3.1	  
KRT6B	   2.6	   2.8	   3.0	   2.8	  
IGHV@	   2.8	  
	   	   	  CD44	   3.0	   2.9	   2.8	   2.5	  
FAM176A	   2.7	   2.7	   2.8	   2.9	  
EGFL6	   2.9	   2.9	   2.9	   2.5	  
UCA1	   2.7	   2.6	   2.7	   3.1	  
PLAU	   2.4	   2.8	   3.1	   2.7	  
ENC1	   3.0	   2.7	   2.6	   2.7	  
AQP9	   2.2	   3.1	   3.1	   2.6	  
APOD	   2.2	   2.5	   2.9	   3.4	  
PPAPDC1A	   2.1	   2.8	   3.1	   2.9	  
PTMS	   2.8	   2.7	   2.8	   2.6	  
CD74	   2.9	   2.9	   2.8	   2.3	  
MET	   2.7	   2.8	   2.7	   2.7	  
HTRA1	   2.3	   2.7	   3.1	   2.8	  
C14ORF34	   2.5	   2.9	   2.7	   2.7	  
FCGR3B	   2.5	   3.1	   2.9	   2.3	  
CCL25	   2.8	   2.8	   2.5	   2.7	  
TNFAIP6	  
	  
2.8	   3.0	   2.2	  
FABP6	   2.7	   2.5	   2.4	   3.0	  
COL4A2	   2.4	   2.7	   2.8	   2.8	  
IGFBP7	   2.4	   2.6	   2.8	   2.9	  
SNTB1	   2.4	   2.6	   2.6	   3.1	  
ANXA6	   2.4	   2.7	   2.8	   2.7	  
DDIT4	   2.3	   2.7	   2.8	   2.8	  
HOMER1	   2.4	   2.6	   2.7	   2.8	  
NNMT	  
	  
2.5	   2.9	   2.5	  
MMP12	   2.9	   2.4	   2.6	  
	  FCER1G	   2.3	   2.8	   2.9	   2.5	  
TRAV27	   2.6	   2.6	   2.6	   2.7	  
HS6ST2	   2.4	   2.7	   2.8	   2.6	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APPENDIX G 
 
UPREGULATED	  CRC	  GENES	  
Gene Symbol Dukes	  A	  FC	   Dukes	  B	  FC	   Dukes	  C	  FC	   Dukes	  D	  FC	  
CLCA4	   -­‐53.3	  
	  
-­‐43.5	   -­‐63.0	  
MS4A12	   -­‐52.1	  
	  
-­‐36.3	   -­‐45.0	  
AQP8	   -­‐46.1	  
	  
-­‐33.1	   -­‐43.6	  
ZG16	   -­‐27.6	  
	  
-­‐27.4	   -­‐32.2	  
GCG	   -­‐27.4	   -­‐24.0	   -­‐23.0	   -­‐25.0	  
UGT2B17	   -­‐26.6	   -­‐18.8	   -­‐25.9	   -­‐20.7	  
ABCG2	   -­‐25.8	  
	  
-­‐20.5	   -­‐19.8	  
ADH1C	   -­‐20.5	  
	  
-­‐19.9	   -­‐25.1	  
CA1	   -­‐21.0	  
	  
-­‐16.4	   -­‐21.0	  
CA2	   -­‐19.7	  
	  
-­‐16.2	   -­‐22.0	  
PKIB	   -­‐20.2	  
	  
-­‐16.7	   -­‐19.1	  
HSD17B2	   -­‐20.5	  
	  
-­‐16.5	   -­‐17.8	  
AKR1B10	   -­‐17.8	  
	  
-­‐16.4	   -­‐17.4	  
SLC26A3	   -­‐17.9	   -­‐17.8	   -­‐13.1	   -­‐18.6	  
DHRS9	   -­‐17.8	  
	  
-­‐12.6	   -­‐17.6	  
SLC30A10	   -­‐16.6	  
	  
-­‐15.0	   -­‐15.7	  
CLDN8	   -­‐14.6	   -­‐14.1	   -­‐12.4	   -­‐16.2	  
GUCA2A	   -­‐14.3	  
	  
-­‐13.3	   -­‐15.2	  
CA4	   -­‐12.4	  
	  
-­‐11.0	   -­‐15.1	  
CD177	   -­‐12.9	  
	  
-­‐10.3	   -­‐14.9	  
MT1M	   -­‐12.6	   -­‐11.9	   -­‐10.0	   -­‐12.6	  
SI	   -­‐12.3	   -­‐12.1	   -­‐10.0	   -­‐12.5	  
CHP2	   -­‐11.2	  
	  
-­‐11.4	   -­‐11.2	  
ANPEP	   -­‐12.6	   -­‐10.4	   -­‐9.6	   -­‐12.5	  
CLCA1	   -­‐6.2	   -­‐10.1	   -­‐14.2	   -­‐12.5	  
TUBAL3	   -­‐11.0	  
	  
-­‐11.1	   -­‐9.5	  
CLDN23	   -­‐10.5	  
	  
-­‐9.6	   -­‐11.2	  
HEPACAM2	   -­‐7.2	   -­‐9.7	   -­‐11.9	   -­‐11.3	  
C6ORF105	   -­‐7.1	   -­‐10.4	   -­‐9.6	   -­‐11.5	  
ABCA8	   -­‐10.8	   -­‐9.8	   -­‐9.2	   -­‐8.4	  
PDE9A	   -­‐9.8	  
	  
-­‐9.8	   -­‐8.6	  
AGPAT9	   -­‐10.4	  
	  
-­‐8.8	   -­‐9.0	  
FAM55D	   -­‐9.0	  
	  
-­‐9.3	   -­‐9.6	  
SLC26A2	   -­‐8.5	   -­‐10.3	   -­‐8.5	   -­‐9.4	  
CEACAM7	   -­‐8.1	   -­‐9.3	   -­‐8.1	   -­‐10.2	  
SLC16A9	   -­‐8.4	   -­‐9.1	   -­‐9.0	   -­‐8.1	  
OSTBETA	   -­‐9.0	   -­‐8.6	   -­‐8.2	   -­‐8.9	  
CWH43	   -­‐8.3	   -­‐8.9	   -­‐8.9	   -­‐8.4	  
ARL14	   -­‐8.4	  
	  
-­‐7.9	   -­‐9.6	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LGALS2	   -­‐6.5	   -­‐9.2	   -­‐7.5	   -­‐10.2	  
BEST4	   -­‐8.5	  
	  
-­‐8.0	   -­‐8.5	  
NPY1R	   -­‐9.4	   -­‐8.3	   -­‐7.5	   -­‐8.0	  
UGT2A3	   -­‐6.1	   -­‐9.6	   -­‐8.3	   -­‐9.1	  
PCK1	   -­‐10.0	   -­‐7.9	   -­‐7.2	   -­‐7.7	  
SCNN1B	   -­‐8.1	   -­‐8.0	   -­‐7.6	   -­‐8.6	  
LRRC19	   -­‐6.6	   -­‐9.1	   -­‐8.6	   -­‐7.8	  
ITLN1	   -­‐5.8	   -­‐7.7	   -­‐8.5	   -­‐10.1	  
LAMA1	   -­‐7.8	   -­‐7.4	   -­‐7.6	   -­‐8.6	  
OSTALPHA	   -­‐8.8	   -­‐7.5	   -­‐7.4	   -­‐7.2	  
BEST2	   -­‐7.5	   -­‐7.4	   -­‐7.5	   -­‐8.0	  
SST	   -­‐8.0	   -­‐7.4	   -­‐7.7	   -­‐7.2	  
LOC100506782	   -­‐7.6	   -­‐7.3	   -­‐7.5	   -­‐6.9	  
GUCA2B	   -­‐7.2	   -­‐7.3	   -­‐7.0	   -­‐7.8	  
MUC4	   -­‐5.6	   -­‐6.8	   -­‐6.6	   -­‐9.7	  
CNTN3	   -­‐6.6	   -­‐7.5	   -­‐7.6	   -­‐6.4	  
PLCE1	   -­‐6.7	  
	  
-­‐6.9	   -­‐7.4	  
LOC100133944	   -­‐4.8	   -­‐6.3	   -­‐8.1	   -­‐8.7	  
C2ORF88	   -­‐6.8	  
	  
-­‐6.7	   -­‐7.3	  
HHLA2	   -­‐6.8	   -­‐7.0	   -­‐6.7	   -­‐7.1	  
C10ORF99	   -­‐4.9	   -­‐7.5	   -­‐7.5	   -­‐7.4	  
SLC4A4	   -­‐6.9	   -­‐6.4	   -­‐5.9	   -­‐7.3	  
VSIG2	   -­‐6.4	  
	  
-­‐6.2	   -­‐7.3	  
NR3C2	   -­‐6.3	  
	  
-­‐6.7	   -­‐6.8	  
GBA3	   -­‐6.8	   -­‐6.6	   -­‐6.2	   -­‐6.6	  
HPGD	   -­‐7.6	   -­‐6.2	   -­‐5.3	   -­‐6.9	  
C17ORF91	   -­‐6.8	  
	  
-­‐5.6	   -­‐6.9	  
TMCC3	   -­‐7.2	  
	  
-­‐5.3	   -­‐6.5	  
ABCB1	   -­‐6.6	   -­‐6.3	   -­‐7.5	   -­‐4.7	  
ETFDH	   -­‐6.6	  
	  
-­‐6.3	   -­‐6.0	  
DHRS11	   -­‐6.3	  
	  
-­‐6.1	   -­‐6.4	  
UGT2B15	   -­‐6.4	   -­‐5.6	   -­‐6.6	   -­‐6.3	  
SULT1A1	   -­‐6.6	  
	  
-­‐6.3	   -­‐5.9	  
GCNT3	   -­‐7.6	   -­‐5.5	   -­‐5.2	   -­‐6.5	  
PLAC8	   -­‐6.1	   -­‐6.4	   -­‐4.8	   -­‐7.3	  
LRRC66	   -­‐6.0	   -­‐6.1	   -­‐6.2	   -­‐6.0	  
ISX	   -­‐5.9	   -­‐6.5	   -­‐6.2	   -­‐5.6	  
SCIN	   -­‐7.2	   -­‐5.7	   -­‐5.6	   -­‐5.7	  
IL1R2	   -­‐5.7	   -­‐5.3	   -­‐5.5	   -­‐7.4	  
ADAMDEC1	   -­‐4.9	   -­‐6.7	   -­‐5.8	   -­‐6.5	  
FAM55A	   -­‐5.4	  
	  
-­‐5.9	   -­‐6.3	  
TMEM220	   -­‐5.7	   -­‐6.2	   -­‐5.4	   -­‐6.1	  
ADH1C	   -­‐6.6	   -­‐6.2	   -­‐5.8	   -­‐4.5	  
 146 
CA12	   -­‐5.4	  
	  
-­‐5.8	   -­‐6.1	  
PHLPP2	   -­‐6.0	   -­‐5.8	   -­‐5.7	   -­‐5.5	  
HSD11B2	   -­‐5.4	  
	  
-­‐6.1	   -­‐5.6	  
PLA2G10	   -­‐6.0	   -­‐5.4	   -­‐5.2	   -­‐6.1	  
RUNDC3B	   -­‐5.9	   -­‐5.5	   -­‐5.8	   -­‐5.1	  
HMGCS2	   -­‐5.3	   -­‐6.1	   -­‐5.4	   -­‐5.1	  
PPARGC1A	   -­‐5.4	  
	  
-­‐5.5	   -­‐5.5	  
SULT1A2	   -­‐5.5	   -­‐5.5	   -­‐5.4	   -­‐5.3	  
TSPAN7	   -­‐5.7	  
	  
-­‐5.5	   -­‐5.1	  
SYTL4	   -­‐5.4	  
	  
-­‐5.0	   -­‐5.6	  
UGT1A7	   -­‐5.5	   -­‐5.1	   -­‐5.2	   -­‐5.5	  
EPB41L3	   -­‐5.4	   -­‐5.1	   -­‐5.1	   -­‐5.7	  
NR1H4	   -­‐5.5	   -­‐5.4	   -­‐5.3	   -­‐4.8	  
MEP1A	   -­‐4.0	   -­‐5.7	   -­‐6.3	   -­‐4.6	  
SPINK5	   -­‐5.6	   -­‐4.7	   -­‐4.0	   -­‐6.1	  
SELENBP1	   -­‐3.5	   -­‐5.4	   -­‐5.9	   -­‐5.5	  
RICH2	   -­‐4.6	  
	  
-­‐5.1	   -­‐5.3	  
ZC3H12C	   -­‐3.8	   -­‐5.0	   -­‐5.8	   -­‐5.4	  
GDPD3	   -­‐5.2	   -­‐4.8	   -­‐4.7	   -­‐5.1	  
SLC3A1	   -­‐4.3	   -­‐5.1	   -­‐6.1	   -­‐4.2	  
SDCBP2	   -­‐5.3	  
	  
-­‐4.4	   -­‐5.0	  
PLCL2	   -­‐4.8	   -­‐4.7	   -­‐4.8	   -­‐5.3	  
GHR	   -­‐5.3	   -­‐4.8	   -­‐5.0	   -­‐4.3	  
PTPRR	   -­‐5.7	   -­‐4.6	   -­‐4.2	   -­‐4.8	  
CEACAM1	   -­‐5.2	   -­‐4.6	   -­‐4.7	   -­‐4.8	  
SLC17A4	   -­‐4.9	   -­‐4.7	   -­‐4.8	   -­‐4.9	  
TMED6	   -­‐5.0	   -­‐5.1	   -­‐4.8	   -­‐4.2	  
BMP2	   -­‐4.5	  
	  
-­‐4.6	   -­‐5.2	  
SLC22A5	   -­‐4.7	   -­‐4.8	   -­‐4.8	   -­‐4.7	  
PAG1	   -­‐4.9	   -­‐4.9	   -­‐4.3	   -­‐4.8	  
STYK1	   -­‐4.9	   -­‐4.6	   -­‐4.6	   -­‐4.6	  
PTPRH	   -­‐4.8	  
	  
-­‐4.3	   -­‐4.9	  
LOC100505633	   -­‐5.0	   -­‐4.6	   -­‐4.4	   -­‐4.6	  
EYA2	   -­‐4.7	   -­‐4.4	   -­‐4.6	   -­‐4.8	  
SMPDL3A	   -­‐4.3	   -­‐4.6	   -­‐4.6	   -­‐5.0	  
EDN3	   -­‐4.6	  
	  
-­‐4.3	   -­‐4.8	  
TMEM171	   -­‐4.9	   -­‐4.4	   -­‐4.2	   -­‐4.8	  
GGT6	   -­‐4.0	   -­‐4.5	   -­‐4.7	   -­‐4.9	  
PNLIPRP2	   -­‐4.0	   -­‐4.8	   -­‐5.2	   -­‐4.2	  
PIGZ	   -­‐4.3	   -­‐4.6	   -­‐4.9	   -­‐4.4	  
APOBEC3B	   -­‐5.3	   -­‐4.3	   -­‐4.3	   -­‐4.0	  
XDH	   -­‐4.4	   -­‐4.3	   -­‐4.4	   -­‐4.8	  
CDKN2B	   -­‐5.3	   -­‐4.4	   -­‐3.9	   -­‐4.2	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FABP1	   -­‐3.9	   -­‐5.8	   -­‐4.5	   -­‐3.4	  
MIR29C	   -­‐4.4	   -­‐4.6	   -­‐4.3	   -­‐4.2	  
AHCYL2	   -­‐4.2	   -­‐4.5	   -­‐4.1	   -­‐4.7	  
ZNF575	   -­‐4.4	   -­‐4.3	   -­‐4.4	   -­‐4.4	  
TCEA3	   -­‐4.0	  
	  
-­‐4.7	   -­‐4.3	  
HSD3B2	   -­‐4.5	   -­‐4.3	   -­‐4.0	   -­‐4.3	  
SLC41A2	   -­‐4.2	   -­‐4.2	   -­‐4.2	   -­‐4.5	  
KIAA1211	   -­‐4.1	   -­‐4.3	   -­‐3.9	   -­‐4.8	  
NR5A2	   -­‐4.2	   -­‐4.4	   -­‐4.1	   -­‐4.3	  
UPP1	   -­‐4.9	   -­‐4.1	   -­‐3.6	   -­‐4.2	  
PCDH20	   -­‐3.9	   -­‐4.5	   -­‐4.6	   -­‐3.9	  
POU2AF1	   -­‐2.8	   -­‐4.7	   -­‐4.4	   -­‐4.9	  
MATN2	   -­‐4.0	   -­‐4.2	   -­‐4.8	   -­‐3.8	  
NAT2	   -­‐3.4	   -­‐4.1	   -­‐4.7	   -­‐4.5	  
KBTBD11	   -­‐3.5	   -­‐4.3	   -­‐4.2	   -­‐4.7	  
CAPN8	   -­‐4.1	   -­‐4.1	   -­‐3.8	   -­‐4.7	  
ASPA	   -­‐4.3	   -­‐4.2	   -­‐4.0	   -­‐4.0	  
ZFP3	   -­‐3.8	  
	  
-­‐4.4	   -­‐4.1	  
CCDC68	   -­‐3.6	   -­‐3.8	   -­‐3.8	   -­‐5.1	  
FOXP1-­‐IT1	   -­‐3.9	   -­‐4.1	   -­‐4.2	   -­‐4.2	  
NAAA	   -­‐4.1	  
	  
-­‐4.0	   -­‐4.2	  
MAMDC2	   -­‐4.6	   -­‐3.9	   -­‐4.0	   -­‐3.8	  
KRT20	   -­‐4.3	   -­‐4.7	   -­‐4.0	   -­‐3.2	  
AMPD1	   -­‐4.0	   -­‐4.1	   -­‐4.1	   -­‐4.0	  
TP53INP2	   -­‐4.5	   -­‐4.0	   -­‐3.9	   -­‐3.7	  
C4ORF19	   -­‐3.5	   -­‐3.9	   -­‐4.1	   -­‐4.5	  
TEX11	   -­‐4.0	   -­‐4.0	   -­‐3.9	   -­‐4.0	  
EPHX2	   -­‐3.3	  
	  
-­‐4.4	   -­‐4.2	  
TNFRSF17	   -­‐3.0	   -­‐4.4	   -­‐4.3	   -­‐4.2	  
C17ORF73	   -­‐3.7	   -­‐4.4	   -­‐3.8	   -­‐3.8	  
SGK2	   -­‐3.7	   -­‐4.0	   -­‐4.2	   -­‐3.8	  
CD163L1	   -­‐3.8	   -­‐4.0	   -­‐3.9	   -­‐4.0	  
HIST1H1C	   -­‐4.1	   -­‐3.9	   -­‐3.7	   -­‐3.9	  
SECTM1	   -­‐4.4	   -­‐3.6	   -­‐3.4	   -­‐4.2	  
HSBP1L1	   -­‐4.0	  
	  
-­‐3.5	   -­‐4.1	  
HIGD1D	   -­‐3.8	   -­‐3.9	   -­‐3.7	   -­‐4.1	  
MAOA	   -­‐4.0	   -­‐3.8	   -­‐4.2	   -­‐3.5	  
FLJ32810	   -­‐4.0	   -­‐4.0	   -­‐3.6	   -­‐3.9	  
LOC100505989	   -­‐4.0	   -­‐3.6	   -­‐4.1	   -­‐3.7	  
OPN3	   -­‐3.7	   -­‐4.2	   -­‐3.6	   -­‐3.8	  
ZDHHC23	   -­‐3.6	  
	  
-­‐4.0	   -­‐3.9	  
FLJ22763	   -­‐4.0	   -­‐4.0	   -­‐3.6	   -­‐3.7	  
NAT1	   -­‐2.9	  
	  
-­‐4.1	   -­‐4.4	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IL18	   -­‐3.9	   -­‐3.7	   -­‐3.5	   -­‐4.2	  
AMY2B	   -­‐3.5	   -­‐3.9	   -­‐3.8	   -­‐4.0	  
ELOVL6	   -­‐3.9	   -­‐3.7	   -­‐3.6	   -­‐3.9	  
INSL5	   -­‐3.9	   -­‐3.7	   -­‐3.6	   -­‐4.0	  
CCNYL1	   -­‐3.7	   -­‐3.9	   -­‐3.6	   -­‐3.8	  
CHGA	   -­‐3.7	   -­‐3.9	   -­‐4.0	   -­‐3.5	  
CHST5	   -­‐3.7	   -­‐3.7	   -­‐3.8	   -­‐3.9	  
CPM	   -­‐3.9	   -­‐3.8	   -­‐3.5	   -­‐3.8	  
LOC643008	   -­‐3.8	   -­‐3.6	   -­‐3.8	   -­‐3.8	  
CD1D	   -­‐3.7	   -­‐3.8	   -­‐3.7	   -­‐3.9	  
PTGDR	   -­‐3.9	   -­‐3.7	   -­‐3.7	   -­‐3.7	  
FMO5	   -­‐3.8	   -­‐4.0	   -­‐3.9	   -­‐3.3	  
CES2	   -­‐3.9	   -­‐3.9	   -­‐3.5	   -­‐3.6	  
DNASE1L3	   -­‐3.1	   -­‐4.0	   -­‐4.0	   -­‐3.9	  
PBLD	   -­‐3.4	   -­‐4.0	   -­‐3.9	   -­‐3.7	  
RSAD2	   -­‐4.5	   -­‐3.5	   -­‐3.2	   -­‐3.7	  
SLC46A3	   -­‐4.1	   -­‐3.7	   -­‐3.4	   -­‐3.7	  
EMP1	   -­‐4.1	   -­‐3.6	   -­‐3.3	   -­‐3.9	  
DDX26B	   -­‐3.8	   -­‐3.7	   -­‐3.7	   -­‐3.5	  
MYO1A	   -­‐3.4	   -­‐3.9	   -­‐3.6	   -­‐3.8	  
ARRDC4	   -­‐3.6	  
	  
-­‐3.6	   -­‐3.9	  
ABCA5	   -­‐3.6	   -­‐3.5	   -­‐3.8	   -­‐3.8	  
AIFM3	   -­‐3.6	   -­‐3.7	   -­‐3.9	   -­‐3.5	  
AKR1C2	   -­‐4.0	   -­‐3.7	   -­‐3.5	   -­‐3.4	  
TINAG	   -­‐3.7	   -­‐3.6	   -­‐3.9	   -­‐3.3	  
TLCD2	   -­‐3.6	  
	  
-­‐3.4	   -­‐3.9	  
ST6GALNAC1	   -­‐2.8	   -­‐3.6	   -­‐3.8	   -­‐4.4	  
HRCT1	   -­‐3.6	   -­‐3.6	   -­‐3.5	   -­‐3.8	  
CHGB	   -­‐3.9	   -­‐3.6	   -­‐3.8	   -­‐3.2	  
CDHR5	   -­‐3.6	   -­‐3.6	   -­‐3.5	   -­‐3.8	  
VIPR1	   -­‐3.4	   -­‐3.6	   -­‐3.6	   -­‐3.8	  
SQRDL	   -­‐3.4	  
	  
-­‐3.6	   -­‐3.8	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APPENDIX H 
 
function [output, output2] = QLISA_2_1(directory) 
%processess all of the images within a given directory 
%output is list of files 
%output2 calculates the avg intensity and standard deviation of the ROI 
%within each file 
  
%FILE FINDER ALGORITHM 
contents=dir(directory); 
filenames = {contents.name}'; 
for k=1:1:size(filenames,1) 
    x(k,1) = strfind(filenames(k,1), '.BMP'); 
    x2 = cell2mat(x(k,1)); 
    tf(k,1) = isempty(x2); 
    if tf(k,1)==0 
        z(k,1).value = filenames(k); 
    else z(k,1).value = []; 
    end 
    if ~isempty(z(k,1).value) 
        output(k,1) = {z(k,1).value}; 
    end 
end 
  
for k = 1:1:size(output,1) 
    G(k) = iscellstr(output{k}); 
end 
G = G'; 
n = size(output,1)-sum(G); 
first = n+1; 
  
%IMAGE PROCESSING 
for b = first:1:size(output,1)                   
    filename = output{b,1}{1,1}; 
    img=imread(filename); 
    info = imfinfo(filename); 
  
    img=imread(filename); 
    info = imfinfo(filename); 
    %figure, imshow(img); 
  
    %DUST FILTER 
    [M N]=size(img);                        %M is rows, N is columns 
    threshold = graythresh(img); 
    bw = im2bw(img,threshold); 
    bw2 = bwareaopen(bw,100); 
    dust = imsubtract(bw,bw2); 
    img1=img; 
    for k=1:1:M 
        for c=1:1:N 
            if dust(k,c)==1 
               img1(k,c)=0;            
            else img1(k,c)=img(k,c); 
            end 
        end 
    end 
    %figure, imshow(img1); 
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    threshold2 = graythresh(img1); 
    bw3 = im2bw(img1,threshold2); 
    %figure, imshow(bw3);                   %BW ROI 
  
    %CROP IMAGE along X 
    x = sum(img)/M;                         %average row intensities 
    %figure, plot(x);     
    [C xidx] = max(x);                   %C is the value, xidx is the 
index 
    img2 = img1(:,xidx-5:xidx+5); 
    %figure, imshow(img2); 
     
    threshold3 = graythresh(img2); 
    bw4 = im2bw(img2,threshold3); 
     
    %BOUNDARY FILTER 
    [B,L] = bwboundaries(bw4); 
    %imshow(label2rgb(L, @jet, [.5 .5 .5])) 
    %hold on 
    %for k = 1:length(B) 
    %    boundary = B{k}; 
    %    plot(boundary(:,2), boundary(:,1), 'w', 'LineWidth', 2) 
    %end 
     
    k = cell2mat(B); 
    idx = mean(k); 
    %xidx = round(idx(1,2)); 
    yidx = round(idx(1,1)); 
  
    %CROP IMAGE 
    xmin = xidx - 5; 
    ymin = yidx - 5; 
    width = 10; 
    height = 10; 
  
    rect = [xmin ymin width height]; 
    img2 = imcrop(img,rect); 
    figure, imshow(img2);                  %cropped image 
     
    %Compile Data 
    avg1 = mean(img2); 
    avg_intensity = mean(avg1); 
    standard_dev = std(avg1); 
  
    z = cat(1,filename); 
    x = cat(1,avg_intensity); 
    y = cat(1,standard_dev); 
    output2{b,1} = z; 
    output2{b,2} = x; 
    output2{b,3} = y; 
end 
  
  
  
